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This cross-sectional study examined the influence that age/disease severity, pain, and/or 
family functioning have on different domains of health-related quality of life (HRQOL) from the 
perspectives of patients with a degenerative neuromuscular disease and their parents. Participants 
included 44 parents/caregivers and 39 patients between the ages of 6- and 25-years, who have a 
confirmed genetic diagnosis of Becker Muscular Dystrophy (BMD) or Duchene Muscular 
Dystrophy (DMD). Patients and/or their caregivers completed measures of HRQOL (PedsQLTM 
4.0 Generic Core scales, Varni et al., 1999) and family functioning and well-being (PedsQLTM 
2.0 Family Impact Module, Varni et al., 2004), as well as provided general child and family 
demographic information. Details regarding patients’ disease status (i.e., usage of steroids and 
respiratory-related devices, secondary medical conditions, and comorbid psychiatric and 
neurodevelopmental disorders) were also obtained from their medical charts. Univariate analyses 
were used to explore characteristics of the sample, disease-specific variables, and all survey data. 
Overall, patients and their caregivers reported low levels of physical and psychosocial HRQOL. 
Mean scores of caregiver well-being and family functioning were lower for this sample than for 
other studies using the same measure with families of pediatric populations. Furthermore, a 
series of multivariable regression analyses were conducted to assess associations between 




significant amount of the variance in child-reported and parent-reported Psychosocial Health 
Summary scores. The child-reported Physical Health Summary score also demonstrated a 
statistically significant model, with age and family functioning having a large influence.  
These results suggest that assessing and addressing concerns regarding pain and family 
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In the United States, a rare disease is defined as a condition that affects less than 200,000 
people (U.S. Department of Health and Human Services, 1989). Although any one rare disease is 
unlikely to afflict an individual, collectively, 25 to 30 million Americans are diagnosed with one 
of the more than 6,500 that exist (Bavisetty et al., 2013; Boat & Field, 2010). These diseases are 
often severe and chronic, but far too many are also progressive, debilitating, and ultimately, fatal. 
Nearly half of these disorders manifest in childhood (Batshaw et al., 2014; Zurynski et al., 2008), 
with most requiring ongoing and complex care due to the lack effective treatment options. 
Across these pediatric populations, healthcare has primarily focused on medical outcomes such 
as reducing mortality and morbidity and minimizing the number of hospitalizations. Similarly, 
medical professionals often arbitrarily used the degree of physical impairment or disease severity 
as key indicators of potential psychosocial problems among individuals with chronic health 
conditions (Harper & Peterson, 2000), overlooking the importance of formally assessing well-
being, adjustment to illness, and psychological functioning from the perspectives of patients and 
their families.  
However, over the last 40 years, developments in research and advancements in medicine 
and technology have dramatically changed the clinical course and survival rates of youth with 




al., 2016). In light of these accomplishments, there has been greater emphasis on understanding 
youths’ perception of how their illness affects their well-being, daily functioning, and 
psychological adjustment. Health-related quality of life (HRQOL) has emerged as a particularly 
salient area of interest in clinical practice and pediatric research (Eiser & Jenney, 2007; Varni et 
al., 2007). This multidimensional construct examines the impact of an illness, its associated 
complications, and treatment regimen on various aspects of an individual’s life (Panepinto, 
2008). Within the last decade, there has been an increase in the development and utilization of 
pediatric HRQOL measures to improve the health and well-being of children with chronic 
diseases and their families (Matza et al., 2004). Along with standard clinical measures and the 
expertise of health-care providers, patient-reported outcomes (i.e., assessments of HRQOL) can 
provide a more comprehensive evaluation of a child’s functioning across a range of domains 
(Bradlyn et al., 2003; Lin et al., 2013), leading to more opportunities for targeted interventions in 
areas that are more readily modifiable. Although the number of studies examining HRQOL in 
pediatric populations (e.g., epilepsy, cancer, sickle cell disease, and spina bifida) has steadily 
grown in recent years, Duchenne muscular dystrophy (DMD), a rare, incurable disease, with a 
shortened life expectancy, has received far less attention. Further, the identification of 
mechanisms that may explain variations in HRQOL among individuals with DMD may have 
significant implications for interventions, health outcomes, and provision of care.  
Significance of the Problem 
Dystrophinopathies, including Duchenne and Becker muscular dystrophies, are a subset 
of progressive neuromuscular disorders. DMD is on the severe end of the dystrophinopathy 
spectrum and is considered to be the most common and severest pediatric neuromuscular 




related to DMD and the subsequent information is largely focused on DMD. This disabling 
disease is caused by genetic mutations in the DMD gene, leading to insufficient levels of 
dystrophin, a protein essential for muscle function (Crean & Tirupathi, 2019; Shenk & Rodino-
Klapac, 2014). It is transmitted via an X-linked pattern, meaning it almost exclusively affects 
males, with an estimated incidence of approximately 1 in every 5,000 births (Mendell et al., 
2012; Moat et al., 2013; Romitti et al., 2015). The hallmark feature of DMD is degenerative 
muscle weakness and wasting, which results in multisystem complications and comorbidities 
(Morrison, 2011; Pegoraro et al., 2011). Clinical symptoms usually present in early childhood in 
the form of gross motor delays (Bushby et al., 1999; Ciafaloni et al., 2009) and eventually 
progresses to loss of ambulation during adolescence and limited use of upper limbs at later stages 
(Bushby et al., 2010).  
The majority of affected boys will struggle with life-threatening respiratory, orthopedic, 
and cardiac problems, as well as secondary medical conditions such as pain, sleep problems, 
gastrointestinal issues, and swallowing dysfunction (Birnkrant et al., 2018; Eagle et al., 2007; 
Mercuri & Muntoni, 2013). Youth with DMD are also at higher risk for neurodevelopmental 
disorders (e.g., intellectual disability, autism spectrum disorder, attention-deficit/hyperactivity 
disorder) and psychiatric conditions (e.g., obsessive-compulsive disorder, anxiety, and 
depression), as well as mild levels of externalizing problems (Banihani et al., 2015; Hendriksen 
& Vles, 2008; Pane et al., 2012; Sarrazin et al., 2014; Schmid et al., 2013), all of which may 
exacerbate disease severity and affect overall well-being. The profound impairment in muscle 
function and multi-organ complications leads to a gradual deterioration in functional abilities, 
restricted participation in age-related activities, and increased dependence on caregivers 




As the disease progresses, boys with DMD require consistent utilization of community, 
medical, and educational resources and services. The annual direct costs associated with DMD 
are approximately seven times higher than the average health expenditures in the United States 
(Landfeldt et al., 2016). Equally alarming are the findings regarding the indirect annual costs on 
households caring for a boy with DMD (e.g., income loss and monetary value of lost leisure time 
and quality of life), which has been estimated between $58,440 and $71,900 (Landfeldt et al., 
2014; Larkindale et al., 2014). Not only do families experience a substantial financial burden, but 
also the severity and progressive nature of the disease necessitates routine multidisciplinary care 
and adherence to a complex treatment regimen (Birnkrant et al., 2018; Strauss et al., 2015). 
While the benefits of the DMD standards of care are well-documented (Ishikawa et al., 2011; 
Rall & Grimm, 2012), these therapeutic efforts can also be particularly burdensome, unpleasant, 
expensive, and even overwhelming for children and families (Poysky & Kinnett, 2009).  
Beyond navigating the complexities of treatment and financial strain of complex medical 
care, parents and/or other family members often assume the role of long-term caregiver by 
addressing the majority of the medical and non-medical needs of boys with DMD (Boyer et al., 
2006). These responsibilities and potential limitations on employment, personal care, and 
involvement in social and leisure activities place caregivers at risk for increased stress, reduced 
parental HRQOL, and poorer physical health and psychosocial functioning (Landfeldt et al., 
2014; Magliano et al., 2015; Mah et al., 2008; Nereo, 2003). Similarly, the chronic and 
progressive nature of the disease may impair aspects of the family unit including communication, 
cohesion, problem-solving, and relationships (Chen & Clark, 2007; Thompson et al., 1998; 
Tomiak et al., 2007). Additionally, disruptions in the family’s routine activities and daily 




uncommon. Consistent with the literature on pediatric chronic illnesses (Driscoll et al., 2018; 
Herzer et al., 2011; Leeman et al., 2016), reduced family functioning and parental well-being 
may subsequently affect health outcomes and HRQOL among individuals with DMD. 
Due to improvements in medicine and science, individuals with DMD are now expected 
to live into their early 30s (Eagle et al., 2007; Passamano et al., 2012), although this is a 
significant medical accomplishment, it has created a growing population with new, under-studied 
physical and psychosocial needs, like HRQOL. Given the clinical manifestations of the illness, 
the treatment demands, family impact, and the associated functional limitations, it is not 
surprising that youth with DMD generally report reduced HRQOL when compared to their 
healthy counterparts and youth with other chronic illnesses (Baiardini et al., 2011; Bendixen et 
al., 2012; Bray et al., 2011; Henricson et al., 2013; Uzark et al., 2012; Wei et al., 2016). Despite 
the important role parents’ play in the lives of their children, especially those with DMD, little is 
known about the effects of family functioning and parental well-being on the HRQOL of boys 
with DMD. Thus far, extant research has tended to focus on demographic and illness-specific 
variables and resulted in mixed evidence regarding the importance of factors such as disease 
severity, steroid use, respiratory function, and ambulation status. Elucidating factors that are 
potentially and more readily modifiable may prove to be particularly important in informing the 
development of interventions that are tailored to the unique needs of the child and their family.  
Theoretical Framework 
  
The literature on pediatric chronic illness has established various theoretical models that 
guide research and can be used to inform the investigation of HRQOL. Based on the work of 
Urie Bronfenbrenner, this theory provides an organizing framework for understanding the 




living with a rare disease, like DMD (Tate & Pledger, 2003). According to the bioecological 
theory, the child is embedded within multiple layers of influence: microsystem, mesosystem, 
exosystem, and macrosystem, all of which are constantly interacting and influencing each other 
(Bronfenbrenner, 1979). The microsystem is the most proximal level and is thought to have the 
greatest influence on child development and functioning (Bronfenbrenner & Morris, 1998). It 
consists of the child’s immediate surroundings, such as family, friends, teachers, and others who 
the child interacts with regularly. Also, the microsystem of a child with DMD extends to include 
their symptoms, mental health status, and treatment, exerting influence on both the child and the 
family outcomes (Kazak et al., 1995). The mesosystem accounts for the bidirectional interactions 
between the structures of the child’s microsystems (Bronfenbrenner, 1986). At this level, the 
quality of the family’s relationship and level of communication with the child’s medical team is 
critical. The exosystem influences the child indirectly by impacting their immediate 
environments. For example, parents have acknowledged that the caregiving demands of children 
with DMD can have a significant effect on their social relationships and available financial 
resources (Mah et al., 2008), which may heighten parental stress and subsequently affect their 
child’s well-being. Similarly, for working parents of children with DMD, workplace policies, 
like employee leave time, access to health insurance, and their schedule, can indirectly affect 
their child. In this case, a parent may be limited in their ability to leave work without advance 
notice when their child with DMD experiences an unexpected change in their health status. The 
macrosystem represents the broader cultural context that includes societal norms, values, and 
beliefs. For children with a rare genetic disease, like DMD, laws and policies can directly impact 
the services that are available or access to care. For example, pediatric research on rare diseases 




Administration, 1983), which provided incentives to pharmaceutical companies to develop drugs 
and treatments for rare diseases. Lastly, the chronosystem was added to the model more recently, 
and it accounts for the influence of environmental changes, transitions, and experiences on 
development across the lifespan, including puberty, death, chronic illness, etc. (Bronfenbrenner, 
1986). The chronosystem also captures broad societal changes across time and in the case of 
DMD, advances in science and the focus on HRQOL and well-being are trends that have 
contributed to the functioning of the children with DMD and their families. Overall, this 
theoretical framework supports the value and importance of examining factors that extend 
beyond the individual to include contextual variables when understanding HRQOL among 
individuals with chronic diseases. 
Rationale for the Study 
Although the life expectancy of individuals living with DMD has increased, there is still 
no cure and medical treatments are limited in their ability to mitigate symptoms and associated 
complications; thus, HRQOL has been recognized as a priority (Cohen & Biesecker, 2010) that 
needs to be considered in the clinical decision-making process. Some researchers even argue that 
improving HRQOL is the ultimate goal of healthcare, especially when managing incurable 
diseases (Birnkrant et al., 2018; Graf et al., 2006). Despite the growing appreciation of HRQOL 
as a valuable outcome measure for children and adolescents with DMD, the body of literature is 
still limited, especially when compared to other chronic illnesses. Some researchers have made 
efforts to identify factors associated with HRQOL, but most have focused on demographic, 
clinical, and disease-specific variables, resulting in mixed findings and limited opportunities to 




contextual factors, such as caregiver well-being and family functioning, even though the family 
plays such a critical role in caring for these children. 
Of the available studies examining HRQOL in this pediatric population, several 
methodological weaknesses have been identified including the utilization of samples with 
various neuromuscular diseases, single informant reports, (i.e., parent proxy only), and 
measurement tools with poor psychometric properties. Another common issue across the field is 
the variation in the way in which researchers conceptualize the construct of HRQOL. 
Specifically, some studies use HRQOL and quality of life interchangeable, but as Wei et al. 
(2017) determined, these concepts are related, but distinct.  
Purpose of the Study 
The current study seeks to address these gaps and weaknesses in the literature by using 
information from multiple methods and multiple informants to explore child and family factors 
that may contribute to HRQOL in youth with DMD. Such efforts are necessary for identifying 
modifiable factors that influence HRQOL, which may serve as potential targets for intervention 
and subsequently improve the functioning and well-being of youth with DMD and their families.  
Research Questions  
Q1  Does age/disease severity, pain, and family functioning  
explain child-reported HRQOL scores? 
 
Q2 Does age/disease severity and family functioning  




The most notable delimitation of this study was that a global pandemic occurred at the 
outset of data collection, which greatly impacted the achieved sample size and led to changes in 




participants from a single clinic in the western region of the United States; thus, the results may 
not be representative of all boys with DMD and their families. However, it has been argued that 
given the severity of the disease, it is reasonable to assume that almost all boys with DMD are 
managed at a tertiary-care clinic; thus, patients recruited through such clinics are likely to be 
representative of the DMD population. Cognitive and/or other neuropsychological impairments 
of some of the participants may have interfered with their ability to complete the measures 
and/or impacted the validity of the data obtained from the self-report measures. Lastly, the cross-
sectional nature of this study limited the casual conclusions that can be made about the results.  
Definition of Terms  
Cardiomyopathy is a progressive disease that results in aspects of the heart muscle  
becoming enlarged, thickened, or stiffened. Overtime, the heart becomes weaker and 
ineffective in its ability to pump blood and maintain an adequate electrical rhythm 
(McCartan et al., 2012).  
Duchenne muscular dystrophy is a neuromuscular disorder that is characterized by  
degenerative muscle weakness and wasting, resulting in multisystem complications and 
comorbidities, as well as a shortened life expectancy (Morrison, 2011; Pegoraro et al., 
2011). 
Dystrophin is a protein that is essential for maintaining the function and structure of 
skeletal and cardiac muscle cells. Small amounts of dystrophin have also been found in 
the brain and other tissues (e.g., kidneys and retina), but less is known about its role in 
these areas (Chelly & Desguerre, 2013; Rando, 2001; Shenk & Rodino-Klapac, 2014). 
Dystrophinopathies, including Duchenne and Becker muscular dystrophies, are a subset of X-




Tirupathi, 2019; Shenk & Rodino-Klapac, 2014). DMD is at the severe end of the 
dystrophinopathy spectrum, while Becker muscular dystrophy (BMD) tends to be less 
severe and has a longer life expectancy (Bushby et al., 2010). 
Family functioning refers to the “social and structural properties” of the family unit and  
larger environment, including the interactions and relationships within the family, 
communication patterns, and the roles of the family members (Lewandowski et al., 2010, 
p. 2). 
Forced vital capacity (FVC) is a measure of pulmonary function that encompasses the  
maximum amount of air that can be forcibly exhaled into the hose of 
a spirometer (Moore, 2012).  
Gowers’ Maneuver is often considered to be an early sign of DMD, in which children use  
their hands to push themselves upright when rising from the floor (Emery et al., 2015). 
Health-related quality of life is a multidimensional construct examining one’s illness and  
associated treatment on their physical, psychological, and social functioning (Panepinto, 
2008). 
Neuromuscular disorders are a class of inherited and acquired medical conditions, where  
the primary pathology is associated with the peripheral nervous system, which includes 
the anterior horn cell, the peripheral nerve, the neuromuscular junction, and the muscle 
(Dowling et al., 2017). 
Parental health-related quality of life encompasses the impact of a pediatric medical  












REVIEW OF LITERATURE 
This chapter offers a review of the extant literature relevant to the proposed study. The 
first section provides a description of DMD including etiology, diagnosis, disease progression, 
and associated complications and comorbidities. The second section addresses current methods 
of disease management and clinical care guidelines. The third section includes a broad overview 
of HRQOL and considerations when measuring this construct. Finally, the chapter concludes 
with a discussion regarding known factors associated with HRQOL in children and adolescents 
with DMD. 
Duchenne Muscular Dystrophy 
DMD is recognized as a genetically acquired neuromuscular disorder that is transmitted 
via a X-linked recessive inheritance pattern (Dowling et al., 2017). This mode of inheritance 
indicates that the disease is the result of a defective gene on the X chromosome. Consequently, 
this disease primarily affects males, who receive the mutation on their only copy of the X 
chromosome from a “carrier” mother (Khadilkar et al., 2018). Females who receive the faulty 
gene on one of their two X chromosomes, rarely develop DMD, and instead are considered 
“carriers,” with a 50% chance of passing the mutation to their offspring (Morrison, 2011). 




(Soltanzadeh et al., 2010; Verhaert et al., 2011). Although the majority of cases are inherited, 
there is a high spontaneous mutation rate, with nearly one-third of boys acquiring the disease as a 
new random alteration, where there is no known familial history (Bladen et al., 2015).  
DMD is caused by a mutation, in one of the largest human genes, the dystrophin gene 
(Crean & Tirupathi, 2019; Grigore et al., 2015; Mah, 2016). This gene is responsible for the 
production of dystrophin, a protein essential to maintaining muscle function and structure (Shenk 
& Rodino-Klapac, 2014). Dystrophin is primarily expressed in skeletal and cardiac muscle cells, 
but small amounts have also been found in the brain (Chelly & Desguerre, 2013), as well as 
other tissues, including the retina and kidneys (Rando, 2001). Mutations associated with the 
DMD phenotype typically result in the absence or a non-functional level of dystrophin in skeletal 
and cardiac muscle and other tissues (Aartsma-Rus et al., 2016; Gao & McNally, 2015). In 
healthy muscle, dystrophin is part of a large multi-protein complex (i.e., dystrophin-associated 
glycoprotein complex [DGC]) that helps to stabilize and protect muscle fibers from damage 
during contraction and relaxation (Aartsma-Rus et al., 2016; Lapidos et al., 2004). Thus, 
dystrophin deficiency is thought to destabilize the DGC, and in turn, muscle fibers become 
susceptible to tearing (Falzarano et al., 2015; Mah, 2016). Over time, the sustained damage 
impairs the regenerative capacity of the muscle and allows for an influx of calcium in the cell, 
gradually resulting in cell death and the replacement of muscle with fat and scar tissue (Gillis, 
1999; Hoffman et al., 1987; Mercuri & Muntoni, 2013). Consequently, muscles do not function 
properly and are unable to tolerate the stress of normal contractions, ultimately leading to 






Onset and Diagnosis  
 
Newborn screening for DMD is not currently conducted in the United States as part of 
the Recommended Uniform Screening Panel (Watson et al., 2006); thus, the disease is rarely 
diagnosed during infancy. Skeletal muscles are affected at birth, but most boys do not present 
with overt symptoms until early childhood (Darras et al., 2015). Clinical indicators of DMD may 
present as early as the first two years of life, in the form of mild delays in gross motor 
development (Ciafaloni et al., 2009). Nearly half of all affected boys do not begin walking until 
approximately 18 months of age (Emery et al., 2015). Speech and language deficits have also 
been noted in 50-70% of children with DMD and may present before concerns of motor 
functioning (Ciafaloni et al., 2009). Despite early signs and symptoms, most boys are diagnosed 
between 4-5 years-old, when their physical abilities fall behind same-aged peers (Bushby et al., 
1999). Studies have consistently found a delay of two and a half years between the initial 
identification of symptoms and a definitive diagnosis (Ciafaloni et al., 2009). 
When clinical manifestations of abnormal muscle function are suspected or there is a 
family history of DMD, creatine kinase (i.e., an enzyme found in muscle tissues; CK) levels are 
often measured (Burtis et al., 2007). Elevations of CK in the blood is indicative of muscle 
damage. Regardless of the presence of increased CK levels, genetic testing is necessary to 
establish a diagnosis of DMD (Bushby et al., 2010). However, if genetic analyses do not identify 
the mutation, a muscle biopsy can be performed to assess for the presence of the dystrophin 




DMD is characterized by gradual development of muscle weakness and wasting that 




symptoms of the disease are usually observed before age 5, when most boys exhibit gross motor 
difficulties including frequent falls and problems running, jumping, and climbing stairs (Parsons 
et al., 2004; van Ruiten et al., 2014). Additionally, short stature is often noted, with growth 
curves below age expectations during early childhood (Eiholzer et al., 1988). A physical 
examination is indicative of abnormal enlargement of the calf muscles by four to five years of 
age due to increased muscle bulk, which over time is replaced by fat and scar tissue (Gao & 
McNally, 2015). It is not uncommon for families to notice slight gains in their child’s strength 
and motor skills between three- and six-years-old, but this is attributed to normal development 
outpacing the disease progression (Shenk & Rodino-Klapac, 2014). Unfortunately, these 
improvements are short-lived and followed by a gradual deterioration in functioning.  
Rigidity in the Achilles tendons forces boys to walk on their toes or the balls of their feet 
(Mercuri & Muntoni, 2013). A child with DMD will begin to walk stiffly with a wide-based gait 
and his belly pushed out and his shoulders pulled back. Due to weakness in the knees and hips, 
Gowers’ Maneuver is also commonly seen, as children use their hands to push themselves 
upright when rising from the floor (Emery et al., 2015). These compensatory efforts eventually 
become ineffective with the steady deterioration of muscle strength, function, and flexibility in 
the hips, thighs, shoulders, and pelvis, and will progress to the point that consistent physical 
support and/or the use of assistive devices will be required (D’Angelo et al., 2009).  
 As the disease progresses, deep tendon reflexes diminish and joint contractures develop, 
both of which greatly contributes to the need for leg braces by age 10 and eventually full-time 
use of a wheelchair by early adolescence, typically around 13-years-old (Bakker et al., 2002). 
However, in recent years, the use of steroids has extended ambulation by two to five years (Eagle 




with most boys only able to engage in simple hand movements (Darras et al., 2015). With 
declining physical functioning, youth with DMD often find themselves increasingly dependent 
on their caregivers to provide assistance with daily living tasks and day-to-day functioning 
(Biggar, 2006). 
 Around the time of the loss of ambulation, the risk of scoliosis (i.e., curvature of the spine) 
and/or kyphosis (i.e., hunchback) often increases (Strauss et al., 2015) and further exacerbates 
already compromised respiratory and cardiac function. Additionally, DMD is associated with 
poor bone health including osteoporosis, which greatly contributes to the high incidence of 
fractures within this population (Buckner et al., 2015; Quinlivan et al., 2005). Glucocorticoid 
use, weight-bearing exercise restrictions, changes in body fat composition, and immobility have 
all been identified as risk factors for reduced bone growth and strength (Joyce et al., 2012).  
Respiratory Complications 
Progressive deterioration of respiratory function follows a predictable pattern that 
coincides with muscle strength, in which initial age-related growth is observed, followed by a 
plateau and then a gradual decline, usually during the non-ambulatory stages (Aliverti et al., 
2015; Gayraud et al., 2010). Studies have shown that a global indicator of respiratory function, 
forced vital capacity (FVC), is consistently above 70% (i.e., mild level of impairment) in 
ambulant boys and generally begins to decrease around age 10, with an average decline of 4-8% 
per year (Khirani et al., 2014; Mayer et al., 2015; Phillips et al., 2001). With the loss of 
ambulation, FVC usually drops below 50% (i.e., severe pulmonary insufficiency), at which time, 
youth begin to experience breathing problems at night that result in morning headaches, sleep 
disturbances, daytime fatigue, and loss of appetite (Bushby et al., 2005; Guglieri & Bushby, 




(e.g., obstructive sleep apnea), secondary to upper airway muscle weakness and weight gain 
associated with glucocorticoid therapy (Hoque, 2016). As the disease progresses, FVC will 
continue to decline, to the point that difficulties breathing during the day will occur, and survival 
beyond 10 months is unlikely without the initiation of ventilatory support (LoMauro et al., 2013; 
Toussaint et al., 2007). 
Cardiac Complications 
With the increase in life expectancy and the advent of ventilatory support, cardiac 
dysfunction is beginning to emerge as the leading cause of death in individuals with DMD 
(Birnkrant et al., 2015; Kamdar & Garry, 2016; McNally et al., 2015). All individuals with DMD 
are at risk of developing cardiac complications, but the course is variable, and studies have not 
confirmed reliable markers with prognostic utility (Ashwath et al., 2014). The lack of dystrophin 
expression in the heart often manifests as cardiomyopathy, resulting from progressive 
replacement of muscle by fibrofatty tissue (Kaspar et al., 2009; Silvestri et al., 2018). Clinical 
indicators of cardiomyopathy are usually apparent after age 10, with symptomology steadily 
increasing with age, affecting nearly all individuals over 18-years-old (Finsterer & Stöllberger, 
2003; Nigro et al., 1990). However, James and colleagues (2011) identified pre-clinical 
indicators of cardiac manifestations on electrocardiograms (ECG) in nearly 78% of boys under 
age 6, with left ventricle impairment commonly noted. Boys often remain asymptomatic well 
into adolescence due to limited physical activity, with the diagnosis of cardiomyopathy often 
occurring around 14-years-old (Andrews & Wahl, 2018). Furthermore, as the disease progresses, 
abnormalities of cardiac rhythm may also develop including atrial fibrillation, ventricular 










 Less is known about the function of dystrophin in the brain, but research has established 
that DMD is associated with a distinct cognitive and neurobehavioral profile. Although there is 
variability in the cognitive functioning of affected youth, full-scale intellectual quotient (FSIQ) 
scores of boys with DMD is approximately 1.0-1.5 standard deviations below the mean (Cotton 
et al., 2001, 2005; Donders & Taneja, 2009; Hinton et al., 2004; Pane et al., 2012; Snow et al., 
2013; Taylor et al., 2010; Wingeier et al., 2011), with greater impairment in verbal skills than 
nonverbal abilities (Bresolin et al., 1994; Cotton et al., 2001, 2005). Specific weaknesses on 
subtests measuring short-term memory and expressive language have been identified (D’Angelo 
& Bresolin, 2006; Wicksell et al., 2004). Academically, studies have suggested that boys with 
DMD are at higher risk for learning disabilities, particularly within the area of reading (Billard et 
al., 2008; Hendriksen & Vles, 2006; Hinton et al., 2001, 2004). Youth with DMD have been 
found to have lower reading, writing, and math scores on standardized academic tests. Hinton et 
al. (2001) reported that the mean standard scores for reading, writing, and math were more than 
10 points lower in children with DMD than in the control group, with the most notable issues 
observed on the math subtests of the Woodcock-Johnson (WJ) Achievement Battery. 
Impairments in executive functioning have also been noted, as children and adolescents with 
DMD have been found to have deficits in planning, inhibition, problem-solving, and working 
memory (Rae & O’Malley, 2016; Ricotti et al., 2015; Wicksell et al., 2004).  
 Consistent with deficits in executive functioning, ADHD has been recognized as the most 
common neurodevelopmental comorbidity associated with DMD (Hendriksen & Vles, 2008; 




diagnosis of ADHD in 33 out of the 103 participants (Pane et al., 2012). Similarly, based on a 
standardized parent-reported measure (i.e., Child Behavior Checklist (CBCL); Achenbach, 
1991), a high percentage of children between 5- and 16-years-old were rated as above the clinical 
threshold for symptoms of inattention (44% of males) and hyperactivity (24% of males) (Ricotti 
et al., 2015). Several studies have also highlighted problems with social functioning. For 
example, Donders and Taneja (2009) demonstrated that boys with DMD received poorer scores 
on the Social Problems and Social Withdrawal scales of the CBCL, while controlling for FSIQ. 
When compared to children with cerebral palsy and unaffected siblings, youth with DMD were 
rated as having more social behavior problems (Hinton et al., 2006). These findings align with 
the emerging body of evidence that has identified higher rates of autism spectrum disorder in this 
pediatric population (Hendriksen & Vles, 2008; Wu et al., 2005). Furthermore, children and 
adolescents with DMD may exhibit emotional and behavioral difficulties. When compared to the 
normative sample, higher rates of internalizing problems were endorsed on the CBCL (i.e., 
Internalizing Problems and Anxious/Depressed Problems) among a sample of 47 Italian boys 
with DMD (Colombo et al., 2017). On the other hand, several studies found elevations in both 
externalizing (i.e., aggression and hyperactivity) and internalizing (i.e., anxiety and mood 
disorders) problems on parent rating scales in this pediatric population (Fee & Hinton, 2011; 
Ricotti et al., 2015).  
Treatment of Duchenne Muscular Dystrophy 
Comprehensive clinical care guidelines developed by the United States Centers for 
Disease Control and Prevention (CDC) in collaboration with international and national 
organizations, have played a critical role in establishing best practices for the diagnosis, 




standardized care recommendations emphasize the need for anticipatory and preventive measures 
to address primary and secondary symptoms across the disease stages: diagnosis, early 
ambulatory, late ambulatory, early non-ambulatory, and late non-ambulatory. A 
multidisciplinary approach to disease management has been widely accepted as the ideal method 
of treatment, as it allows for the collaborative coordination of care from professionals across a 
variety of disciplines (Moxley et al., 2010; Osorio et al., 2018). Not only is a multidisciplinary 
service delivery model beneficial to the quality and efficiency of patient care (Otto et al., 2017; 
Vry et al., 2016), but it also alleviates some of the indirect consequences of having a complex 
condition by limiting travel burden and consolidating visits into a single encounter.  
Neuromuscular multidisciplinary clinics are often held at least once every 6 months and 
typically operate under the leadership of a medical professional with specialized training in 
muscle diseases. The core clinical team is comprised of healthcare providers with a diverse range 
of disease-specific knowledge and expertise including but not limited to, cardiology, pulmonary, 
rehabilitation, gastroenterology, endocrinology, and psychology (Paganoni et al., 2017). The 
contribution of each team member may vary based on the status of individual’s condition across 
the lifespan. Although there is currently no treatment that can prevent or reverse the disease 
progression, multidisciplinary coordination of care and surgical, pharmacological, and 
noninvasive interventions have helped to dramatically increased the life expectancy of 
individuals with DMD (Andrews & Wahl, 2018). The following sections outline the most 
common treatments across the core disciplines. 
Neuromuscular Management 
With no cure, glucocorticoids are the most commonly prescribed medications and have 




and deflazacort (0.9 mg/kg) are the only medications currently available that have proven to be 
effective in delaying the disease progression and preserving functional outcomes (Balaban et al., 
2005; Mah, 2016). Deflazacort recently became the first glucocorticoid for DMD that was 
granted full approval by the US Food and Drug Administration (FDA) (U.S. Food and Drug 
Administration, 2017). Studies have consistently demonstrated that glucocorticoid therapy 
maintains and improves muscle strength and function (Beenakker et al., 2005; Biggar et al., 
2006; Rahman et al., 2001), delays loss of ambulation (Houde et al., 2008; King et al., 2007), 
decreases the onset of spinal deformity (Alman et al., 2004; Lebel et al., 2013), and extends 
respiratory and cardiac function (Markham et al., 2008). Despite the benefits of glucocorticoids, 
there are serious side effects associated with chronic use including behavioral problems, 
Cushingoid facial features (i.e., collection of symptoms that evolve from prolonged use of 
steroids including a round and puffy face, increased fat around the neck, and acne), loss of bone 
mass, growth suppression, and delayed puberty (Guglieri & Bushby, 2015; Houde et al., 2008). 
Adverse side effects are frequently cited as the main reason for dosage changes and 
discontinuation of these medications (Moxley et al., 2010).  
Rehabilitation Management  
 
Prevention of contractures and musculoskeletal deformity requires a combination of 
techniques including active and/or active-assisted elongation, passive stretching of muscles and 
joints, and limb positioning to minimize flexion with splinting, standing devices, and orthoses 
(Skalsky & McDonald, 2012). A stretching program to slow contracture formation should be 
implemented early, before the loss of range of motion. Stretching is recommended 4 to 6 times 
per week, with greater focus on lower limbs (e.g., ankle, knee, and hip) during the early stage of 




preserve muscle strength, children with DMD should also engage in daily aerobic exercise such 
as swimming, cycling, and light recreational activities, especially early in the disease (Eagle et 
al., 2002).  
The use of various orthopedic and assistive devices helps to optimize quality of life and 
independence. Specifically, studies have demonstrated the effectiveness of ankle-foot orthoses 
(AFOs) in reducing some forms of contractures (de Souza et al., 2016; Hyde et al., 2000). 
Standing motorized wheelchairs are now frequently being used to support standing mobility 
(Case et al., 2018). There are few assistive devices currently available for upper limb 
involvement, but hand splints may help to maintain functional use of hands during the non-
ambulatory stages (Darras, 2018). Assistive technology and adaptive equipment can also 
enhance independence and participation in self-care tasks and leisure activities, as well as 
minimize some caregiving responsibilities. Simple adaptations to compensate for upper 
extremity weakness include elevated lap trays and/or desks, adaptive straws, plates, and utensils, 
and a hands-free water pouch. There is a wide range of technology that may benefit individuals 
with DMD such as fall detection systems with Global Positioning System, voice activation and 
texting systems on smartphones and tablets, eye gaze equipment for speech, tablet, and computer 
accessibility, and smart home systems that are compatible with motorized wheelchairs (Case et 
al., 2018). Home renovations may also be necessary to install equipment and modify 
environmental barriers (e.g., lifts for transfers, ramps, stair lifts, and special beds) in a way that is 
most suitable for the individual and/or the family (Svien & Stuberg, 2001).  
Respiratory Management 
Progressive weakness in respiratory muscles makes breathing difficult and subsequently 




ventilation bag or mechanical insufflation-exsufflation device) are needed to promote greater 
expansion of the lungs and chest wall (Chiou et al., 2017; Katz et al., 2015). Additionally, as the 
chest wall becomes stiffer, individuals experience difficulties clearing secretions from their 
airway (Tzeng & Bach, 2000), at which time, treatment with manual and mechanically assisted 
cough devices are beneficial (Bianchi & Baiardi, 2008; LoMauro et al., 2013; Miske et al., 
2004). By the late non-ambulatory stage, assisted ventilation is used to prolong survival (Phillips 
et al., 2001). Nocturnal noninvasive intermittent positive pressure ventilation (NIV) should be 
initiated when a child’s FVC is less than 50% (Birnkrant et al., 2018; Finder et al., 2004). 
Research has shown that NIV is generally well tolerated and it improves symptoms, sleep, 
quality of life (Baydur et al., 2000; Eagle et al., 2002), and survival (Passamano et al., 2012; Rall 
& Grimm, 2012). With declining pulmonary function, individuals often extend their use of 
assisted ventilation into the daytime, which ultimately, progresses to full-time use. Individuals 
are typically using most of these treatment options between the age of 18- and 21-years-old 
(Stehling et al., 2014). Both permanent NIV and tracheostomy increases the need for extensive 
support from caregivers, likely requiring 24-hour care (Gomez-Merino & Bach, 2002).   
Cardiac Management 
Given the fact that the signs and symptoms of heart failure often go unnoticed in this 
population, a proactive approach of early diagnosis and treatment is essential to maximize 
survival and quality of life. Baseline evaluation of cardiac function including an ECG or 
cardiovascular MRI (CMR) should be conducted at diagnosis or at the latest by age 6, with 
annual follow-up until the onset of abnormalities are noted on imaging (Birnkrant et al., 2015, 
2018). When symptoms of cardiomyopathy are detected on imaging, pharmacological 




or angiotensin receptor blockers (ARBs) are used to treat heart disease in patients with DMD 
(Allen et al., 2013; Ramaciotti et al., 2006). As the disease progresses, cardiac rhythm 
abnormalities may develop, which should promptly be investigated with Holter monitoring, a 
portable device that is worn to track heart activity, and treated with standard antiarrhythmic 
medications (Birnkrant et al., 2018; Corrado et al., 2002). 
Psychosocial Management 
Given the improvements in physical health and increased life expectancy of individuals 
with DMD, psychosocial functioning has garnered greater attention within the last decade. 
Developmental and neuropsychological evaluation can be beneficial in establishing baseline 
cognitive functioning and determining the need for community and educational supports. The 
Muscular Dystrophy Association has emphasized the value of a variety of classroom 
accommodations and adaptive equipment (e.g., a raised desktop or wheelchair tray, physical 
assistance for transfers, communication devices, an emergency evacuation plan, access to an 
elevator, and use of a note-taker or the ability to record lectures) to help facilitate access to the 
educational curriculum and maximize physical abilities (Heller et al., 2008). Although efforts 
have been made by local and national organizations to distribute information about the needs of 
boys with DMD in educational settings, the literature regarding school functioning and academic 
experiences in this population is scarce. A cross-sectional study of caregiver reports of the 
educational experiences of 179 school-aged boys with DMD across six states (Arizona, 
Colorado, Iowa, Georgia, Hawaii, and New York) was conducted through the Muscular 
Dystrophy Surveillance Tracking and Research Network. Results indicated that about a half of 
the respondents were receiving occupational and physical therapies, while almost 60% were also 




participating in a general education setting and more than a quarter of the boys had noted that 
they been retained at some point during their schooling. Researchers also examined access to at 
least two academic accommodations that tend to be reserved for children with a high level of 
special needs. Specifically, approximately 59% of respondents reported that they used a 
paraprofessional in general education classrooms and 58% had access to resource room support 
with an adapted educational curriculum. The majority of the boys with these accommodations 
were identified as non-ambulatory.  
Beyond academic needs, the prevalence of neurodevelopmental disorders and psychiatric 
conditions among children and adolescents with DMD warrants routine screening and 
assessment across the disease stages. Research has also demonstrated that family members are at 
increased risk for depression and anxiety (Abi Daoud et al., 2004; Bothwell et al., 2002; 
Landfeldt et al., 2016), particularly at major transitions in the disease progression; thus, their 
needs and psychological well-being should be evaluated regularly, and intervention or support 
offered. Measuring HRQOL has also been identified as a critical method for evaluating the 
subjective impact of DMD on the life of the affected child and their family (Guyatt, 1993). When 
concerns are identified, the mental health professional on the neuromuscular team should provide 
further evaluation and implement evidence-based cognitive or behavioral interventions to treat 
the comorbid psychiatric condition(s). Pharmacological interventions may also be necessary for 
individuals presenting with psychiatric symptoms.  
Given the degenerative nature of the disease and the extensive treatment demands, it is 
critical to examine the impact of DMD care and management on HRQOL. There needs to be a 
concerted effort to evaluate aspects of functioning beyond just the physical effects of DMD. 




decade, major milestones in diagnosis and disease management, particularly, the use of 
glucocorticoids and standardized care guidelines, have led to a considerable increase in life 
expectancy, with most living into their early 30s (Eagle et al., 2007; Passamano et al., 2012). 
With no cure, treatment is largely focused on prolonging survival, limiting the degree of 
impairment, and enhancing HRQOL (Birnkrant et al., 2018).  
Health-Related Quality of Life 
HRQOL has evolved from the concept of quality of life (QOL), which is described as a 
global dimension of well-being and satisfaction with life circumstances (Edwards et al., 2003). 
HRQOL does not typically involve areas associated with the broader aspects of QOL or non-
medical factors, such as cultural, political, or societal characteristics (Ferrans et al., 2005), as 
these variables cannot be addressed by medical intervention. Although varying definitions and 
conceptualizations of HRQOL exist, there is general consensus that HRQOL is a subjective and 
multidimensional measure of well-being that can be affected by illness, injury, and treatment 
(Kamphuis et al., 2002; Matza et al., 2004).  
There is mounting evidence supporting the utility of measuring HRQOL in pediatric 
healthcare, as a means to facilitate patient-provider communication, improve patient/parent 
satisfaction with medical care, assess intervention effectiveness, and assist in clinical decision-
making (Guyatt et al., 1993; Ronen et al., 2011; Varni et al., 2005). Patient-reported outcomes of 
HRQOL provide critical information about clinical outcomes and the patient experience with 
disease/treatment, all of which may not be readily apparent to the clinician. Thus, along with 
standard clinical measures, incorporating HRQOL into medical care can provide a more 




et al., 2013), leading to more opportunities for targeted interventions to improve health and well-
being (Phipps et al., 2002).  
Measurement of Health-Related  
Quality of Life 
 
Although there has been an increase in the number of HRQOL scales for use with 
pediatric populations (Drotar, 2004), there is variability in the definitions and approaches to 
measuring and assessing this construct. HRQOL instruments are commonly categorized as 
generic or disease-specific, but there is variability in the approaches to measuring and assessing 
pediatric HRQOL. Generic measures usually include an overall or total score across a broad 
range of domains including functional status, social functioning, psychosocial functioning, and 
family functioning (Andresen & Meyers, 2000). They are designed for use with healthy and 
pediatric populations, which allows for comparison of HRQOL scores across groups with 
various diseases and/or healthy controls (Solans et al., 2008). Commonly used generic 
instruments include the Child Health Questionnaire (CHQ-50; Landgraf et al., 1999), the 
Pediatric Quality of Life Questionnaire 4.0 Generic Core (PedsQL 4.0TM; Varni et al., 2001), the 
Child Health and Illness Profile (CHIP; Starfield et al., 1995), and the KIDSCREEN (Ravens-
Sieberer et al., 2005). However, these tools may lack sufficient sensitivity to detect the impact of 
a particular illness (Quittner et al., 2003). 
In contrast, disease-specific measures integrate items that are commonly associated with 
a certain medical condition (Levi & Drotar, 1999; Quittner et al., 2003). Advantages include the 
ability to identify treatment effects and clinically significant changes in a child’s condition or 
functioning (Eiser & Morse, 2001; Quittner et al., 2003; Spieth & Harris, 1996). However, they 
cannot be utilized for comparative analyses across different disease groups or with the general 




range of medical conditions including neuromuscular disorders (Varni et al., 2004), epilepsy 
(Cramer et al., 1999), cystic fibrosis (Modi & Quittner, 2003), and spina bifida (Parkin et al., 
1997).  
Historically, HRQOL has been assessed using parent proxy reports, which in recent 
years, researchers have begun to recognize the poor concordance between proxy-reports and 
child self-reports (Eiser & Morse, 2001). There is now general agreement that self-report is the 
“gold standard” for measuring HRQOL; thus, whenever the child is able and willing to complete 
self-reported HRQOL measures, it is the ideal option when collecting such data (Matza et al., 
2004; Varni et al., 2007). Regardless, obtaining reports from multiple informants (i.e., child and 
proxy reports) is still recommended to gain a more comprehensive perspective of the child’s 
HRQOL (Drotar, 2004; Eiser & Morse, 2001). When the child is too young, sick, or cognitively 
impaired to provide their own HRQOL, parent proxy measures are recommended (Varni et al., 
1999).  
Agreement between self-report and parent-proxy report of HRQOL in boys with DMD is 
inconsistent, with some empirical evidence indicating poor to fair concordance rates (Davis et 
al., 2010; Uzark et al., 2012; Wei et al., 2015) and others noting moderate to high (Bray et al., 
2010; Landfeldt et al., 2016; Lim et al., 2014). Despite this, the results of these studies revealed 
that children with DMD generally rate their HRQOL more favorably than their caregivers. This 
discrepancy is usually more pronounced for the psychosocial HRQOL domain. Researchers have 
hypothesized that parents’ fears, anticipatory grief, and concerns for their child may 
inadvertently affect their assessment of their child’s internal state (Wei et al., 2015). In contrast, 




led some to believe that parents are better at reporting on observable aspects of HRQOL (Bray et 
al., 2010; Uzark et al., 2012).  
Health-Related Quality of Life of Youth with  
Duchenne Muscular Dystrophy 
 
 Given the debilitating medical complications of DMD and treatment demands on daily 
functioning, assessment of HRQOL is critical and should be part of standards of care for this 
population. Literature regarding the HRQOL of children with DMD is somewhat conflicting, but 
likely reflective of the heterogeneity in the methodology (i.e., instrument, informant type) and 
the varying definitions/constructs of HRQOL. Comparative analyses have demonstrated that 
children and adolescents with DMD experience lower overall HRQOL than typically developing 
youth, normative samples (Bendixen et al., 2012; Bray et al., 2010; Davis et al., 2010; Henricson 
et al., 2013; Lim et al., 2014; McDonald et al., 2010; Uzark et al., 2012), and children with other 
chronic illnesses (Bray et al., 2011; Elsenbruch et al., 2013). Across the HRQOL domains (e.g., 
physical, psychological, social, etc.), differences in scores are most consistently observed in the 
areas related to physical functioning (Bendixen et al., 2012; Bray et al., 2010; Davis et al., 2010; 
Uzark et al., 2012). Analysis of psychosocial HRQOL has resulted in more inconsistencies 
across studies. For example, findings have largely revealed that children with DMD receive 
lower HRQOL psychosocial scores when compared to controls (Baiardini et al., 2011; Bendixen 
et al., 2012; Bray et al., 2011; Davis et al., 2010; McDonald et al., 2010), while others have 
found no differences across populations (Opstal et al., 2013; Vuillerot et al., 2010).  
Factors Associated with  
Health-Related Quality  
of Life 
 
In addition to investigating the HRQOL of youth with DMD as compared to unaffected 




disease-specific, and contextual factors associated with lower HRQOL. However, of the 
available research, the majority of studies have focused on disease characteristics as correlates of 
DMD including disease severity/disability level. Given the degenerative nature of DMD, age is 
frequently used as a proxy for disease severity/disability level. Due to the deterioration in 
physical functioning and the array of health complications associated with DMD, it is often 
assumed that HRQOL worsens with increasing age; however, this has not been clearly confirmed 
by the literature. In fact, some researchers have reported deterioration of HRQOL in at least one 
domain  
In a study of 35 parent-child dyads, younger boys (8 to 12 years) endorsed better physical 
HRQOL scores on the PedsQLTM 4.0 Generic Core scale (GCS) than older boys (13 to 17 years), 
but no differences were noted on the HRQOL Psychosocial Health Summary score (Bray et al., 
2010). Elsenbruch et al. (2013) also demonstrated that younger boys obtained lower HRQOL 
scores on all domains of the DISAKIDS Chronic Generic Module, while a social domain (i.e., 
social inclusion) was the most impacted area for adolescents. Interestingly, work conducted by 
Dutch researchers found that children and adolescents with various forms of muscular dystrophy 
(i.e., DMD, Becker muscular dystrophy, and limb girdle muscular dystrophy) reported higher 
scores on the physical symptoms domain of the TNO-AZL Children’s Quality of Life 
Questionnaire (TACQoL), when compared to a normative group (Grootenhuis et al., 2007). 
Another study using the same self-report measure revealed that older boys (13-18 years) 
endorsed better psychosocial HRQOL than in younger boys (8-12 years) (Uzark et al., 2012). 
Likewise, Hendriksen and colleagues (2009) found a similar trend of improved psychosocial 
functioning with age. This phenomenon of older children with deteriorating physical abilities 




“response shift,” which is thought to occur when the experience of living with an illness leads to 
changes in one’s internal standards and self-evaluation (Grootenhuis et al., 2007).  
Ambulation status (i.e., ambulatory or non-ambulatory) and ventilation usage (i.e., does 
not require ventilation or requires ventilatory support) have also been used as a measure of 
disease severity. According to Baiardini et al. (2011), wheelchair use and the need for a 
ventilator were found to be associated with parent-reported physical HRQOL scores on the 
Children Health Questionnaire-Parent Form 50. Specifically, 27 Italian caregivers rated boys 
who were using a wheelchair or ventilatory support as having a lower Physical Summary score 
than boys who were still ambulatory. A study by Mah and colleagues (2008) also established that 
ventilation usage was associated with HRQOL among Canadian children with Duchenne and 
Becker muscular dystrophies, as evidenced by the results revealing that youth who required 
ventilation received a significantly lower parent-proxy PedsQLTM 4.0 GCS Total Score than 
those not on such treatment. Davis et al. (2010) demonstrated that parent and child ratings on the 
PedsQLTM 4.0 GCS and a disease-specific HRQOL measure, the PedsQLTM 3.0 Neuromuscular 
Module (NMM), were indicative of reduced scores on the physical domains for those who were 
full-time wheelchair users. This finding was not maintained for psychosocial HRQOL scores, as 
no differences were found between children who were using a wheelchair and those who were 
ambulatory. Similarly, Kohler et al. (2005) used the Short Form-36 to investigate HRQOL in 35 
boys with DMD between the ages of 8- and 33- years-old. The researchers concluded that those 
who required assisted ventilation did not report significantly lower physical or mental health 
scores than those not requiring ventilation. However, the Short Form-36 is designed to assess 
HRQOL in adults; thus, it is unknown whether the results provide an accurate assessment of the 




Given that HRQOL is widely recognized as an outcome measure in healthcare, it is not 
surprising that there has been more interest in understanding how changes in clinical measures or 
possible functional changes relate to HRQOL. Overall, the physical domains of several HRQOL 
measures have been found to correlate with a measure of upper body strength (i.e., physical 
therapist-rated Vignos rating scale) (Bray et al., 2010) and timed functional performance 
measures (e.g., time to stand from supine, time to climb four stairs) (Elsenbruch et al., 2013; 
McDonald et al., 2010; Opstal et al., 2013). Among a small DMD sample (n=35) of boys from 
Australia (ages 9-17), child-reported Physical Health Summary Score of the PedsQLTM GCS was 
significantly correlated with the Vignos scale (Bray et al. 2010). In contrast, Elsenbruch et al. 
(2013) found no relationship between total self-reported HRQOL on the DISAKIDS chronic 
generic module and the Vignos scale in a German sample of 50 boys with DMD (ages 8-23). 
Researchers have had less success identifying correlations between clinical end points and 
psychosocial domains and overall HRQOL scores. However, a recent longitudinal demonstrated 
that at baseline the PedsQLTM GCS, PedsQLTM NMM, and the PedsQLTM Multidimensional 
Fatigue scale (MFS) were associated with the level of impairment in boys with DMD between 
the ages of 5 and 13 years. However, these findings were negligible at the 12-month follow-up.   
Beyond physical impairment and motor functioning, Lue et al. (2017) reported that pain 
has a significant impact on HRQOL and QOL scores with Taiwanese adolescents and young 
adults with DMD. A mixed methods pilot study with 12 young men between the ages of 11 and 
21 years-old found that the majority of the participants experienced significant daily pain (two-
thirds), largely in their legs and back (Hunt et al., 2016). Further, higher parent-reported pain 
frequency and severity was significantly correlated with lower self-reported QOL scores on the 




interview that pain often or always interfered with their sons’ ability to move, lay down, sit up, 
and sleep. Sadly, the assistive devices and medical procedures (e.g., splints, shower chairs, spinal 
rods) intended to foster independence and extend ambulation, were often described as 
exacerbating their pain. Another concerning finding was that many of these young men rarely 
spontaneously communicated when they were experiencing increased pain and discomfort with 
their parents, teachers, or medical professionals, despite the fact that they were limited in their 
ability to independently manage their pain. Consequently, parents noted that their sons’ pain 
often goes unrecognized until overt changes in their behavioral and emotional functioning are 
noticed (e.g., crying, emotional outbursts, withdrawn, grumpy). Consistent with these findings, 
research with adults living with different muscular dystrophies and other neuromuscular 
disorders have indicated that higher rates of pain are associated with lower HRQOL 
(Grootenhuis et al., 2007; Jensen et al., 2005; Pangalila et al., 2012).  
Contextual Factors 
The physical and psychosocial consequences associated with DMD and other chronic 
diseases extend beyond the individual, impacting a wide range of personal and family aspects of 
life. From a bioecological perspective, a serious stressor, like a chronic childhood disease, plays 
a significant role in the family’s social environment and larger context, which reciprocally 
impacts the child and their experiences (Bronfenbrenner, 1979). Although the majority of 
research on HRQOL in youth with DMD has primarily focused on demographic and clinical 
variables, some studies have begun to assess the role of contextual social-environmental factors. 
For example, Wei and colleagues (2016) explored child and parent-reported HRQOL in 99 
Canadian families of boys with DMD. When compared to a normative sample, child and parent-




physical functioning, emotional functioning, social functioning, and school functioning), with the 
largest difference observed on the Physical Health Summary score. The Social Functioning scale 
was the only psychosocial domain that fell below the cut-off score, which the authors postulated 
was likely related to the physical limitations and/or cognitive deficits commonly seen in this 
population. 
Due to the exploratory nature of the study, the authors used multiple regression with 
backwards elimination to identify a subset of clinical and family variables that were associated 
with child self-reported and parent-proxy reported HRQOL across five scores: Pediatric Quality 
of Life (PedsQLTM) 4.0 Generic Core total score, PedsQLTM 4.0 Generic Core Physical Summary 
score, PedsQLTM Generic Core Psychosocial Summary score, PedsQLTM 3.0 Neuromuscular 
Module Total score, and PedsQLTM DMD Module Total score. In terms of sociodemographic 
variables, the results revealed that parental education level, annual household income, and family 
stress (i.e., Family Inventory of Life Events and Changes (FILE) were the only family 
characteristics that correlated with some of the HRQOL scores. This is one of the few studies 
that made an effort to investigate family characteristics that impact HRQOL through the use of 
both child and parent reports, but these variables were largely limited to demographic 
information (e.g., annual household income, marital status, employment status, and educational 
level). Although the FILE was included as an index of family stress, it is a unidimensional 
instrument that measures general life stressors, not the impact of pediatric chronic conditions on 
parent and family functioning. 
Another international cross-sectional study by Otto et al. (2017) investigated the 
influences of sociodemographic, disease-specific, and social-environmental factors on HRQOL 




Germany, Hungary, Poland, Czech Republic, and United Kingdom). Over 300 participants were 
recruited via national DMD patient registries, but the majority of the questionnaires were 
completed by parents or caregivers. Several HRQOL measures were used in this study including 
the KIDSCREEN-10 index, the Pediatric Quality of Life Inventory (PedsQL), and the 
Neuromuscular Module of the PedsQL (NMM). The results revealed that boys with DMD from 
households with middle to high income levels endorsed better overall HRQOL scores on the 
KIDSCREEN-10 index when compared to boys from low income households. Further, better 
HRQOL on the KIDSCREEN-10 index, the PedsQL Total Score, and the PedsQL Psychosocial 
Summary Score were reported by boys who spent 6–7 days outside of the home compared to 
those who usually spent little time outside the home. Higher HRQOL scores on the 
KIDSCREEN-10 index, the PedsQL Total Score, and the PedsQL Psychosocial Summary Score 
were also indicative of a better perceived community attitude of boys with DMD compared to 
those who felt that community members rarely or never viewed the person with DMD on equal 
terms. These results suggest that income, involvement in activities outside the home, and the 
perception of the attitudes of the community towards families and their children with DMD may 
affect the HRQOL of this pediatric population, which highlights the value of examining the 
family context and environmental factors in relation to HRQOL in boys with DMD. 
Limitations of Previous Studies 
The research on HRQOL among children and adolescents with DMD is still relatively 
new, but there are a number of limitations of the existing body of literature that must be 
considered. It is important to note that the PEDSQL questionnaires are the only HRQOL 
measures that have been specifically validity with this pediatric population (Davis et al., 2010). 




for DMD youth. Furthermore, many of the studies have relied solely on proxy reports, which as 
was previously discussed, is problematic because caregivers often underestimate their child’s 
HRQOL. Another issue that cannot be overlooked is the use of one method to generate 
information on both dependent and independent variables, as it introduces common method 
variance due to single source bias (Podsakoff et al., 2003).  
Given that DMD is a rare disease, it is not surprising that several researchers have 
attempted to increase their sample sizes by including participants with other neuromuscular 
diagnoses; however, this makes it challenging to elucidate the HRQOL of boys with DMD. 
Recruitment of participants through national registries have also commonly been used in 
previous research, which naturally can lead to selection bias, minimize the diversity of the 
sample, and reduce the diagnostic uncertainty of the participants. A clinic-based sample may 
allow for a more representative sample and the ability to confirm participants’ diagnostic profile.  
Although the available studies have provided valuable information, many of the socio-
environmental variables that have been included are generally non-modifiable (i.e., 
demographic) and/or do not capture the larger family context within which children and 
adolescents with DMD function. In fact, very few studies have comprehensively assessed the 
influence of the family environment and other parent variables on HRQOL in youth with DMD. 
There is a need for a more comprehensive examination of HRQOL from both children’s and 
parent’s perspectives and exploring factors that are associated with HRQOL. 
Summary 
The literature has generally established that youth with DMD report reduced HRQOL 
when compared to their healthy counterparts and youth with other chronic illnesses. Within 




tend to endorse lower levels of physical HRQOL. Psychosocial HRQOL across the disease is 
more variable, with some studies acknowledging better scores among older children and others 
reporting no differences. Similarly, several clinical measures of strength and functioning have 
been found to be associated with physical domains of HRQOL, but the same cannot be said for 
psychosocial HRQOL. Poor agreement among self- and parent-reports of child and adolescent 
HRQOL within this pediatric population have also been noted. Despite the importance of 
parents’ in the lives of their children, especially those with DMD, there is little information 
known about the effects of family functioning and parental well-being on the HRQOL of boys 
with DMD. Thus far, extant research has largely focused on demographic and illness-specific 
variables, but elucidating factors that are potentially and more readily modifiable may prove to 
be particularly important in informing the development of interventions that are tailored to the 
unique needs of the child and their family. Thus, this study seeks to examine how child (i.e., age 
and presence of pain) and family variables (i.e., family functioning) impact the HRQOL of boys 



















METHODOLOGY   
This chapter outlines the participants, setting, instrumentation, and procedures that were 
used in this study to sufficiently answer the research questions. The procedure for recruiting 
participants and collecting data is also presented. Lastly, a broad overview of the plan for data 
analysis is provided. This study examined the influence of pain, family functioning, and/or 
disease severity (i.e., age) on physical and psychosocial HRQOL scores within this medically 
complex population. 
Participants and Setting 
Given that DMD is a rare disease, a nonprobability convenience sampling technique was 
used to recruit this targeted population of children and adolescents with dystrophinopathies and 
their families. This study was conducted at a multidisciplinary neuromuscular outpatient clinic at 
a private, nonprofit hospital located in the western region of the United States. The hospital 
serves a seven-state catchment area that covers urban, suburban, and rural populations with 
families from a diverse range of races/ethnicities and socioeconomic levels. This clinic is 
designated as a Muscular Dystrophy Association (MDA) Care Center, which means it is one of 
the less than 200 sites in the United States that offers multidisciplinary care from healthcare 




clinic are generally seen every six or twelve months by the multidisciplinary team. The team is 
comprised of healthcare providers from the following disciplines: neurology, rehabilitation 
medicine, pulmonary, physical therapy, respiratory therapy, clinical nutrition, neuropsychology, 
social work, and genetic counseling. The contribution of each team member may vary based on 
the child’s health status.  
Patients were eligible for participation, if they were male between the ages of 5 and 25 
with a confirmed genetic diagnosis of a dystrophinopathy and attended their clinic appointment 
with a parent or caregiver. Due to the genetic nature of the disease, it is not uncommon for 
families to have multiple children with a dystrophinopathy; thus, all children who met eligibility 
criteria were asked to participate. Female patients, patients with other neuromuscular disorders, 
non-English speaking patients, and those who did not attend clinic with a parent or caregiver 
were excluded from this study. Patients who participated in virtual clinic visits were also not 
asked to participate.  
An a priori power analysis was performed for sample size estimation using G*Power 3.1 
(Faul et al., 2009). The alpha utilized for this analysis was .05, as this is the accepted standard in 
the behavioral sciences (Cohen et al., 2003). Similarly, as it is the recommended criterion in the 
behavioral sciences, power was set at .8 (Cohen, 1988). An effect size of f 2=.35 was chosen for 
this study to detect large effects. Thus, with these numbers entered into G*power’s linear 
multiple regression: fixed model, R2 increase test, the suggested sample size was calculated at 
46. However, due to COVID-19 the sample size was smaller than expected.  
Procedures 
Institutional Review Board (IRB) approval was obtained concurrently from the 




conducting data collection. Potential participants were identified from the clinic schedule, and 
the clinic coordinator was also consulted to assess families’ eligibility for the study. As children 
and their families arrived for their regularly scheduled clinic visit and were placed in a private 
exam room, a research team member explained the purpose and nature of the study and the 
requirements for participation. The research team members were trained in the process of 
informed consent and HIPAA research guidelines, as well as the standards of the sponsoring 
IRBs. Participants were informed that consent to participate was completely voluntary and that 
they were under no obligation to disclose information or complete any questions that made them 
feel uncomfortable. Similarly, it was emphasized that their participation, refusal, or withdrawal 
from the study would not influence their current and/or future ability to access medical treatment 
with the clinic or hospital. For interested families, parental informed consent (Appendix B) 
and/or youth assent (Appendix B) was obtained, prior to the distribution of measures. For 
methodological purposes, only one parent’s participation from each household was requested.  
Children and their caregivers completed a set of questionnaires in paper form, which 
were counterbalanced to control for order effects. Parents and children were instructed to 
complete the measures independently. In instances where the research team member and/or 
family determined that a patient was unable to complete the questionnaires due to low cognitive 
functioning, parents were still offered the opportunity to complete the questionnaires designated 
for parent participants. Parents were asked to complete a demographic questionnaire (Appendix 
C) and two instruments: The PedsQLTM 4.0 Generic Core scales and the PedsQLTM 2.0 Family 
Impact Module. Children completed The PedsQLTM 4.0 Generic Core scales. Medical chart 




Due to the sensitive nature of the data collected, specific measures were taken to ensure 
that the confidentiality of participants and their families were maintained. Individual names were 
not included on any of the questionnaires, instead a unique identifying number was generated for 
each participant and their family and was used in place of their names on all data and 
questionnaires. To allow for medical chart abstraction, a list linking the participants’ name to 
their identifying number was stored in a password protected excel spreadsheet and saved on an 
encrypted hospital computer and server. The relevant medical information that was extracted 
from participants’ electronic medical charts and the data from the completed questionnaires were 
entered into a HIPAA-compliant database, Research Electronic Data Capture (RedCap). The 
completed paper questionnaires and informed consents/assents were stored in a locked filing 
cabinet. Further, the consent/assent forms were removed from the rest of the raw data and stored 
separately to ensure confidentiality of the participants. 
It is important to note that shortly after IRB approval, a global pandemic (i.e., COVID-
19) occurred and the hospital temporarily shut down all non-essential research for several 
months. Eventually, hospital research re-entry procedures were implemented, but limitations 
were placed on the number of providers and patients that could be present in clinic at one time. 
Efforts were also made to decrease the amount of time that patients and their families were 
spending in clinic by offering telehealth appointments when feasible and/or eliminating their 
visits with providers for non-emergent needs. Consequently, the anticipated sample size was not 
achieved, data collection occurred across fewer months, a measure was eliminated, and the 







This study used data from a set of demographic questions and two measures that examine 
HRQOL and family functioning. Additionally, disease-specific information was extracted from 
patients’ medical charts.  
Demographic Questionnaire  
Parents completed a demographic questionnaire (Appendix C), which was used to gather 
information regarding their child’s age, race and ethnicity, primary language, gender, grade 
level, age of diagnosis, ambulation status, recent need for emergency services, current 
educational supports, and family characteristics (e.g., annual household income, employment 
status, parental marital status, living arrangements, parental mental health, primary language 
spoken in the home, and parental education level, and maternal disease carrier status).  
Disease-Specific Indicators  
Electronic medical chart abstractions were conducted to obtain information about disease 
characteristics and associated variables for all participants including history of glucocorticoid 
use, respiratory status, and the total number of comorbid medical, neurodevelopmental, and 
psychiatric diagnoses.  
Pediatric Quality of Life Inventory (PedsQLTM) 
The PedsQLTM offers a collection of generic and disease-specific instruments that 
measure HRQOL in healthy children and adolescents and those with medical conditions. The 
PedsQLTM 4.0 Generic Core scales were developed to be used along with the PedsQLTM Disease-
Specific Modules. Unless otherwise stated below, the information described in this section 
applies to all the PedsQLTM instruments that were used in this study. Across the questionnaires, 




(5-7 years-old), child (8-12 years-old), teen (13-18 years-old), young adult (18-25 years old), and 
adult (ages 26 and older). A 5-point Likert scale is utilized across child self-report for ages 8 to 
18 and parent-proxy report, with responses ranging from “Never” (coded 0) to “Almost Always” 
(coded 4). Child self-report for ages 5 to 7 uses a 3-point Likert scale with responses ranging 
from “Not at all” (coded as 0) to “A lot” (coded 4). Visual anchors are also provided with the 
response options for this younger age group. In terms of scoring, items are reverse scored and 
linearly transformed to a 0-100 scale (i.e., 0=100, 1=75, 3=25, 4=0), with a higher score 
indicating better HRQOL. It is recommended that scale scores are not computed if more than 
50% of items in the scale are missing. The PedsQLTM scales are protected by copyright and the 
conditions of use for non-funded academic research requires electronic completion of a user 
agreement (Appendix D).  
Generic Health-Related  
Quality of Life  
 
Child self-report and proxy-report versions of the PedsQLTM 4.0 Generic Core scales 
were used to measure general HRQOL (Varni et al., 2001). This instrument was developed for 
application with both healthy and pediatric patient populations, but it was not intended to provide 
detailed information on the specific factors that influence HRQOL in youth with chronic 
diseases, like DMD (Iannaccone et al., 2009; Varni et al., 2001). Consistent with the World 
Health Organization’s core dimensions of health, this 23-item instrument allows parents and 
children to rate their or their child’s functioning during the past month across specific domains: 
physical (8 items), emotional (5 items), social (5 items), and school (5 items). It takes 
approximately 5 to 10 minutes to complete and provides three overall scores. The Psychosocial 
Health Summary Score is obtained by calculating the average of the items across the Emotional, 




items on the Physical Functioning scale. The Total Score is obtained by calculating the average 
of all the items. Higher scores are indicative of better HRQOL. The Peds-QLTM 4.0 Generic Core 
scales have been shown to have adequate internal consistency for the Total Summary Score 
(youth self-report: a=.88; parent report: a=.90), Physical Health Summary Score (youth self-
report: a=.80; parent report: a=.88), and Psychosocial Health Summary Score (youth self-report: 
a=.83; parent report: a=.86). (Varni et al., 2001). researchers explored cut-off point scores for 
designating Psychosocial HRQOL Health Summary scores as impaired among children in the 
general pediatric population. 
Family Functioning and  
Well-Being 
 
The PedsQLTM 2.0 Family Impact Module (FIM; Varni et al., 2004) is a measure of 
parents’ perceived HRQOL and the impact of their child’s chronic medical condition on family 
functioning during the past month. The FIM includes 36 items across eight dimensions: Physical 
Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive 
Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items), 
and Family Relationships (5 items). The Parent HRQOL Summary Score is obtained by 
calculating the average of the items across the Emotional, Social, and Cognitive Functioning 
scales. The Family Functioning Summary Score is the average of the items on the Daily 
Activities and Family Relationships scales. The Total Score is obtained by calculating the 
average of all the items. Higher scores are indicative of better functioning. The initial validation 
study reported internal consistency estimates across the FIM scales ranging from .82 to .97 







 The current study utilized a quantitative and cross-sectional research design with 
information from parents, children, and medical records to address the specific research 
questions. A cross-sectional design was deemed suitable for this exploratory study that attempted 
to identify patterns and relationships between multiple variables (Somekh & Lewin, 2005). 
Given that this study was conducted in a hospital setting during patients’ clinic visits, a survey 
method and medical chart abstraction was selected due to the minimal time commitment required 
for participation and the identification of validated methods of measurement that target the 
selected variables. 
Data Analysis 
All questionnaire and demographic data were analyzed with the IBM Statistical Package 
for Social Sciences (SPSS) version 27. Data was checked for completeness prior to entry and 
double-checked after entry. The scoring guidelines for each instrument were used to generate 
total scores and subscale scores. Univariate analyses were used to explore characteristics of the 
sample, disease-specific variables, and all survey data (i.e., mean and standard deviation for 
continuous variables and frequencies and percentages for categorical variables). Further, the 
reliability of the instruments were examined using Cronbach’s alpha in order to provide 
information about the reliability of the investigated measures in the analyzed sample. Pearson 
product-moment correlations were used to determine the strength and direction of the 
relationships between continuous variables. Point-biserial correlations were conducted between 
continuous variables and dichotomous variables. All the demographic data and disease-related 
variables were dummy-coded, with the exception of caregiver age. All inferential statistical 




Simultaneous multiple regression was selected as the main method of data analysis 
because it has been identified as a powerful tool when conducting explanatory research to 
determine the influence of one or more independent variables on an outcome (Keith, 2006). 
Further, this data analysis technique enables the researcher to establish the overall effect of all 
the variables and the effect of each variable (Keith, 2006). Given that HRQOL is an emerging 
area of interest with pediatric populations, even more so for this rare disease, the literature is still 
limited; thus, this study is exploratory. As such, the variables were largely chosen on the basis of 
clinical experience, expert opinion, and research with other chronic pediatric diseases.  
Prior to examining each of the multiple regression analyses, the necessary assumptions 
were tested and are described below in the results section. Four separate regression analyses 
were conducted to investigate the influence of age, pain, and/or family functioning on the parent- 
and child-reported scores on the PedsQLTM 4.0 GCS psychosocial domain and the PedsQLTM 4.0 
GCS physical domain. All the applicable variables were entered into the models simultaneously. 
The F-test was used to assess whether the variables were significantly contributing to the 
explanation of the HRQOL scores. Next, R-squared, was assessed to determine how much 
variance in the dependent variables, HRQOL scores, were accounted for by the independent 
variables. The regression coefficients were used to determine the relative importance of each 
variable and the magnitude of their effects. Bonferroni corrections were applied to account for 
















The current sample consisted of 44 parents/caregivers and 39 patients between the ages 
of 6- and 25-years old (M=14.02; SD=4.81), who have a confirmed genetic diagnosis of a 
dystrophinopathy. Four of the participants had a diagnosis of Becker Muscular Dystrophy 
(BMD) and the remainder of the sample had Duchene Muscular Dystrophy (DMD). As 
documented in the literature review, children with a diagnosis consistent with Becker tend to 
have less severe physical outcomes and a slower disease progression than commonly associated 
with DMD. Although the inclusion of these participants in the sample may have skewed the data, 
the researcher opted to include these participants in the analyses due to the small sample size and 
the lack of research that is available on the psychosocial outcomes of this population.  
The sample was comprised of boys who largely identified as White or Caucasian (n=26; 
59.1%). Participants’ age at initial diagnosis ranged from 1- to 9-years-old (M=4.86; SD=2.45), 
and the time since diagnosis, which was calculated by subtracting their current age from their age 
at diagnosis, ranged from 1- to 21-years-old (M=9.20; SD=5.24). Regarding disease-specific 
characteristics, the majority of the patients in this study use a wheelchair full-time (n=22; 50%), 




devices (n=30; 68.2%). Most of the participants indicated that they have not been seen in an 
emergency department (n=40; 90.9%) nor have they been hospitalized (n=41; 93.2%) within the 
last 12 months.  
The median number of psychiatric and/or neurodevelopmental diagnoses and medical 
conditions in the sample was one (SD=1.54; Range=0-6) and four (SD=2.53; Range=0-11), 
respectively. Over seventy-five percent (n=34) of the boys had at least one psychiatric condition 
or neurodevelopmental disorder. Some of the diagnoses that were listed in patient medical charts 
included attention-deficit/hyperactivity disorder (n=12; 27.27%), learning disabilities (n=9; 
20.45%), anxiety disorders (n=6; 13.64%), intellectual disability (n=6; 13.64%), autism spectrum 
disorder (n=5; 11.36%), speech-language disorders (n=5; 11.36%), and depression (n=3; 6.82%). 
Similarly, over 95% (n=42) of patients had been diagnosed with secondary conditions associated 
with their dystrophinopathy (e.g., heart-related issues (n=18; 46.15%), obesity (n=19; 48.72%), 
scoliosis/spinal curvature (n=15; 38.46%), osteoporosis (n=6; 15.38%), sleep disorders (n=11; 
28.21%), and restrictive lung disease (n=23; 58.97%). The grade levels of the boys in this sample 
spanned from kindergarten to college, but there were also six older participants who were not 
enrolled in any educational programming. Of the participants currently attending elementary and 
secondary school, the majority had formal supports and services via an Individualized Education 
Program (IEP; n=27; 61.4%) or a Section 504 Plan (n=4; 9.1%), but seven of the boys were not 
receiving academic accommodations (15.9%). However, it is important to note that two of these 
boys were attending college and could have been receiving accommodations in this setting, but 
this information was not obtained. 
The parent/caregiver participants primarily indicated that they were their child’s mother 




Caregivers ranged in age from 31- to 69-years-old (M=44.41; SD=8.63) and largely identified as 
White, Non-Hispanic (n=28; 63.6%). Most participants noted that they were married (n=33; 
75%) and part of a two-parent household (n=36; 81.8%). Half of the sample acknowledged that 
they were employed full- (n=26; 59.1%) or part-time (n=11; 25%), meaning that more than 84% 
of caregivers were employed. No information was available regarding their partners’ 
employment status. Most respondents had received some form of post-secondary education 
(n=34; 77.2%). In terms of annual household income, approximately 30% (n=13) reported an 
income between $75,000 and $99,000. One individual opted to not disclose information 
regarding their current income.  
Participants were also asked to provide information regarding specific aspects of their 
own mental health and genetic testing for disease carrier status. A quarter of caregivers reported 
a history of diagnosed mental health problems (n=11). Interestingly, seven of the female 
caregivers with a mental health diagnosis had not undergone carrier genetic testing. Given that 
DMD is often inherited from a “carrier” mother, the decision to complete genetic testing can be 
emotional, with mothers of children with DMD potentially experiencing guilt and self-blame for 
learning that they passed the defective gene to their son (Lehmann et al., 2011). However, testing 
may also help to alleviate these feelings and provide a sense of control when making decisions 
regarding family planning (Colvin et al., 2018). Carrier genetic testing had been completed 
within most of the families in this study (n=26; 59.1%), with female caregivers most commonly 
having been assessed (n=21; 80.8%). Over 65% (n=17) of those who were tested obtained 
positive results for a mutation in the DMD gene. Of the female caregivers who tested positive for 
a mutation in the DMD gene, three had a formal mental health diagnosis. Participants’ 





Demographic information and clinical characteristics of participants 
 
Category          n   M (SD)  %  
     
Patients’ Age         39   14.02 (4.81) 
Race 
 Asian/Pacific Islander       1      2.3  
 Hispanic or Latino                     13      29.5 
 More than one race       4      9.1 
 White, Non-Hispanic       26      59.1 
 
Age of Diagnosis       4.86 (2.45) 
  
Ambulation Status     
 Walking              9      20.5 
 Walking with the use of             1      2.3 
  Orthotics 
 Intermittent wheelchair use            12      27.3 
 Full-time wheelchair use            22      50.0 
 
Number of Psychiatric Conditions/  
Neurodevelopmental Disorders  
 0         10      22.7 
1-2         24      54.5 
3-4         7      15.9 
 5-6         3      6.8  
 
Number of Medical Conditions 
 0         2      4.5 
 1-2         7      15.9 
 3-4         14      31.8 
 5-6         14      31.8 
 7-8         3      6.8  
 9-11         4      9.2 
 
Grade 
 Kindergarten-5th              12      27.3  
 6th-8th          10      22.7 
 9th-12th               14      31.8  
 College              2      4.5 
 Not enrolled        6      13.6 
 
Educational Supports 
IEP         27      61.4 
 Section 504 Plan            4      9.1 
 None         7      15.9 
Not enrolled        6      13.6 
 
Caregiver  
 Mother         36      81.8 
 Father         6      13.6 





Table 4.1, Continued 
Demographic information and clinical characteristics of participants 
 
Category          n   M (SD)  %  
 
Caregiver Age       44.41 (8.63)    
Relationship Status     
Single         8      18.2 
Living with partner       3      6.8 
Married              33      75.0 
 
Educational Status 
 6th-8th grade        1      2.3 
 9th-12th grade        4      9.1 
 High school graduate       5      11.4 
 Some college or certification      12      27.3 
 Associate degree             3      6.8 
 Trade/Vocational Training            4      9.1 
 Bachelor’s degree       8      18.2 
Graduate or professional                    7      15.9 
             degree 
 
Family Annual Income 
 $20,000 to $34,999       6      13.6  
 $35,000 to $49,999       5      11.4 
 $50,000 to $74,999       9      20.5 
 $75,000 to $99,999      13      29.5 
 Over $100,000       10      22.7 
 
Employment Status 
 Full-time       26      59.1 
 Part-time       11      25.0 
 Unemployed        2      4.5 
 Retired        1      2.3 
 Homemaker       4      9.1 
 
Household Composition 
 Two-parent household          36      81.8 
 One-parent household      8      18.2 
 
Genetic Carrier Testing 
 Yes        26      59.1 
 No        18      40.9 
 
Results of Carrier Testing (n=26) 
 Positive for a DMD mutation     17      65.4  
 Negative for a DMD mutation         9      34.6 
 
Parental Mental Health Diagnosis 
 Yes        11      25.0 







The PedsQLTM 4.0 Generic Core scales and the PedsQLTM 2.0 Family Impact Module 
were scored using the instruments’ guidelines and composite and subscale scores were generated 
to use as the dependent variables and/or independent variables. All reliability estimates using 
Cronbach’s alpha fell above the recommended minimum (≥ .70). The child version of the 
PedsQLTM 4.0 Generic Core scales demonstrated good internal consistency for the psychosocial 
score (α = .85) and total score (α = .83). The physical score generated the lowest internal 
consistency, although it still fell within the acceptable range (α = .78). The parent version of the 
PedsQLTM 4.0 Generic Core scales was also indicative of adequate internal consistency across 
the physical (α = .82) and psychosocial (α =.89) scales and the total score (α =.87). Regarding 
the PedsQLTM 2.0 Family Impact Module, the reliability analyses for the Parent HRQOL 
subscale (α = .95) and Family Functioning subscale (α = .93) were excellent. The Total Impact 
Score also yielded strong internal consistency (α = .96).  
As presented in Table 4.2, correlational analyses were examined to assess the 
relationships between HRQOL scores and patient (i.e., age and presence of psychological and 
neurodevelopmental conditions) and environmental (i.e., parent HRQOL and family functioning) 
variables. Given the smaller than expected sample size, it was important to closely evaluate these 
univariate analyses to determine the appropriateness of using all of the potential predictors in the 
regression models. Child-reported and parent-reported Psychosocial Summary Scores were 
positively correlated with age, suggesting that as patients get older, better psychosocial well-
being is observed from the perspectives of patients and caregivers. Age was negatively correlated 




physical HRQOL score tend to be lower. Interestingly, age was not found to be related to the 
Physical Health Summary Score as reported by parents. Family functioning and parent HRQOL 
were positively correlated with the child-reported psychosocial  and physical scores. Similarly, 
parent-reported psychosocial and physical scores were positively associated with family 
functioning and parent HRQOL. Thus, better family functioning and parent well-being were 
related to higher ratings on the psychosocial and physical domains from the perspectives of both 
patients and caregivers. The presence of neurodevelopment disabilities and psychiatric 
conditions were not correlated with any of the HRQOL scores. Thus, given the exploratory 
nature of the study, the unanticipated smaller sample size, and the lack of associations between 
this variable and any of the HRQOL scores, this researcher opted to not include it in any of the 
regression analyses. Additionally, due to the strong correlation between parent HRQOL and 
family functioning (r=.714, p=.000), as well as the overlapping items between the HRQOL 
measure and the FIM, this researcher opted to remove parent HRQOL as a variable in these 
analyses to avoid any potential issues with multicollinearity. 
Table 4.2 
Correlations of Variables  
 









Participants’ Age .400** -.324* .392** -.150 
 




.244     
 
.016         
 
.109     
 
-.048         
Family Functioning Score  .312*        .336*        .595**      .353*      
 






.527**      
 
.264*       
* Correlation is significant at the 0.05 level (2-tailed). 





 Additionally, efforts were made to examine the relationships between some of the 
demographic data, disease-related variables, and the HRQOL scores to determine the need to 
enter any of these variables into the regression models. Variables that were significant at a p 
value of  ≤ 0.005 were included in the appropriate model. All variables were dummy-coded so 
that they were dichotomous, with the exception of caregiver age. Relationship status and 
household composition were associated with the parent-reported Physical Health Summary 
Score, meaning that parents in a relationship/married and caregivers of two-parent households 
endorsed higher scores on the physical domain. No associations were identified between annual 
income level and the HRQOL scores. Caregiver age was positively correlated with patient- and 
parent-reported psychosocial well-being. However, caregiver gender and parental mental health 
status (i.e., the presence of a formal diagnosis) were not related to HRQOL domains. Regarding 
disease-specific variables, pain was correlated with patient ratings on the psychosocial  domain, 
indicating that youth reporting lower levels (i.e., “Never” or “Almost Never”) of pain had higher 
psychosocial scores. Pain was also significantly correlated with parent-reported psychosocial 
scores. In contrast, relationships between steroid usage, sleep problems, and HRQOL scores 
were not detected in this study. 
Table 4.3 




Annual Income  
Household Composition 



















































Table 4.3, Continued 
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Patient: 






































           -.104 
 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
 
Participants were asked to complete the PedsQLTM 4.0 Generic Core scales to assess the 
HRQOL of this medically complex population from the perspectives of patients and their 
caregivers. Completed measures were obtained for 39 children and 44 parents. Five of the 
patients did not complete this measure for various reasons. Two of the children were young (ages 
6 and 7) and were reportedly unwilling to complete the measure. One of the patients’ parents 
were not comfortable with their child completing the measure because they stated that reflecting 
on these areas would “make him sad.” The two other participants that did not complete the 
measure had a diagnosis of an intellectual disability; thus, the family and/or the research team 
determined that the children may struggle to understand the questions.  
As shown in Table 4.3, mean scores of parent ratings were slightly lower across all 
HRQOL domains when compared to the child’s self-reported scores, with the largest difference 
noted for the Psychosocial Summary Scores. Cut-off point scores from a validation study of the 
PEDSQL 4.0 Generic Core Scales (Varni et al., 2003) were developed to identify individuals 




deviations for children from the validation sample with at least one chronic medical or 
psychiatric condition (e.g., ADHD, asthma, diabetes, depression, or “other”). In this study, 
nearly 65% (n= 25) of pediatric patients’ overall psychosocial score (i.e., Psychosocial HRQOL 
Health Summary Score) fell below the clinical cutoff (<66.03), while over 72% (n=32) of parent 
scores were lower than the cut-off (<64.38). According to the cut-off scores for the psychosocial 
subscale scores, the most problematic area was the social domain, with nearly 75% (n= 22) of 
patients’ and parents’ (n=33) scores below the clinical threshold (<66.61 and <62.07, 
respectively). The emotional subscale was the domain that led to the largest discrepancy between 
the respondents, as 46% (n=18) of child scores (<59.57) and 61% (n=27) of parent scores 
(<63.29) were considered impaired. Although the school subscale score was clinically impaired 
(<62.99) for nearly 45% of children, it was the area that the fewest number of participants 
identified as an area of concern (n=17). In contrast, 50% (n= 22) of parent scores for the school 
domain were impaired (<56.75). Regarding physical functioning, scores were comparable across 
both groups, with 100% of patient ratings and over 95% of parent ratings below the clinical 
cutoff for physical impairment (<72.98 and <63.28, respectively). Overall, pediatric patients and 
their caregivers reported low levels of physical and psychosocial HRQOL. Child scores were 
higher than parent ratings of psychological functioning (e.g., emotional, social, and school 
functioning), suggesting that children perceive their psychological well-being as being better 


































































Regarding the PedsQLTM 2.0 Family Impact Module, 44 caregivers completed this 
measure to assess parents’ perceived HRQOL and family functioning within the context of a 
family with a child with a chronic medical condition. Clinical cutoffs have not been established 
for this instrument, but mean scores across most scales were lower for this sample than for other 
studies using the same measure with families of pediatric populations. For example, a 
preliminary study from Varni and colleagues (2004) found that 11 caregivers with children with 
various severe medical conditions (e.g., cerebral palsy and birth defects) obtained a mean Parent 
HRQOL Summary Score of 62.94 (standard deviation (SD)=19.83), a Family Functioning Score 
of 68.81 (SD=24.11), and a Total Impact Score of 62.49 (SD=7.26). Similarly, 69 families with 
children who were post heart-transplant (mean time since transplant was about 4 years) obtained 




75.5 (SD=21.8), and a Total Impact Score of 70.9 (SD=17.1) (Tadros et al., 2020). Given the 
terminal and progressive nature of DMD and the associated treatment demands, it is not 
surprising that caregivers generally reported lower scores than parents with children with other, 
potentially less severe diagnoses. 
Table 4.5 
 
The PedsQLTM 2.0 Family Impact Module 
 
 Mean SD 
 
Parent HRQOL Summary Score 63.55 18.37 
     






























































Simultaneous multiple regression was utilized to determine the extent to which age (i.e., 
proxy for disease severity) and specific environmental variables were associated with the 
PedsQLTM 4.0 GCS Psychosocial Summary Score and Physical HRQOL Summary Scores as 




expected sample size with a disproportionately higher number of participants whose ambulation 
status was limited, the differences between the Psychosocial Summary Scores and Physical 
Summary Scores for both parent and patient ratings were quite pronounced. Deriving an overall 
mean functioning score would not have reflected a meaningful representation of the child. 
Therefore, the PEDSQL Total Scores were not considered clinically meaningful and ultimately 
led this researcher to conduct the analyses with each separate score (Psychosocial Total and 
Physical Total). Bonferroni correction was applied because four separate regressions were 
conducted. Thus, the significance level of p < .05 was divided by the number of regression 
analyses to determine the new significance level of p < .0125. Additionally, due to the 
relatedness of the parent HRQOL and family functioning, this researcher opted to eliminate 
parent HRQOL as a predictor to avoid the measures confounding the individual effects of each 
construct.  
Prior to examining each of the multiple regression analyses, the data were evaluated to 
ensure that all assumptions were met. The assumption of independence of observations was 
checked using the Durbin-Watson statistic, which indicated that the assumption of independent 
errors was reasonable across the models with values ranging from 1.73 to 2.02. Values between 
1.50 to 2.50 are generally considered acceptable (Keith, 2006). Scatterplots of the residuals and 
predicted values confirmed that the relationship between the dependent variables and 
independent variables were generally linear. Similarly, a scatterplot of each model was examined 
for the spread of the residuals across the predicted values, indicating that the assumption of 
homoscedasticity was met. The Variance Inflation Factor (VIF) values ranged from 1.141 to 
2.356, which is well below the guideline of 10 (Pituch & Stevens, 2016), confirming that the 




reviewing for any studentized residuals greater than ± 3 standard deviations (Laerd Statistics, 
2018). Two outliers were identified for the parent-reported Psychosocial Summary Score. 
Inspection of these outliers indicated that one of the cases had the lowest parent-reported 
psychosocial score (8.33;`x = 56.02), while the other outlier had the lowest scores on the parent 
HRQOL (25;`x = 63.55) and family functioning (0;`x = 57.96) domains. The results with and 
without the outliers are presented below. The Cook’s distance test confirmed that none of the 
cases were placing an undue influence on the models, as none of the data points exceeded 1.00. 
Lastly, histograms of the standardized residuals and P-P Plots demonstrated that the psychosocial 
models were approximately normally distributed. However, the Physical Health Summary Scores 
were indicative of non-normal distributions; thus, a square root transformation was utilized on 
the parent- and child-reported physical scores in order to produce more normal distributions. 
Following these transformations, the data were re-examined and this researcher again confirmed 
that the assumptions were met.  
Child-Reported Psychosocial  
Health-Related Quality  
of Life Model 
 
The results of the first model were significant at the adjusted significance level (F (3, 35) 
=6.70, p = .001). The model with all three variables (i.e., age, pain, and family functioning) 
accounted for 31% of the total variance of the child-reported Psychosocial Summary score, 
which is indicative of a large effect size (f2=.15), according to Cohen (1988). Age (b = 1.16, β = 
.334, p = .021) and pain (b = 14.80, β = .398, p = .006) had a significant influence on the model. 
Using Keith’s criteria for judging the magnitude of effects, the β associated with age (β = .334) 
and pain (β = .398) are considered large (Keith, 2006). Thus, age had a large positive effect on 




older, they report higher psychosocial scores. Pain also had a large positive effect on patients’ 
ratings on the Psychosocial Health Summary score, indicating that youth who indicated that they 
experienced pain tended to have a lower HRQOL score. 
Table 4.6 
Summary of Analysis of Variance for Child-Reported Psychosocial Summary Score  
Model   Sum of Squares df Mean Square        F  Sig. (p)  
 
1 Regression 3742.973  3 1247.658     6.699 .001 
Residual 6518.173  35 186.234   
Total  10261.146  38   
Notes. Predictors: Age, Pain, and Family Functioning 
Table 4.7 
Summary of Coefficients for Child-Reported Psychosocial Summary Score  
Model Measure B SE(B) β t Sig. (p)  
 
1 Age 1.156 .480 .334 2.407 .021 
 
 Family Functioning .120 .096 .174 1.245 .221 
 Pain 14.798 5.058 .398 2.926    .006 
 
Child-Reported Physical  
Health-Related Quality  
of Life Model 
 
The results of the second model were significant at the adjusted significance level (F (2, 
36) =7.33, p = .002). The model with two variables (i.e., age and family functioning) accounting 
for 25.0% of the total variance of the child-reported Physical Summary score, which is indicative 
of a medium effect size (f2= .15), according to Cohen (1988). Age (b = -.162, β = -.443, p = .005) 




Using Keith’s criteria for judging the magnitude of effects, the β associated with age (β = -.443) 
and family functioning (β = .440) are considered large (Keith, 2006). Thus, age had a large 
negative effect on patients’ ratings on the Physical Health Summary score, suggesting that as 
patients get older, they report lower physical scores. Family functioning also had a large positive 
effect on patients’ ratings on the Physical Health Summary score, indicating that patients from 
families who endorse better family functioning reported higher physical scores.    
Table 4.8 
Summary of Analysis of Variance for Child-Reported Physical Summary Score   
Model   Sum of Squares df Mean Square        F  Sig. (p) 
1 Regression 34.918   2 17.459      7.337 .002 
Residual 85.666   36 2.380   
Total  120.584  38    
Notes. Predictors: Age and Family Functioning 
Table 4.9 
Summary of Coefficients for Child-Reported Physical Summary Score  
Model Measure B SE(B) β t Sig. (p)  
 
1 Age -.162 .054 -.443 -2.992      .005 
 
 Family Functioning .033 .011 .440 3.042 .004 
 
 
Parent-Reported Psychosocial  
Health-Related Quality  
of Life Model 
 
The results of the overall model for the third multiple linear regression model were 
statistically significant at the adjusted significance level, (F (2, 41) =14.49, p =.000). The model 




Health Summary score, which is indicative of a large effect size (f2=.35), according to Cohen 
(1988). Age (b = .915, β = .254, p = .047) and family functioning (b = .384, β = .529, p = .000) 
had an explanatory effect on the model. Using Keith’s criteria for judging the magnitude of 
effects, the β associated with age (β = .254) and family functioning (β = .529) are considered 
large (Keith, 2006). Thus, age had a large positive effect on patients’ ratings on the Psychosocial 
Health Summary score, suggesting that as patients get older, their caregivers report better 
psychosocial functioning. Family functioning also had a large positive effect on parents’ ratings 
on the Psychosocial Health Summary score, indicating that parents who endorsed better family 
functioning perceived their child’s psychosocial HRQOL to be higher.  
As noted above, two outliers were identified in this model, without these outliers (n=42), 
the overall model remained statistically significant (F (2, 39) =24.13, p =.000) and accounted for 
55.3% of the total variance of the parent-reported Psychosocial Health Summary Score, with 
both variables having an explanatory influence on the model (age: b = .819, β = .240, p = .034; 
family functioning: b = .467, β = .659, p = .000). However, given the smaller than expected 
sample size and the unique contribution of these participants to the diversity of this sample, this 
researcher opted to retain the outliers.  
Table 4.10 
Summary of Analysis of Variance for Parent-Reported Psychosocial Summary Score  
 
Model   Sum of Squares df Mean Square        F           Sig. (p) 
1 Regression 5343.040  2 2671.520    14.493 .000 
Residual 7557.503  41 184.329   
Total  12900.542  43    





Summary of Coefficients for Parent-Reported Psychosocial Summary Score  
Model Measure B SE(B) β t Sig. (p) 
 
1 Age  .915 .446 .254 2.051 .047 
 
 Family Functioning .384 .090 .529 4.268 .000 
 
Parent-Reported Physical  
Health-Related Quality  
of Life Model 
 
The final multiple linear regression model was not significant at the adjusted significance 
level of p < .0125. Age and family functioning did not predict the parent ratings on the Physical 
Summary score (F (2,41) = 4.74, p = .014); R2=.148), although the model would have been 
significant without the Bonferroni correction for multiple tests. 
Table 4.12 
Summary of Analysis of Variance for Parent-Reported Physical Summary Score   
 
Model   Sum of Squares df Mean Square        F            Sig. (p) 
1 Regression 39.222   2 19.611      4.738 .014 
Residual 169.692  41 4.139   
Total  208.913  43    










Summary of Coefficients for Parent-Reported Physical Summary Score 
 
Model Measure B SE(B) β t Sig. (p) 
 
1 Age  -.119 .067 -.261 -1.787 .081 
 
 Family Functioning .039 .013 .421 2.887 .006 
 
Conclusion 
 Overall, this exploratory analysis led to several key findings. Patient and caregiver 
ratings on the Psychosocial and Physical Health Summary Scales fell below the clinical cutoffs, 
with the social domain identified as the most problematic area across both respondent groups. 
Mean scores across scales of a measure of caregiver well-being and family functioning (i.e., 
PedsQLTM 2.0 Family Impact Module) were lower for this sample than for other studies using 
the same measure with families of pediatric populations. Several demographic variables were 
correlated with the HRQOL scores (i.e., relationship status, household composition, and 
caregiver age). Similarly, a disease-specific factor, pain was indicative of a strong correlation 
with patient ratings on the psychosocial domain. Thus, the strong correlation that was identified 
for pain and child-reported psychosocial HRQOL, warranted inclusion in the regression model. 
A series of multivariable regression analyses were conducted to assess associations 
between potential correlates and HRQOL scores from the perspectives of patients and their 
caregivers. Age, family functioning, and/or pain accounted for a significant amount of the 
variance in child-reported and parent-reported Psychosocial Health Summary scores. The child-
reported Physical Health Summary score also demonstrated a statistically significant model, with 




parent-reported Physical Health Summary Score was approaching significance with age and 

































Dystrophinopathies, including Duchenne and Becker muscular dystrophies, are a subset 
of X-linked neuromuscular disorders that are characterized by degenerative muscle weakness and 
wasting and multisystem complications that impact physical, cognitive, social, and psychological 
functioning (Birnkrant et al., 2018; Darras et al., 2015; Morrison, 2011). Youth with 
dystrophinopathies are also at a higher risk for neurodevelopmental disorders and psychiatric 
conditions (Banihani et al., 2015; Conway et al., 2016; Sarrazin et al., 2014), all of which likely 
further exacerbates disease severity and affects overall well-being. The profound impairment in 
physical function and complex treatment regimen leads to increased dependence on caregivers 
(Bendixen et al., 2012), especially after loss of ambulation. Research has demonstrated that youth 
with DMD present with reduced HRQOL, but much less is known about predictors of this 
multidimensional construct. The aim of this exploratory study was to assess disease severity via 
age and potential modifiable psychosocial factors of HRQOL from the perspective of pediatric 






Overview of the Results 
 As measured by the PedsQLTM 4.0 Generic Core scales, patient and parent ratings across 
all domains of HRQOL (i.e., physical, emotional, social, and school) were below proposed cut-
off scores, with the physical subscale rated as the most problematic area across both respondent 
groups. Given that the hallmark feature of this disease is progressive muscle wasting, it is not 
surprising that physical HRQOL emerged as the lowest mean score within this sample, especially 
since it was comprised of more boys whose ambulation status required part-time or full-time 
wheelchair use. An item-level examination indicated that over 25% of patients endorsed 
experiencing pain/aches “often” or “almost always” within the last month of completing this 
measure. Almost 40% of parents felt that pain was an area of concern for their children. Within 
the psychosocial domain, the social subscale was the area that was most impacted as reported by 
both parents and patients. It is likely that diminished social HRQOL in this pediatric population 
is related to a combination of factors including cognitive deficits, physical limitations and 
secondary symptoms of pain and fatigue, and feelings of self-consciousness with changes in 
functioning. Consequently, children with DMD may be less inclined to seek out peer 
relationships and social activities. Research has also shown that youth with DMD are at higher 
risk for social skills deficits (Hinton et al., 2006). In fact, this sample was comprised of patients 
with formal diagnoses (i.e., ADHD, autism spectrum disorder, and speech-language disorders) 
that have been found to be associated with weaknesses in social functioning. Overall, the trend in 
scores in this study aligns with other research using this measure with boys with 
dystrophinopathies (Baiardini et al., 2011; Bendixen et al., 2012; Bray et al., 2011; Davis et al., 




Given the progressive nature of DMD and the increased reliance on caregivers for 
support, disease management, and daily functioning, it is not surprising, that the mean scores on 
the PedsQLTM 2.0 Family Impact Module were lower in this study than for other pediatric 
samples using the same measure (Tadros et al., 2020; Varni et al., 2004). It is important to note 
that the diagnoses of the samples in these studies are not considered to be as severe as a 
condition like DMD, a progressive, life-limiting, and ultimately, terminal disease. Furthermore, 
the subscale that was identified by caregivers as being most impacted in this sample was the 
worry subscale, with the majority of respondents acknowledging that they experience worries 
“often” or “almost always” in one or more of the following areas: their child’s future, medical 
treatments, side effects, others’ reactions to their child, and/or the impact of the illness on other 
family members. This finding is consistent with other prior work demonstrating that the worry 
subscale emerged as the lowest outcome on this measure (Jastrowski Mano et al., 2011; Tadros 
et al., 2020).  
Although not a formal research question, correlational analyses were conducted between 
demographic variables and disease-specific factors and the HRQOL scores. Pain was indicative 
of strong correlations with patient ratings on the psychosocial domain. Research has 
demonstrated that these secondary symptoms of DMD have emerged as correlates of HRQOL 
(Hunt et al., 2016; Ozyurt et al., 2015). Several demographic variables (i.e., family composition, 
relationship status, and caregiver age) were found to be correlated with the HRQOL scores, 
which aligns with the existing research that has shown mixed evidence for the significance of 
such factors on HRQOL. For example, a longitudinal, multi-site international study with children 
with DMD and their families found that boys with DMD living in a household with a medium to 




those living in a low income household (Otto et al., 2017). In contrast, other studies have found 
no associations between income level and HRQOL scores (Wei et al., 2016). In this study, the 
sample does not reflect the diverse population in terms of race, disease stage, parental marital 
status, income level, and family composition. Thus, it is possible that the limited diversity in this 
sample contributed to the largely non-significant socio-demographic findings. 
The first set of research questions aimed to determine which modifiable psychosocial 
variables contributed to the child-reported HRQOL scores. For the psychosocial HRQOL score, 
30% of the variance was explained by age, pain, and family functioning, but age and pain were 
the only variables that had a significant influence on the model. This study demonstrated that 
patients who indicated that they experienced pain/aches “never” or “almost never” had higher 
psychosocial HRQOL scores. Pain has been reported to be associated with reduced HRQOL in 
various pediatric populations (Gold et al., 2009; Jones et al., 2015; Sawyer et al., 2005). Yet, 
there is limited research on the pain experiences of youth with DMD. The few studies that have 
examined pain in children with DMD have used different measures to assess for pain or 
HRQOL, making it difficult to make direct comparisons to these studies. For example, a pilot 
study by Hunt et al. (2016) found that parent’s ratings of pain frequency and severity correlated 
with lower patient-reported HRQOL scores on the Youth Quality of Life Scale among 12 
Taiwanese men with DMD.  
Furthermore, age emerged as a predictor that had a large effect on patients’ ratings on the 
Psychosocial Health Summary score, suggesting that as patients get older, they report higher 
psychosocial scores. Although age and other proxies of disease severity (e.g., ventilator use) 
have resulted in mixed evidence (Hendriksen et al., 2009; Otto et al., 2017; Uzark et al., 2012), 




which better psychosocial HRQOL outcomes found in older youth with more severe disease 
symptomology may be related to changes in values, priorities, internal standards, or 
conceptualization of well-being, as they adapt to their diagnosis (Sprangers & Schwartz, 1999; 
Szabo et al., 2020). 
For the physical HRQOL score, 25% of the variance was explained by age and family 
functioning, with both variables contributing to the model. This suggests that patients rated their 
physical HRQOL higher when their caregivers endorsed better family functioning. This is the 
first study to examine the predictive influence of family functioning (i.e., PedsQLTM 2.0 Family 
Impact Module) on HRQOL within this pediatric population using a multidimensional measure 
for families with children with medical complexities. Prior work in the broader pediatric 
literature demonstrates that indicators of general family functioning (i.e., family cohesion, 
communication, problem-solving, distress level) are related to better HRQOL (Cipolletta et al., 
2015; Fee & Hinton, 2011; Herzer et al., 2011; Moreira et al., 2013; Quast et al., 2018). 
However, given that these studies used more general measures of family functioning, it is likely 
that they do not take into account the disease experience (e.g., treatment demands, caregiving 
burden), which is the likely culprit that is greatly contributing to their stress and dysfunction.  
Furthermore, age had a large negative effect on patients’ ratings on the Physical Health 
Summary score, suggesting that as patients get older, they report lower physical scores. Existing 
research with youth with DMD has demonstrated that increasing age has generally been 
associated with poorer self-reported physical HRQOL (McDonald et al., 2010; Uzark et al., 
2012). Given that the disease progression of DMD leads to worsening physical limitations over 




The final set of research questions aimed to determine which modifiable psychosocial 
variables contributed to the parent-reported HRQOL scores. For the psychosocial HRQOL score, 
39% of the variance was explained by age and family functioning, with all the variables having a 
significant influence on the model. This suggests that caregivers rated their child’s psychosocial 
HRQOL higher when they endorsed better family functioning. As mentioned above, family 
functioning has not been evaluated as a predictor of HRQOL in DMD. Existing research has 
largely been restricted to general family functioning or parenting stress measures, which likely 
do not include stressors and experiences commonly experienced in families with a child with a 
complex medical condition. Consistent with the patient-reported outcomes, age also 
demonstrated a large negative effect on their child’s psychosocial HRQOL in DMD. For the 
physical score, the model was not significant at the adjusted significance level of p < .0125, 
which is likely due to the small sample size. Given the moderate correlations that were identified 
between some of the demographic variables (i.e., caregiver relationship status and household 
composition) and the parent-reported physical HRQOL score, it is also possible that these 
demographic variables may serve as more relevant predictors of this outcome.  
Implications 
Historically, individuals with DMD were not expected to live past their teens, but 
improvements in medicine and science, have led to a considerable increase in life expectancy, 
with many living into early adulthood (Eagle et al., 2007; Passamano et al., 2012). Although this 
is a significant medical accomplishment, there is still no cure and medical treatments are limited 
in their ability to mitigate symptoms and associated complications; thus, as patients have begun 
to live longer, psychosocial care has increasingly become a priority (Cohen & Biesecker, 2010). 




focus on prevention and interventions efforts to address well-being in patients and their families 
across the disease stages. Pediatric psychologists and mental health providers have been 
recognized as integral to the multidisciplinary medical team for youth with DMD, particularly as 
it relates to screening, monitoring, and implementing therapeutic interventions for patients and 
their families, as well as involvement in care coordination (Birnkrant et al., 2018; Bushby et al., 
2010).  
HRQOL, a potentially modifiable outcome, has been recognized as a multidimensional 
construct that can be used to inform both medical and mental health treatment with pediatric 
populations. Much of the existing research has examined HRQOL from the perspective of the 
parent only, but this study examined HRQOL via both caregiver report and child self-report, 
which offers a more comprehensive overview of HRQOL in this medically complex population. 
Historically, HRQOL has been assessed using parent proxy reports, but there is growing 
consensus that self-report is critical for measuring HRQOL (Matza et al., 2004; Varni et al., 
2007), especially as research has demonstrated poor agreement between parent and child ratings 
(Bray et al., 2010; Eiser & Morse, 2001). Mean scores of parent ratings were slightly lower 
across all HRQOL domains when compared to the child’s self-reported scores. The most 
pronounced differences emerged on the psychosocial subscales, with parents perceiving their 
children as presenting with more social, emotional, and school difficulties than their children. 
Although only slight discrepancies between youth and caregiver reports were identified in this 
study, discordance has consistently been observed in the literature. Unless clinically warranted 
(i.e., cognitive deficits), efforts should be made to obtain data from multiple sources when 
assessing HRQOL. Relying on a single source for examining HRQOL may also impact referrals 




Consistent efforts to engage in screening and monitoring of HRQOL in youth with DMD 
can aid in identifying children who are at risk for impaired well-being and guide decision making 
related to treatment and intervention. Results of this study suggest that boys with 
dystrophinopathies present with low levels of physical and psychosocial health-related quality of 
life from the perspectives of both parents and patients. Given the clinical manifestations of 
DMD, it is not surprising that parent and child ratings of physical HRQOL were severely 
compromised. Thus, clinicians should ensure that efforts are made to help support patients and 
their families in identifying equipment, assistive technology, and other resources to facilitate 
accessibility and independence, all of which may also ease caregiver burden. Assisting families 
in connecting with community-based waiver programs and financial resources for modifications 
to their homes would also likely be valuable.  
Beyond physical functioning, psychosocial scores fell below the clinical cut-offs for the 
majority of the sample as reported by both children and parents. The social domain of HRQOL 
was identified as the most problematic area across respondents. As physical impairment worsens 
and secondary symptoms of pain, fatigue, and sleep problems become more pronounced, youth 
may begin to experience increased feelings of self-consciousness and be less inclined to seek out 
peer relationships and social activities. Given that schools are a main source of socialization for 
children, collaboration with school professionals is an ideal way to support this area of need. In 
my professional experiences, patients have found therapeutic benefits in formally sharing their 
experiences living with a medically complex disease with their teachers and classmates, which 
may also help to foster disability awareness and a more inclusive environment of social 




questions from peers and/or helping them to develop a simple description of their medical 
condition has anecdotally helped youth with DMD feel more at ease in social situations. 
Educational teams are well-positioned to be able to facilitate accessible extracurricular 
activities and individualized supports in the school setting that enhance interpersonal 
relationships, while also limiting the burden on families of pursuing these resources and/or 
activities in alternate environments. For example, an Australian school-based group intervention 
study (i.e., MD Mafia) for boys with muscular dystrophies identified several positive qualitative 
themes from participants and their parents after their involvement in this unique experience 
including increased opportunities for belongingness, accessible social interactions independent of 
their families, and improvements in self-confidence (Parkyn & Coveney, 2013). Although 
limitations in physical functioning may interfere with youths’ level of social engagement, 
research has also shown that patients with DMD are at higher risk for social skills deficits 
(Hinton et al., 2006). This sample was comprised of patients with formal diagnoses of ADHD 
(27%), autism spectrum disorder (12%), and speech-language disorders (11%), all of which are 
neurodevelopmental conditions that are commonly associated with weaknesses in social 
functioning. Thus, social skills training may be a suitable option to consider for youth with DMD 
and comorbid psychiatric and neurodevelopmental diagnoses to address a potential skill deficit 
and increase peer connections.  
Thankfully, the majority of the school-aged participants acknowledged that they had 
formal academic supports (n=31; 82%) in place through an Individualized Education Program 
(IEP) or Section 504 Plan. Despite this, HRQOL scores as it pertains to the school setting were 
impaired for a significant portion of respondents. Pediatric psychologists can support families in 




their legal rights, and assist them in connecting with school-based advocates or community 
resources for tutoring. Additionally, efforts should be made to collaborate with patients’ 
educational teams, especially when patients experience notable changes in their health status or 
unexpected hospitalizations. 
The emotional subscale was the domain that led to the largest discrepancy between the 
respondents, with parents perceiving their children as having more problems in this area. 
Regardless, a significant portion of parents and patients endorsed scores below the clinical 
threshold for emotional well-being. These findings highlight the importance of screening as a 
mechanism to identify at-risk patients and provide necessary interventions. When formal 
treatment is deemed necessary, evidence-based interventions that have been validated for 
populations with chronic medical conditions are ideal. For example, ACT-based interventions 
have demonstrated positive effects on adjustment, quality of life, life satisfaction, adherence 
issues, and mood-related concerns among individuals with neuromuscular disorders (Ahlström & 
Sjöden, 1996; Graham et al., 2015; Kratz et al., 2013). Traditional CBT approaches have also 
been shown to be effective in managing distress, functional impairment, and mental health 
symptoms associated with chronic medical conditions (Law et al., 2019; Thompson et al., 2011).  
Not only did this study extend the existing research regarding the HRQOL of youth with 
DMD from the perspectives of both patients and caregivers, but it sought to identify potentially 
modifiable predictors that influence different HRQOL domains across respondents. Specifically, 
this study identified family functioning as a factor associated with a number of HRQOL 
outcomes (i.e., patient-reported physical HRQOL and parent-reported psychosocial HRQOL), 
which is a concept that has been neglected in the research with youth with DMD. Clinically, the 




with chronic medical conditions has also been an area that has not been the focus of standard 
clinical care for patients with DMD. Measures that better understand the impact of disease and 
treatment on family functioning and parenting may be more specific and sensitive to capturing 
the distinct problems that families’ experience with children with medical complexities (Geffken 
et al., 2008), and subsequently lead to more tailored interventions that more adequately address 
the needs of these families. Thus, family-level screenings and interventions focused on 
alleviating parenting stress and improving family functioning in this population could have 
significant effects not only on parents, but also for youth with DMD. Given the high level of 
stress associated with caring for youth with DMD, parent support groups can be implemented to 
address adjustment to illness and coping and enhance social connections. Problem-solving 
therapy has also been shown to be an effective method of treatment for parents with children 
with chronic diseases (Law et al., 2014).  
Additionally, the boys’ experience of pain was found to be a contributing factor to child-
reported psychosocial HRQOL. It is reasonable to assume that frequent episodes of pain likely 
lead to increased distress and interferes with one’s ability to participate in school and social 
events, which aligns with the findings of this study. Thus, objective multidimensional assessment 
and treatment of pain symptoms should be a standard part of clinical care and may aid in 
improving HRQOL in youth with DMD. Implementing interventions to enhance youth’s ability 
to manage and cope with pain should be a priority. Acceptance and commitment therapy (ACT) 
and cognitive behavioral therapy (CBT) have been found to be efficacious for chronic pain 
patients by addressing illness perceptions and pain-related interference in daily tasks and valued 




the treatment of boys with DMD would be ideal, as such services can be valuable for pain 
management and symptom relief (Janisch et al., 2020). 
Age was also consistently identified as an indicator of HRQOL across nearly all domains. 
The results suggest that although disease progression is associated with reduced physical 
HRQOL, it may not be related to poorer psychosocial HRQOL, as older patients in this sample 
endorsed better psychosocial outcomes. This finding is also supported by prior work, but it is 
important to emphasize that longitudinal studies are needed to truly confirm this information. 
Although age is not a modifiable factor, psychologists frequently provide psychoeducation-based 
interventions to empower patients/families, relieve uncertainty, address misconceptions, and 
promote adjustment to illness (Barlow & Ellard, 2006; Thompson & Young-Saleme, 2015). 
Thus, learning that advancing age does not necessarily coincide with a progressive deterioration 
in psychosocial well-being could serve as a source of comfort and hope for children and parents, 
especially for those who are in the early stages of the disease or recently diagnosed. Similarly, 
anticipatory guidance regarding the disease progression and planning and preparing for changes 
in functioning across the disease stages are also critical in supporting patients and their families 
with adjusting to the illness.  
Limitations 
Despite the various strengths that have been previously discussed, this study is not 
without its limitations. The most pronounced and unexpected complication that arose during this 
study was the global pandemic, which halted all non-essential research activities at the hospital 
for over four months. Upon obtaining approval to resume the study with COVID-19 protocols in 
place, there were added logistical challenges to conducting research in a hospital setting with a 




who could be present in clinic simultaneously. Efforts were also made to significantly reduce the 
amount of time that patients and their families were spending in clinic and/or limiting the 
number of contacts with providers by offering telehealth appointments when feasible and/or 
eliminating their visits with providers for non-emergent needs. Thus, the principal investigator 
was not allowed to be present in clinic and had to rely on members of the research team to 
confirm eligibility, consent, and distribute the questionnaires. Due to the shortened appointments 
and need to minimize contact, members of the research team were limited in their ability to assist 
DMD participants in completing the questionnaires as needed and instead parents had to provide 
support. This arrangement may have resulted in some parents inadvertently influencing their 
child’s responses or resulted in some boys opting to answer questions differently than if a 
research team member was helping them. Furthermore, cognitive and/or other 
neuropsychological impairments of some of the participants may have interfered with their 
ability to complete the measures and/or impacted the validity of the data obtained from the self-
report measures. 
Beyond the hospital-wide protocols, it should not come as a surprise that there was an 
increase in the number of appointments that were re-scheduled or cancelled, as families 
expressed concerns about leaving their homes and going to the hospital with their medically 
compromised loved ones. Consequently, data collection occurred across fewer months and the 
anticipated sample size was not achieved. Despite the small sample size of this study (39 
pediatric patients and 44 caregivers) power analyses demonstrated that the sample met the 
suggested N. The sample size was also similar to other studies conducted with patients with 




Additionally, the sample that was utilized was obtained via convenience sampling within 
a single multidisciplinary clinic at a large pediatric hospital in Western United States, which may 
limit the generalizability. It has been argued that given the severity of the disease, it is reasonable 
to assume that almost all boys with DMD are managed at a tertiary-care clinic; thus, patients 
recruited through such clinics are likely to be representative of the DMD population. However, 
the shortened timeframe for data collection did not allow for the opportunity to connect with all 
patients and their families with DMD, resulting in a sample that likely did not capture the 
breadth and depth of diversity in terms of ethnicity, disease stage, parental marital status, income 
level, and family composition. Similarly, 81% of caregivers identified as female, indicating that 
the perspectives of male caregivers/fathers are largely missing from this study. Not only were 
questionnaire ratings obtained from a single caregiver, but the cross-sectional nature of this study 
only provided a snapshot of HRQOL and family impact at one time point. Common-method 
variance also cannot be overlooked as a potential limitation, as the parent-reported models 
integrated variables that were from a single reporter. This is important to consider in this 
population as stress experienced by parents may bias their perception of their child’s functioning. 
Furthermore, although this study incorporated multiple methods of assessment, it still 
relied on self-reported questionnaires, which inherently runs of the risk of being biased. It is also 
worth noting that there is no way of knowing just how much parent and child fears and worries 
and activity restrictions related to COVID-19 impacted their responses on the measures of well-
being and HRQOL. COVID-19 has had an impact on all of our lives, but individuals with 
significant medical complexities and compromised immune systems, like those with DMD, and 
their families have been even more restricted, with many children transitioning to remote 




home and dramatically reducing the number of direct interactions with people not residing in 
their household. Consequently, it is reasonable to assume that living with special healthcare 
needs in the midst of a pandemic may have led to poorer outcomes on rating scales than if this 
study had occurred before the start of COVID-19. 
Another potential limitation is the accuracy of patients’ medical charts. Patient medical 
charts are supposed to be updated each time a patient visits the clinic and/or the hospital, but it is 
reasonable to assume that these updates are not always made and information regarding medical, 
psychiatric, and/or neurodevelopmental diagnoses may not be adequately documented in the 
chart. However, many of the patients have undergone recent comprehensive neuropsychological 
evaluations, which provides increased confidence in the accuracy of the psychiatric and 
neurodevelopmental diagnoses outlined in their medical charts. 
Future Directions 
Given the exploratory nature of this study and the paucity of research related to this topic, 
there are many areas to continue exploring within this medically complex population. Overall, 
correlations were identified between many of the independent and dependent variables examined 
in this study, but it is possible that the predictive relationships would have been stronger if a 
larger sample size had been achieved. It would be important to replicate these findings with a 
larger, more diverse sample, potentially via a national multi-site study. Also, the sample was 
largely comprised of female caregivers; thus, greater attention should be given to recruiting male 
caregivers/fathers in future studies to better understand their perception of their child’s HRQOL. 
Although HRQOL ratings were obtained from both caregivers and patients, this study still relied 
on self-report measures. The use of observational data and qualitative information may deepen 




HRQOL ratings between female caregivers identified as being carriers of the DMD mutation and 
mothers who are unaware of their carrier status and/or those who do not carry genetic variants 
would be beneficial to explore. It may be possible that mothers with a carrier diagnosis who are 
experiencing guilt and self-blame underestimate their child’s HRQOL and over report the 
severity of their symptoms.  
The cross-sectional nature of the study precluded an examination of the casual links 
between the variables and HRQOL scores; thus, longitudinal research is needed to better 
understand variations in these variables over the course of the disease, from diagnosis through to 
end of life. Efforts should be made to evaluate other potentially modifiable psychosocial, 
behavioral, and environmental predictors of HRQOL. Strong correlations were identified 
between pain and several of the HRQOL scores, warranting further investigation with more 
detailed methods of assessment rather than a single item. Future research also should consider 
investigating the effects of illness perceptions and beliefs, patient and caregiver coping 
strategies, symptoms of anxiety and depression, and/or peer relationships on HRQOL, which 
have been identified as determinants of patient well-being among other pediatric populations 
(Conway et al., 2016; Drakouli et al., 2015; Santos et al., 2016). This researcher had intended to 
examine patient reported quality of family relationships as a predictor variable (i.e., the Patient-
Reported Outcomes Measurement (PROMIS ®) Family Relationships questionnaire), but 
unfortunately this measure had to be eliminated to reduce the amount of time that patients and 
their families were spending in clinic visits. Thus, this would be another avenue worth exploring. 
A greater understanding of factors that influence HRQOL should result in more intervention-




Finally, given the predictive relationships between family functioning on child-reported 
physical and/or psychosocial summary scores, further research is warranted to investigate how 
neuromuscular clinics are identifying at-risk patients and families and addressing areas of 
concern, as well as the ways in which they are evaluating the impact of targeted psychological 
interventions on patient and family outcomes. More importantly, it will be critical to understand 
which specific interventions and recommendations are associated with improvements in HRQOL 
and family well-being.  
Conclusion 
The hallmark feature of DMD is degenerative muscle weakness and wasting, which 
results in multisystem, life-threatening complications and secondary symptoms (e.g., pain, sleep 
problems, gastrointestinal issues, and swallowing dysfunction), and ultimately, a shortened life 
expectancy. The profound impairment in muscle function and multi-organ complications leads to 
a gradual deterioration in functional abilities, restricted participation in age-related activities, and 
increased dependence on caregivers (Bendixen et al., 2012; Mah et al., 2008; McDonald, 2002). 
With no cure, treatment is largely focused on prolonging survival, limiting the degree of 
impairment, and enhancing HRQOL (Birnkrant et al., 2018).  
This study replicated previous work that youth with DMD present with low levels of 
physical and psychosocial HRQOL from the perspectives of parents and caregivers. The social 
aspects of HRQOL was identified as the most problematic area across both respondent groups. 
More importantly, this study sought to expand the limited knowledge of modifiable psychosocial 
factors affecting youth with DMD. The results indicated that age, pain, and/or family functioning 




importance of formally assessing pain and family functioning and providing therapeutic 
























Aartsma-Rus, A., Ginjaar, I. B., & Bushby, K. (2016). The importance of genetic  
diagnosis for Duchenne muscular dystrophy. Journal of Medical Genetics,53(3), 145-
151. doi:10.1136/jmedgenet-2015-103387 
Abi Daoud, M. S., Dooley, J. M., & Gordon, K. E. (2004). Depression in parents of children with  
Duchenne muscular dystrophy. Pediatric Neurology, 31(1), 16–19. 
https://doi.org/10.1016/j.pediatrneurol.2004.01.011 
Ahlström, G., & Sjöden, P. O. (1996). Coping with illness-related problems and quality of life in  
adult individuals with muscular dystrophy. Journal of psychosomatic research, 41(4), 
365–376. https://doi.org/10.1016/s0022-3999(96)00191-2 
Aliverti, A., Lomauro, A., & Dangelo, M. G. (2015). Assessment and management of  
respiratory function in patients with Duchenne muscular dystrophy: Current and 
emerging options. Therapeutics and Clinical Risk Management,1475. 
doi:10.2147/tcrm.s55889 
Allen, H. D., Flanigan, K. M., Thrush, P. T., Dvorchik, I., Yin, H., Canter, C., Connolly, A. M.,  
Parrish, M., McDonald, C. M., Braunlin, E., Colan, S. D., Day, J., Darras, B., & Mendell, 
J. R. (2013). A randomized, double-blind trial of lisinopril and losartan for the treatment 
of cardiomyopathy in duchenne muscular dystrophy. PLoS Currents, 5, 
ecurrents.md.2cc69a1dae4be7dfe2bcb420024ea865. 
https://doi.org/10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865 
Allen, P. J., Vessey, J. A., & Schapiro, N. (2009). Primary Care of the Child with a Chronic  





Alman, B. A., Raza, S. N., & Biggar, W. D. (2004). Steroid Treatment and the  
Development of Scoliosis in Males with Duchenne Muscular Dystrophy. The Journal of 
Bone & Joint Surgery,86(3), 519-524. doi:10.2106/00004623-200403000-00009 
Andresen, E. M., & Meyers, A. R. (2000). Health-related quality of life outcomes  
measures. Archives of Physical Medicine and Rehabilitation, 81(12 Suppl 2), S30–S45. 
https://doi.org/10.1053/apmr.2000.20621 
Andrews, J. G., & Wahl, R. A. (2018). Duchenne and Becker muscular dystrophy in  
adolescents: Current perspectives. Adolescent Health, Medicine and Therapeutics, 9, 53-
63. doi:10.2147/ahmt.s125739 
Arechavala-Gomeza, V., Kinali, M., Feng, L., Brown, S. C., Sewry, C., Morgan, J. E., &  
Muntoni, F. (2009). Immunohistological intensity measurements as a tool to assess 
sarcolemma-associated protein expression. Neuropathology and Applied 
Neurobiology,36(4), 265-274. doi:10.1111/j.1365-2990.2009.01056.x 
Ashwath, M. L., Jacobs, I. B., Crowe, C. A., Ashwath, R. C., Super, D. M., & Bahler, R.  
C. (2014). Left Ventricular Dysfunction in Duchenne Muscular Dystrophy and Genotype. 
The American Journal of Cardiology,114(2), 284-289. 
doi:10.1016/j.amjcard.2014.04.038 
Baiardini, I., Minetti, C., Bonifacino, S., Porcu, A., Klersy, C., Petralia, P., Balestracci, S.,  
Tarchino, F., Parodi, S., Canonica, G. W., & Braido, F. (2011). Quality of life in  
duchenne muscular dystrophy: The subjective impact on children and parents. Journal of  
Child Neurology, 26(6), 707-713. https://doi.org/10.1177/0883073810389043 




Cessation of Ambulation in Patients with Duchenne Muscular Dystrophy. American 
Journal of Physical Medicine & Rehabilitation,81(12), 906-912. doi:10.1097/00002060-
200212000-00004 
Balaban, B., Matthews, D. J., Clayton, G. H., & Carry, T. (2005). Corticosteroid  
treatment and functional improvement in duchenne muscular dystrophy. American 
Journal of Physical Medicine & Rehabilitation,84(11), 843-850. 
doi:10.1097/01.phm.0000184156.98671.d0 
Banihani, R., Smile, S., Yoon, G., Dupuis, A., Mosleh, M., Snider, A., & Mcadam, L.  
(2015). Cognitive and neurobehavioral profile in boys with duchenne muscular 
dystrophy. Journal of Child Neurology,30(11), 1472-1482. 
doi:10.1177/0883073815570154 
Barlow, J. H., & Ellard, D. R. (2006). The psychosocial well-being of children with chronic  
disease, their parents and siblings: An overview of the research evidence base. Child: 
Care, Health and Development, 32(1), 19–31. https://doi.org/10.1111/j.1365-
2214.2006.00591.x 
Batshaw, M. L., Groft, S. C., & Krischer, J. P. (2014). Research into rare diseases of  
childhood. Journal of the American Medical Association, 311(17), 1729.  
doi:10.1001/jama.2013.285873 
Bavisetty, S., Grody, W. W., & Yazdani, S. (2013). Emergence of pediatric rare  
diseases. Rare Diseases,1(1). doi:10.4161/rdis.23579 
Baydur, A., Layne, E., Aral, H., Krishnareddy, N., Topacio, R., Frederick, G., & Bodden, W.  
(2000). Long term non-invasive ventilation in the community for patients with 




Beenakker, E. A., Fock, J. M., Tol, M. J., Maurits, N. M., Koopman, H. M., Brouwer, O.  
F., & Hoeven, J. H. (2005). Intermittent prednisone therapy in duchenne muscular 
dystrophy. Archives of Neurology,62(1), 128. doi:10.1001/archneur.62.1.128 
Bendixen, R. M., Senesac, C., Lott, D. J., & Vandenborne, K. (2012). Participation and  
quality of life in children with duchenne muscular dystrophy using the international 
classification of functioning, disability, and health. Health and Quality of Life 
Outcomes,10(1), 43. doi:10.1186/1477-7525-10-43 
Bianchi, C., & Baiardi, P. (2008). Cough peak flows: Standard values for children and  
adolescents. American Journal of Physical Medicine & Rehabilitation,87(6), 461-467. 
doi:10.1097/phm.0b013e318174e4c7 




Biggar, W. D., Harris, V., Eliasoph, L., & Alman, B. (2006). Long-term benefits of  
deflazacort treatment for boys with duchenne muscular dystrophy in their second decade. 
Neuromuscular Disorders,16(4), 249-255. doi:10.1016/j.nmd.2006.01.010 
Billard, C., Gillet, P., Barthez, M., Hommet, C., & Bertrand, P. (2008). Reading ability  
and processing in duchenne muscular dystrophy and spinal muscular atrophy. 
Developmental Medicine & Child Neurology,40(1), 12-20. doi:10.1111/j.1469-
8749.1998.tb15351.x 
Birnkrant, D. J., Ararat, E., & Mhanna, M. J. (2015). Cardiac phenotype determines  





Birnkrant, D. J., Ashwath, M. L., Noritz, G. H., Merrill, M. C., Shah, T. A., Crowe, C. A., & 
Bahler, R. C. (2010). Cardiac and pulmonary function variability in duchenne/becker 
muscular dystrophy: An initial report. Journal of Child Neurology, 25(9), 1110-1115. 
doi:10.1177/0883073810371003 
Birnkrant, D. J., Bushby, K., Bann, C. M., Apkon, S. D., Blackwell, A., Brumbaugh, D., Case, L.  
E., Clemens, P. R., Hadjiyannakis, S., Pandya, S., Street, N., Tomezsko, J., Wagner, K.  
R., Ward, L. M., Weber, D. R., & DMD Care Considerations Working Group (2018). 
Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and 
neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional 
management. The Lancet. Neurology, 17(3), 251–267. https://doi.org/10.1016/S1474-
4422(18)30024-3 
Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., Dawkins, H.,  
Lamont, L., Roy, A. J., Chamova, T., Guergueltcheva, V., Chan, S., Korngut, L., 
Campbell, C., Dai, Y., Wang, J., Barišić, N., Brabec, P., Lahdetie, J., ... Lochmüller, H. 
(2015). The TREAT-NMD DMD Global database: Analysis of more than 7,000 
Duchenne muscular dystrophy mutations. Human Mutation, 36(4), 395-
402. https://doi.org/10.1002/humu.22758 
Boat, T. F., & Field, M. J. (2010). Rare diseases and orphan products: Accelerating  
research and development. Washington, DC: National Academies Press.  
doi:https://www.ncbi.nlm.nih.gov/books/NBK56189/ 
Bothwell, J. E., Dooley, J. M., Gordon, K. E., MacAuley, A., Camfield, P. R., & MacSween, J.  





Boyer, F., Drame, M., Morrone, I., & Novella, J. L. (2006). Factors relating to carer burden for  
families of persons with muscular dystrophy. Journal of Rehabilitation Medicine, 38(5),  
309–315. https://doi.org/10.1080/16501970600731578 
Bradlyn, A. S., Varni, J. W., & Hinds, P. S. (2003). Appendix c assessing  
health-related quality of life in end-of-life care for children and adolescents. In M. J. 
Field (Ed.), When Children Die: Improving Palliative and End-of-Life Care for Children 
and Their Families (pp. 476-508). Washington (DC): National Academies Press. 
doi:https://www.ncbi.nlm.nih.gov/books/NBK220804/ 
Bray, P., Bundy, A. C., Ryan, M. M., North, K. N., & Burns, J. (2011). Health status of  
boys with Duchenne muscular dystrophy: A parent’s perspective. Journal of Paediatrics 
and Child Health,47(8), 557-562. doi:10.1111/j.1440-1754.2011.02022.x 
Bray, P., Bundy, A. C., Ryan, M. M., North, K. N., & Everett, A. (2010). Health-related  
quality of life in boys with duchenne muscular dystrophy: Agreement between parents 
and their sons. Journal of Child Neurology, 25(10), 1188-1194. 
doi:10.1177/0883073809357624 
Bresolin, N., Castelli, E., Comi, G. P., Felisari, G., Bardoni, A., Perani, D., Grassi, F., Turconi,  
A., Mazzucchelli, F., Gallotti, D., Moggio, M., Prelle, A., Ausenda, C., Fazio, G., & 
Scarlato, G. (1994). Cognitive impairment in Duchenne muscular dystrophy. 
Neuromuscular Disorders, 4(4), 359-369. https://doi.org/10.1016/0960-8966(94)90072-8 
Bronfenbrenner, U. (1979). The ecology of human development. Boston: Harvard 
University Press. 




Research perspectives. Developmental Psychology,22(6), 723-742. doi:10.1037/0012-
1649.22.6.723 
Bronfenbrenner, U., & Morris, P. (1998). The ecology of developmental processes. In RM.  
Lerner (Ed.), Theoretical models of human development (5 ed., pp. 993-1028).  
(Handbook of Child Psychology; Vol. 1). Wiley. 
Buckner, J. L., Bowden, S. A., & Mahan, J. D. (2015). Optimizing bone health in  
duchenne muscular dystrophy. International Journal of Endocrinology,2015, 1-9. 
doi:10.1155/2015/928385 
Burtis, C. A., Ashwood, E. R., & Bruns, D. E. (Eds.). (2007). Tietz fundamentals of clinical  
chemistry. Saunders Elsevier.  
Bushby, K., Bourke, J., Bullock, R., Eagle, M., Gibson, M., & Quinby, J. (2005). The  
multidisciplinary management of duchenne muscular dystrophy. Current Paediatrics. 15. 
292-300. 10.1016/j.cupe.2005.04.001. 
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett,  
K., McDonald, C., Pandya, S., Poysky, J., Shapiro, F., Tomezsko, J., & Constantin, C.  
(2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, 
and pharmacological and psychosocial management. The Lancet Neurology,9(1), 77-93. 
doi:10.1016/s1474-4422(09)70271-6 
Bushby, K., Hill, A., & Steele, J. (1999). Failure of early diagnosis in symptomatic  
Duchenne muscular dystrophy. The Lancet,353(9152), 557-558. doi:10.1016/s0140-
6736(98)05279-9 




Posselt, H. F. (2018). Rehabilitation management of the patient with duchenne muscular 
mystrophy. Pediatrics, 142(Suppl 2), S17–S33. https://doi.org/10.1542/peds.2018-0333D 
Chelly, J., & Desguerre, I. (2013). Progressive muscular dystrophies. Handbook of  
Clinical Neurology Pediatric Neurology Part III,1343-1366. doi:10.1016/b978-0-444-
59565-2.00006-x 
Chen, J. Y., & Clark, M. J. (2007). Family function in families of children with Duchenne  
muscular dystrophy. Family & Community Health: The Journal of Health Promotion &  
Maintenance, 30(4), 296–304. https://doi.org/10.1097/01.FCH.0000290542.10458.f8 
Chiou, M., Bach, J., Jethani, L., & Gallagher, M. (2017). Active lung volume recruitment  
to preserve vital capacity in Duchenne muscular dystrophy. Journal of Rehabilitation 
Medicine, 49(1), 49-53. doi:10.2340/16501977-2144 
Ciafaloni, E., Fox, D. J., Pandya, S., Westfield, C. P., Puzhankara, S., Romitti, P. A., Mathews,  
K. D., Miller, T. M., Matthews, D. J., Miller, L. A., Cunniff, C., Druschel, C. M., & 
Moxley, R. T. (2009). Delayed diagnosis in duchenne muscular dystrophy: Data from the 
muscular dystrophy surveillance, tracking, and research network (MD STARnet). The 
Journal of pediatrics, 155(3), 380–385. https://doi.org/10.1016/j.jpeds.2009.02.007 
Cipolletta, S., Marchesin, V., & Benini, F. (2015). Family functioning as a constituent  
aspect of a child's chronic illness. Journal of Pediatric Nursing,30(6). 
doi:10.1016/j.pedn.2015.01.024 
Cohen, J. (1988). The Effect Size. Statistical Power Analysis for the Behavioral Sciences.  
Abingdon: Routledge, 77-83. 
Cohen, J., Cohen, P., West, S. G., & Aiken, L. S. (2003). Applied multiple regression/correlation  




Cohen, J. S., & Biesecker, B. B. (2010). Quality of life in rare genetic conditions: A  
systematic review of the literature. American Journal of Medical Genetics Part 
A,152A(5), 1136-1156. doi:10.1002/ajmg.a.33380 
Colombo, P., Nobile, M., Tesei, A., Civati, F., Gandossini, S., Mani, E., Molteni, M., Bresolin,  
N., & D’Angelo, G. (2017). Assessing mental health in boys with duchenne muscular 
dystrophy: Emotional, behavioural and neurodevelopmental profile in an italian clinical 
sample. European Journal of Paediatric Neurology, 21(4), 639-647. 
https://doi.org/10.1016/j.ejpn.2017.02.007 
Colvin, M. K., Poysky, J., Kinnett, K., Damiani, M., Gibbons, M., Hoskin, J., Moreland, S.,  
Trout, C. J., & Weidner, N. (2018). Psychosocial management of the patient with 
duchenne muscular dystrophy. Pediatrics, 142(Suppl 2), S99–S109. 
https://doi.org/10.1542/peds.2018-0333L 
Conway, L., Smith, M. L., Ferro, M. A., Speechley, K. N., Connoly, M. B., Snead, O. C.,  
Widjaja, E., & PEPSQOL Study Team (2016). Correlates of health-related quality of life 
in children with drug resistant epilepsy. Epilepsia, 57(8), 1256–1264. 
https://doi.org/10.1111/epi.13441 
Corrado, G., Lissoni, A., Beretta, S., Terenghi, L., Tadeo, G., Foglia-Manzillo, G., Tagliagambe,  
L. M., Spata, M., & Santarone, M. (2002). Prognostic value of electrocardiograms, 
ventricular late potentials, ventricular arrhythmias, and left ventricular systolic 
dysfunction in patients with Duchenne muscular dystrophy. The American journal of 
cardiology, 89(7), 838–841. https://doi.org/10.1016/s0002-9149(02)02195-1 




dystrophy: Full-scale, verbal, and performance intelligence quotients. Developmental 
medicine and child neurology, 43(7), 497–501. 
https://doi.org/10.1017/s0012162201000913 
Cotton, S. M., Voudouris, N. J., & Greenwood, K. M. (2005). Association between  
intellectual functioning and age in children and young adults with duchenne muscular 
dystrophy: Further results from a meta-analysis. Developmental Medicine and Child 
Neurology, 47(4), 257-65.  
Cramer, J. A., Westbrook, L. E., Devinsky, O., Perrine, K., Glassman, M. B., &  
Camfield, C. (1999). Development of the quality of life in epilepsy inventory for 
adolescents: The QOLIE-AD-48. Epilepsia, 40(8), 1114-1121. doi:10.1111/j.1528-
1157.1999.tb00828.x 
Crean, P. M., & Tirupathi, S. (2019). Essentials of neurology and neuromuscular disorders. 
(Sixth ed., pp. 580.e4) doi:10.1016/B978-0-323-42974-0.00024-0  
D'Angelo, M. G., Berti, M., Piccinini, L., Romei, M., Guglieri, M., Bonato, S., Degrate, A.,  
Turconi, A. C., & Bresolin, N. (2009). Gait pattern in Duchenne muscular 
dystrophy. Gait & posture, 29(1), 36–41. https://doi.org/10.1016/j.gaitpost.2008.06.002 
D'Angelo, M. G., & Bresolin, N. (2006). Cognitive impairment in neuromuscular  
disorders. Muscle & nerve, 34(1), 16–33. https://doi.org/10.1002/mus.20535 
Darras, B. T. (2018). Duchenne and becker muscular dystrophy: Management and prognosis. In:  
Patterson MC, Dashe JF, eds. UpToDate®. Philadelphia, PA: Wolters Kluwer Health. 
Darras, B. T., Menache-Starobinski, C. C., Hinton, V., & Kunkel, L. M. (2015). Chapter  





Davis, E., Shelly, A., Waters, E., Boyd, R., Cook, K., & Davern, M. (2010). The impact  
of caring for a child with cerebral palsy: Quality of life for mothers and fathers. Child: 
Care, Health and Development, 36(1), 63-73. doi:10.1111/j.1365-2214.2009.00989.x 
de Souza, M. A., Figueiredo, M. M., de Baptista, C. R., Aldaves, R. D., & Mattiello-Sverzut, A.  
C. (2016). Beneficial effects of ankle-foot orthosis daytime use on the gait of Duchenne  
muscular dystrophy patients. Clinical biomechanics (Bristol, Avon), 35, 102–110.  
https://doi.org/10.1016/j.clinbiomech.2016.04.005 
Donders, J., & Taneja, C. (2009). Neurobehavioral characteristics of children with  
duchenne muscular dystrophy. Child Neuropsychology,15(3), 295-304. 
doi:10.1080/09297040802665777 
Dowling, J. J., Gonorazky, H. D., Cohn, R. D., & Campbell, C. (2017). Treating pediatric  
neuromuscular disorders: The future is now. American Journal of Medical Genetics Part 
A,176(4), 804-841. doi:10.1002/ajmg.a.38418 
Drakouli, M., Petsios, K., Giannakopoulou, M., Patiraki, E., Voutoufianaki, I., & Matziou, V.  
(2015). Determinants of quality of life in children and adolescents with CHD: A 
systematic review. Cardiology in the young, 25(6), 1027–1036. 
https://doi.org/10.1017/S1047951115000086 
Driscoll, C., Buscemi, J., & Holmbeck, G. N. (2018). Parental Distress and stress in association  
with health-related quality of life in youth with spina bifida: A longitudinal  
study. Journal of developmental and behavioral pediatrics: JDBP, 39(9), 744–753.  
https://doi.org/10.1097/DBP.0000000000000603 




health-related quality of life: Key methodological challenges and strategies. Ambulatory 
Pediatrics, 4(4), 358-364. doi:10.1367/a03-101r.1 
Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., & Bushby, K.  
(2002). Survival in duchenne muscular dystrophy: Improvements in life expectancy since 
1967 and the impact of home nocturnal ventilation. Neuromuscular Disorders,12(10), 
926-929. doi:10.1016/s0960-8966(02)00140-2 
Eagle, M., Bourke, J., Bullock, R., Gibson, M., Mehta, J., Giddings, D., Straub, V., & Bushby,  
K. (2007). Managing duchenne muscular dystrophy--the additive effect of spinal surgery 
and home nocturnal ventilation in improving survival. Neuromuscular disorders: 
NMD, 17(6), 470–475. https://doi.org/10.1016/j.nmd.2007.03.002 
Edwards, T. C., Patrick, D. L., & Topolski, T. D. (2003). Quality of life of adolescents  
with perceived disabilities. Journal of Pediatric Psychology, 28(4), 233-241. 
doi:10.1093/jpepsy/jsg011 
Eiholzer, U., Boltshauser, E., Frey, D., Molinari, L., & Zachmann, M. (1988). Short  
stature: A common feature in Duchenne muscular dystrophy. European Journal of 
Pediatrics,147(6), 602-605. doi:10.1007/bf00442472 
Eiser, C., & Jenney, M. (2007). Measuring quality of life. Archives of Disease in  
Childhood,92(4), 348-350. doi:10.1136/adc.2005.086405 
Eiser, C., & Morse, R. (2001). A review of measures of quality of life for children with 
chronic illness. Archives of Disease in Childhood, 84, 205–211. 
Elsenbruch, S., Schmid, J., Lutz, S., Geers, B., & Schara, U. (2013). Self-reported quality of life  
and depressive symptoms in children, adolescents, and adults with Duchenne muscular 




Emery, A., Muntoni, F., & Quinlivan, R. (2015). Duchenne Muscular Dystrophy. Oxford, UK:  
Oxford University Press. Retrieved 15 Apr. 2021, from 
https://oxfordmedicine.com/view/10.1093/med/9780199681488.001.0001/med-
9780199681488. 
Falzarano, M. S., Scotton, C., Passarelli, C., & Ferlini, A. (2015). Duchenne muscular dystrophy:  
From diagnosis to therapy. Molecules (Basel, Switzerland), 20(10), 18168-18184. 
https://doi.org/10.3390/molecules201018168 
Faul, F., Erdfelder, E., Buchner, A., & Lang, A. G. (2009). Statistical power analyses using  
G*Power 3.1: Tests for correlation and regression analyses. Behavior research 
methods, 41(4), 1149–1160. https://doi.org/10.3758/BRM.41.4.1149 
Fee, R. J., & Hinton, V. J. (2011). Resilience in children diagnosed with a chronic  
neuromuscular disorder. Journal of Developmental & Behavioral Pediatrics,32(9), 644-
650. doi:10.1097/dbp.0b013e318235d614 
Ferrans, C. E., Zerwic, J. J., Wilbur, J. E., & Larson, J. L. (2005). Conceptual model of  
health‐related quality of life. Journal of Nursing Scholarship, 37(4), 336-342. 
doi:10.1111/j.1547-5069.2005.00058.x 
Finder, J. D., Birnkrant, D., Carl, J., Farber, H. J., Gozal, D., Iannaccone, S. T., Kovesi, T.,  
Kravitz, R. M., Panitch, H., Schramm, C., Schroth, M., Sharma, G., Sievers, L., Silvestri, 
J. M., Sterni, L., & American Thoracic Society (2004). Respiratory care of the patient 
with Duchenne muscular dystrophy: ATS consensus statement. American journal of 
respiratory and critical care medicine, 170(4), 456–465. 
https://doi.org/10.1164/rccm.200307-885ST 




Cardiology,99(1), 1-19. doi:10.1159/000068446 
Gao, Q. Q., & McNally, E. M. (2015). The dystrophin complex: Structure, function, and  
implications for therapy. Comprehensive Physiology, 5(3), 1223–1239. 
https://doi.org/10.1002/cphy.c140048 
Gayraud, J., Ramonatxo, M., Rivier, F., Humberclaude, V., Petrof, B., & Matecki, S.  
(2010). Ventilatory parameters and maximal respiratory pressure changes with age in 
Duchenne muscular dystrophy patients. Pediatric Pulmonology. doi:10.1002/ppul.21204 
Geffken, G. R., Lehmkuhl, H., Walker, K. N., Storch, E. A., Heidgerken, A. D., Lewin, A.,  
 
Williams, L. B., & Silverstein, J. (2008). Family functioning processes and  
 
diabetic ketoacidosis in youths with type I diabetes. Rehabilitation Psychology,  
 
53(2), 231–237. https://doi.org/10.1037/0090-5550.53.2.231 
 
Gillis, J. M. (1999). Journal of Muscle Research and Cell Motility,20(7), 605-625.  
doi:10.1023/a:1005545325254 
Gold, J. I., Mahrer, N. E., Yee, J., & Palermo, T. M. (2009). Pain, fatigue, and health-related  
quality of life in children and adolescents with chronic pain. The Clinical Journal of 
Pain, 25(5), 407–412. https://doi.org/10.1097/AJP.0b013e318192bfb1 
Goldstein-Leever, A., Bass, J. A., Goyal, A., & Maddux, M. H. (2019). Health-related quality  
of life predicts psychology referral in youth with inflammatory bowel disease. Journal of 
Pediatric Nursing, 47, 73–77. https://doi.org/10.1016/j.pedn.2019.04.016 
Gomez-Merino, E., & Bach, J. R. (2002). Duchenne muscular dystrophy: Prolongation of  
life by noninvasive ventilation and mechanically assisted coughing. American Journal of 





Graf, A., Landolt, M. A., Mori, A. C., & Boltshauser, E. (2006). Quality of life and  
psychological adjustment in children and adolescents with neurofibromatosis type 1. The  
Journal of Pediatrics, 149(3), 348–353. https://doi.org/10.1016/j.jpeds.2006.04.025 
Graham, C. D., Simmons, Z., Stuart, S. R., & Rose, M. R. (2015). The potential of psychological  
 
interventions to improve quality of life and mood in muscle disorders. Muscle &  
 
Nerve, 52(1), 131–136. https://doi.org/10.1002/mus.24487 
 
Grigore, I., Frasin, M., & Diaconu, G. (2015). Cardiac complications in duchenne muscular  
dystrophy in children. Revista Română De Pediatrie, 64(4), 378-382. 
https://doi.org/10.37897/RJP.2015.4.4 
Grootenhuis, M. A., de Boone, J., & van der Kooi, A. J. (2007). Living with muscular dystrophy:  
health related quality of life consequences for children and adults. Health and Quality of 
Life Outcomes, 5, 31. https://doi.org/10.1186/1477-7525-5-31 
Guglieri, M., & Bushby, K. (2015). Recent developments in the management of  
Duchenne muscular dystrophy. Paediatrics and Child Health,25(11), 505-514. 
doi:10.1016/j.paed.2015.07.002 
Guyatt, G. H. (1993). Measuring health-related quality of life. Annals of Internal  
Medicine, 118(8), 622. doi:10.7326/0003-4819-118-8-199304150-00009 
Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of  
life. Annals of Internal Medicine,118(8), 622. doi:10.7326/0003-4819-118-8-199304150-
00009 
Halfon, N., & Newacheck, P. W. (2010). Evolving notions of childhood chronic  





Harper, D. C., & Peterson, D. B. (2000). Neuromuscular and musculoskeletal disorders in  
children. In R. G. Frank & T. R. Elliott (Eds.), Handbook of rehabilitation psychology (p. 
123–144). American Psychological Association. https://doi.org/10.1037/10361-006 
Heller, K. W., Mezei, P. J., & Avant, M. J. T. (2008). Meeting the assistive technology needs  
of students with duchenne muscular dystrophy. Journal of Special Education Technology, 
23(4), 15–30. https://doi.org/10.1177/016264340802300402 
Hendriksen, J. G., Poysky, J. T., Schrans, D. G., Schouten, E. G., Aldenkamp, A. P., & Vles, J.  
S. (2009). Psychosocial adjustment in males with Duchenne muscular dystrophy: 
Psychometric properties and clinical utility of a parent-report questionnaire. Journal of 
pediatric psychology, 34(1), 69–78. https://doi.org/10.1093/jpepsy/jsn067 
Hendriksen, J. G., & Vles, J. S. (2006). Are males with duchenne muscular dystrophy  
at risk for reading disabilities? Pediatric Neurology,34(4), 296-300. 
doi:10.1016/j.pediatrneurol.2005.08.029 
Hendriksen, J. G., & Vles, J. S. (2008). Neuropsychiatric disorders in males with  
duchenne muscular dystrophy: Frequency rate of attention-deficit hyperactivity disorder 
(ADHD), autism spectrum disorder, and obsessive—compulsive disorder. Journal of 
Child Neurology,23(5), 477-481. doi:10.1177/0883073807309775 
Henricson, E., Abresch, R., Han, J. J., Nicorici, A., Keller, E. G., Bie, E. D., &  
McDonald, C. M. (2013). The 6-Minute walk test and person-reported outcomes in boys 
with duchenne muscular dystrophy and typically developing controls: Longitudinal 
comparisons and clinically-meaningful changes over one year. PLoS Currents. 
doi:10.1371/currents.md.9e17658b007eb79fcd6f723089f79e06 




health-related quality of life in adolescents with pediatric inflammatory bowel 
disease. European Journal of Gastroenterology & Hepatology,23(1), 95-100. 
doi:doi:10.1097/MEG.0b013e3283417abb. 
Hinton, V. J., De Vivo, D. C., Fee, R., Goldstein, E., & Stern, Y. (2004). Investigation of  
poor academic achievement in children with duchenne muscular dystrophy. Learning 
Disabilities Research and Practice,19(3), 146-154. doi:10.1111/j.1540-
5826.2004.00098.x 
Hinton, V. J., De Vivo, D. C., Nereo, N. E., Goldstein, E., & Stern, Y. (2001). Selective deficits  
in verbal working memory associated with a known genetic etiology: The 
neuropsychological profile of Duchenne muscular dystrophy. Journal of the International 
Neuropsychological Society, 7(1), 45–54. https://doi.org/10.1017/S1355617701711058  
Hinton, V. J., Nereo, N. E., Fee, R. J., & Cyrulnik, S. E. (2006). Social behavior  
problems in boys with duchenne muscular dystrophy. Journal of Developmental & 
Behavioral Pediatrics,27(6), 470-476. doi:10.1097/00004703-200612000-00003 
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987). Dystrophin: The protein product  
of the duchenne muscular dystrophy locus. Cell,51(6), 919-928. doi:10.1016/0092-
8674(87)90579-4 
Hoque, R. (2016). Sleep-disordered breathing in duchenne muscular dystrophy: An  
assessment of the literature. Journal of Clinical Sleep Medicine,12(06), 905-911. 
doi:10.5664/jcsm.5898 




Lapierre, G., & Vanasse, M. (2008). Deflazacort use in duchenne muscular dystrophy: 
An 8-year follow-up. Pediatric Neurology, 38(3), 200–206. 
https://doi.org/10.1016/j.pediatrneurol.2007.11.001 
Hunt, A., Carter, B., Abbott, J., Parker, A., Spinty, S., & deGoede, C. (2016). Pain experience,  
expression and coping in boys and young men with Duchenne muscular dystrophy - A 
pilot study using mixed methods. European Journal of Paediatric Neurology: EJPN: 
Oofficial Journal of the European Paediatric Neurology Society, 20(4), 630–638. 
https://doi.org/10.1016/j.ejpn.2016.03.002 
Hyde, S. A., FlŁytrup, I., Glent, S., Kroksmark, A. K., Salling, B., Steffensen, B. F., Werlauff,  
U., & Erlandsen, M. (2000). A randomized comparative study of two methods for 
controlling Tendo Achilles contracture in Duchenne muscular dystrophy. Neuromuscular 
Disorders: NMD, 10(4-5), 257–263. https://doi.org/10.1016/s0960-8966(99)00135-2 
Iannaccone, S. T., Hynan, L. S., Morton, A., Buchanan, R., Limbers, C. A., Varni, J. W., &  
AmSMART Group (2009). The PedsQL in pediatric patients with spinal muscular 
atrophy: Feasibility, reliability, and validity of the pediatric quality of life inventory 
generic core scales and neuromuscular module. Neuromuscular Disorders: NMD, 19(12), 
805–812. https://doi.org/10.1016/j.nmd.2009.09.009 
Ishikawa, Y., Miura, T., Ishikawa, Y., Aoyagi, T., Ogata, H., Hamada, S., & Minami, R.  
 
(2011). Duchenne muscular dystrophy: Survival by cardio-respiratory  
 
interventions. Neuromuscular Disorders, 21(1), 47-51. doi: 10.1016/j.nmd.2010.09.006 
 
James, J., Kinnett, K., Wang, Y., Ittenbach, R. F., Benson, D. W., & Cripe, L. (2011).  
 
Electrocardiographic abnormalities in very young Duchenne muscular dystrophy patients  
 







Janisch, M., Boehme, K., Thiele, S., Bock, A., Kirschner, J., Schara, U., Walter, M. C., Nolte- 
 
Buchholtz, S., & von der Hagen, M. (2020). Tasks and interfaces in primary and  
 
specialized palliative care for duchenne muscular dystrophy – A patients’ perspective.  
 




Jastrowski Mano, K. E., Khan, K. A., Ladwig, R. J., & Weisman, S. J. (2011). The impact of  
pediatric chronic pain on parents' health-related quality of life and family functioning: 
reliability and validity of the PedsQL 4.0 Family Impact Module. Journal of Pediatric 
Psychology, 36(5), 517–527. https://doi.org/10.1093/jpepsy/jsp099 
Jensen, M. P., Abresch, R. T., Carter, G. T., & McDonald, C. M. (2005). Chronic pain in persons  
 




Jones, J., Cunningham, N., Kashikar-Zuck, S., & Brunner, H. (2015). Pain, fatigue, and  
 
psychological impact on health-related quality of life in childhood-onset lupus.  
 
Arthritis Care & Research. 68. 10.1002/acr.22650. 
 
Joyce, N. C., Hache, L. P., & Clemens, P. R. (2012). Bone health and associated  
metabolic complications in neuromuscular diseases. Physical Medicine and 
Rehabilitation Clinics of North America,23(4), 773-799. doi:10.1016/j.pmr.2012.08.005 
Kamdar, F., & Garry, D. J. (2016). Dystrophin-deficient cardiomyopathy. Journal of the  
American College of Cardiology,67(21), 2533-2546.  
doi:10.1016/j.jacc.2016.02.081 




Kamphuis, R. P., & Verloove-Vanhorick, S. (2002). Health related quality of life and 
health status in adult survivors with previously operated complex congenital heart 
disease. Heart, 87(4), 356. doi:http://dx.doi.org.unco.idm.oclc.org/10.1136/heart.87.4.356 
Kaspar, R. W., Allen, H. D., & Montanaro, F. (2009). Current understanding and  
management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. 
Journal of the American Academy of Nurse Practitioners,21(5), 241-249. 
doi:10.1111/j.1745-7599.2009.00404.x 
Katz, S. L., Barrowman, N., Monsour, A., Su, S., Hoey, L., & Mckim, D. (2015). Long- 
term effects of lung volume recruitment on maximal inspiratory capacity and vital 
capacity in Duchenne Muscular Dystrophy. Annals of the American Thoracic Society. 
doi:10.1513/annalsats.201507-475bc 
Kazak, A. E., Segal-Andrews, A. M., & Johnson, K. (1995). Pediatric psychology research and  
practice: A family/systems approach. In M. C. Roberts (Ed.), Handbook of pediatric  
psychology (p. 84–104). The Guilford Press. 
Keith, T. Z. (2006). Multiple regression and beyond. New York: Routledge. 
 
Khadilkar, S. V., Yadav, R. S., & Patel, B. A. (2018). Neuromuscular disorders: A  
comprehensive review with illustrative cases. Springer. https://doi.org/10.1007/978-981-
10-5361-0 
Khirani, S., Ramirez, A., Aubertin, G., Boulé, M., Chemouny, C., Forin, V., & Fauroux,  
B. (2014). Respiratory muscle decline in duchenne muscular dystrophy. Pediatric 
Pulmonology,49(5), 473-481. doi:10.1002/ppul.22847 




R., & Kissel, J. T. (2007). Orthopedic outcomes of long-term daily corticosteroid 
treatment in Duchenne muscular dystrophy. Neurology, 68(19), 1607–1613. 
https://doi.org/10.1212/01.wnl.0000260974.41514.83 
Kohler, M., Clarenbach, C. F., Boni, L., Brack, T., Russi, E. W., & Bloch, K. E. (2005).  
Quality of life, physical disability, and respiratory impairment in duchenne  
muscular dystrophy. American Journal of Respiratory Critical Care Medicine, 172, 
1032-1036. 
Kratz, A. L., Hirsh, A. T., Ehde, D. M., & Jensen, M. P. (2013). Acceptance of pain in  
neurological disorders: Associations with functioning and psychosocial well-
being. Rehabilitation Psychology, 58(1), 1–9. https://doi.org/10.1037/a0031727 
Laerd Statistics. (2018). Multiple Regression: SPSS Statistics. Statistical tutorials and software  
guides. Retrieved from https://statistics.laerd.com/  
Landfeldt, E., Lindgren, P., Bell, C. F., Guglieri, M., Straub, V., Lochmüller, H., &  
Bushby, K. (2016). Quantifying the burden of caregiving in Duchenne muscular 
dystrophy. Journal of Neurology,263(5), 906-915. doi:10.1007/s00415-016-8080-9 
Landfeldt, E., Lindgren, P., Bell, C. F., Schmitt, C., Guglieri, M., Straub, V., Lochmüller, H., &  
Bushby, K. (2014). The burden of Duchenne muscular dystrophy: an international, cross-
sectional study. Neurology, 83(6), 529–536. 
https://doi.org/10.1212/WNL.0000000000000669 
Landgraf, J. M., Abetz, L., & Ware, J. E. (1999). The CHQ: A User's Manual (2nd  
printing). Boston, MA: HealthAct, 1996. 
Lapidos, K. A., Kakkar, R., & McNally, E. M. (2004). The dystrophin glycoprotein complex:  





Larkindale, J., Yang, W., Hogan, P. F., Simon, C. J., Zhang, Y., Jain, A., Habeeb-Louks, E. M.,  
Kennedy, A., & Cwik, V. A. (2014). Cost of illness for neuromuscular diseases in the 
United States. Muscle & nerve, 49(3), 431–438. https://doi.org/10.1002/mus.23942 
Law, E., Fisher, E., Eccleston, C., & Palermo, T. M. (2019). Psychological interventions for  
parents of children and adolescents with chronic illness. Cochrane Database of 
Systematic Reviews, 2019(3), [CD009660]. https://doi.org/10.1002/14651858.CD009660 
Law, E. F., Fisher, E., Fales, J., Noel, M., & Eccleston, C. (2014). Systematic review and meta- 
analysis of parent and family-based interventions for children and adolescents with 
chronic medical conditions. Journal of Pediatric Psychology, 39(8), 866–886. 
https://doi.org/10.1093/jpepsy/jsu032 
Lebel, D. E., Corston, J. A., Mcadam, L. C., Biggar, W. D., & Alman, B. A. (2013).  
Glucocorticoid treatment for the prevention of scoliosis in children with duchenne 
muscular dystrophy: Long-term follow-up. The Journal of Bone and Joint Surgery-
American Volume,95(12), 1057-1061. doi:10.2106/jbjs.l.01577 
Leeman, J., Crandell, J. L., Lee, A., Bai, J., Sandelowski, M., & Knafl, K. (2016). Family  
functioning and the well-being of children with chronic conditions: A meta-
analysis. Research in Nursing & Health,39(4), 229-243. doi:10.1002/nur.21725 
Lehmann, A., Speight, B. S., & Kerzin-Storrar, L. (2011). Extended family impact of genetic  
testing: the experiences of X-linked carrier grandmothers. Journal of genetic 
counseling, 20(4), 365–373. https://doi.org/10.1007/s10897-011-9360-2 




Discrepancy in parent-child reports. International Journal of Cancer, 83(S12), 58-64. 
doi:10.1002/(sici)1097-0215(1999)83:12 3.0.co;2-a 
Lewandowski, A. S., Palermo, T. M., Stinson, J., Handley, S., & Chambers, C. T. (2010).  
Systematic review of family functioning in families of children and adolescents with 
chronic pain. The Journal of Pain, 11(11), 1027–1038. 
https://doi.org/10.1016/j.jpain.2010.04.005 
Lim, Y., Velozo, C., & Bendixen, R. M. (2014). The level of agreement between child  
self-reports and parent proxy-reports of health-related quality of life in boys with 
Duchenne muscular dystrophy. Quality of Life Research, 23(7), 1945-1952. 
doi:10.1007/s11136-014-0642-7 
Lin, X., Lin, I., & Fan, S. (2013). Methodological issues in measuring health-related  
quality of life. Tzu Chi Medical Journal,25(1), 8-12. doi:10.1016/j.tcmj.2012.09.002 
LoMauro, A., Romei, M., Dangelo, M. G., & Aliverti, A. (2013). Determinants of cough  
efficiency in Duchenne muscular dystrophy. Pediatric Pulmonology, 49(4), 357-365. 
doi:10.1002/ppul.22836 
Lue, Y. J., Chen, S. S., & Lu, Y. M. (2017). Quality of life of patients with Duchenne muscular  
dystrophy: from adolescence to young men. Disability and Rehabilitation, 39(14), 1408–
1413. https://doi.org/10.1080/09638288.2016.1196398 
Magliano, L., Patalano, M., Sagliocchi, A., Scutifero, M., Zaccaro, A., D'angelo, M. G., Civati,  
F., Brighina, E., Vita, G., Vita, G. L., Messina, S., Sframeli, M., Pane, M., Lombardo, M. 
E., Scalise, R., D'amico, A., Colia, G., Catteruccia, M., Balottin, U., Berardinelli, A., … 




children and young adults with muscular dystrophies. Muscle & nerve, 52(1), 13–21. 
https://doi.org/10.1002/mus.24503 
Mah, J. K. (2016). Current and emerging treatment strategies for Duchenne muscular  
 




Mah, J. K., Thannhauser, J. E., Kolski, H., & Dewey, D. (2008). Parental stress and  
 
quality of life in children with neuromuscular disease. Pediatric  
 
Neurology,39(2), 102-107. doi:10.1016/j.pediatrneurol.2008.04.011 
 
Markham, L. W., Kinnett, K., Wong, B. L., Benson, D. W., & Cripe, L. H. (2008).  
Corticosteroid treatment retards development of ventricular dysfunction in Duchenne 
muscular dystrophy. Neuromuscular Disorders,18(5), 365-370. 
doi:10.1016/j.nmd.2008.03.002 
Matza, L. S., Swensen, A. R., Flood, E. M., Secnik, K., & Leidy, N. K. (2004).  
Assessment of health-related quality of life in children: A review of conceptual, 
methodological, and regulatory issues. Value in Health,7(1), 79-92. doi:10.1111/j.1524-
4733.2004.71273.x 
Mayer, O. H., Finkel, R. S., Rummey, C., Benton, M. J., Glanzman, A. M., Flickinger, J.,  
Lindström, B. M., & Meier, T. (2015). Characterization of pulmonary function in 
Duchenne Muscular Dystrophy. Pediatric pulmonology, 50(5), 487–494. 
https://doi.org/10.1002/ppul.23172 
McCartan, C., Mason, R., Jayasinghe, S. R., & Griffiths, L. R. (2012). Cardiomyopathy  
classification: ongoing debate in the genomics era. Biochemistry research 




McDonald, C. M. (2002). Physical activity, health impairments, and disability in  
neuromuscular disease. American Journal of Physical Medicine & 
Rehabilitation,81(Supplement). doi:10.1097/00002060-200211001-00012 
McDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Elfring, G. L.,  
Atkinson, L., Reha, A., Hirawat, S., & Miller, L. L. (2010). The 6-minute walk test as a 
new outcome measure in Duchenne muscular dystrophy. Muscle & nerve, 41(4), 500–
510. https://doi.org/10.1002/mus.21544 
McNally, E. M., Kaltman, J. R., Benson, D. W., Canter, C. E., Cripe, L. H., Duan, D., Finder, J.  
D., Groh, W. J., Hoffman, E. P., Judge, D. P., Kertesz, N., Kinnett, K., Kirsch, R., 
Metzger, J. M., Pearson, G. D., Rafael-Fortney, J. A., Raman, S. V., Spurney, C. F., 
Targum, S. L., Wagner, K. R., … Parent Project Muscular Dystrophy (2015). 
Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the 
National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular 
Dystrophy. Circulation, 131(18), 1590–1598. 
https://doi.org/10.1161/CIRCULATIONAHA.114.015151 
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al-Dahhak, R., Gastier-Foster, J.,  
Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., Hamil, C., Mahmoud, M., Roush, K., 
Bird, L., Rankin, C., Lilly, H., Street, N., Chandrasekar, R., & Weiss, R. B. (2012). 
Evidence-based path to newborn screening for Duchenne muscular dystrophy. Annals of 
Neurology, 71(3), 304–313. https://doi.org/10.1002/ana.23528 
Mercuri, E., & Muntoni, F. (2013). Muscular dystrophies. The Lancet,381(9869), 845- 
860. doi:10.1016/s0140-6736(12)61897-2 




mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired 
cough. Chest, 125(4), 1406–1412. https://doi.org/10.1378/chest.125.4.1406 
Moat, S. J., Bradley, D. M., Salmon, R., Clarke, A., & Hartley, L. (2013). Newborn  
bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales 
(UK). European Journal of Human Genetics,21(10), 1049-1053. 
doi:10.1038/ejhg.2012.301 
Modi, A. C., & Quittner, A. L. (2003). Validation of a disease-specific measure of health-related  
quality of life for children with cystic fibrosis. Journal of Pediatric Psychology, 28(8), 
535–545. https://doi.org/10.1093/jpepsy/jsg044 
Moore, V. C. (2012). Spirometry: Step by step. Breathe, 8(3), 233-240.  
doi: 10.1183/20734735.0021711 
Moreira, H., Frontini, R., Bullinger, M., & Canavarro, M. C. (2013). Caring for a child with  
 
Type 1 diabetes: Links between family cohesion, perceived impact, and parental  
 




Morrison, L. A. (2011). Dystrophinopathies. In R.C. Griggs & A.A. Amato (Eds.),  
Handbook of Clinical Neurology (pp. 11-39).  
Moxley, R. T., Pandya, S., Ciafaloni, E., Fox, D. J., & Campbell, K. (2010). Change in natural 
history of duchenne muscular dystrophy with long-term corticosteroid treatment: 
Implications for management. Journal of Child Neurology, 25(9), 1116-1129. 
doi:10.1177/0883073810371004 
Nereo, N. E. (2003). Parental stress in mothers of boys with duchenne muscular  




Nigro, G., Comi, L., Politano, L., & Bain, R. (1990). The incidence and evolution of  
cardiomyopathy in Duchenne muscular dystrophy. International Journal of 
Cardiology,26(3), 271-277. doi:10.1016/0167-5273(90)90082-g 
Opstal, S. L., Jansen, M., Alfen, N. V., & Groot, I. J. (2013). Health-related quality of life  
and its relation to disease severity in boys with duchenne muscular dystrophy. Journal of 
Child Neurology, 29(11), 1486-1495. doi:10.1177/0883073813506490 
Osorio, A. N., Cantillo, J. M., Salas, A. C., Garrido, M. M., & Padilla, J. V. (2018).  
Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular 
dystrophy. Neurología (English Edition). doi:10.1016/j.nrleng.2018.01.001 
Otto, C., Steffensen, B. F., Højberg, A. L., Barkmann, C., Rahbek, J., Ravens-Sieberer, U.,  
Mahoney, A., Vry, J., Gramsch, K., Thompson, R., Rodger, S., Bushby, K., Lochmüller,  
H., & Kirschner, J. (2017). Predictors of health-related quality of life in boys with 
duchenne muscular dystrophy from six european countries. Journal of Neurology, 264(4), 
709–723. https://doi.org/10.1007/s00415-017-8406-2 
Ozyurt, G., Bayram, E., Karaoglu, P., Hiz Kurul, S., & Yis, U. (2015). Quality of life and sleep  
in children diagnosed with duchenne muscular dystrophy and their mothers’ level of 
anxiety: a case-control study. Dusunen Adam The Journal of Psychiatry and 
Neurological Sciences, 28(4), 362. 
Paganoni, S., Nicholson, K., Leigh, F., Swoboda, K., Chad, D., Drake, K., Haley, K.,  
Cudkowicz, M., & Berry, J. D. (2017). Developing multidisciplinary clinics for  
neuromuscular care and research. Muscle & Nerve, 56(5), 848–858.  
https://doi.org/10.1002/mus.25725 





Randomized controlled trials of psychological therapies for management of chronic pain  
 




Pane, M., Lombardo, M. E., Alfieri, P., D'Amico, A., Bianco, F., Vasco, G., Piccini, G.,  
Mallardi, M., Romeo, D. M., Ricotti, V., Ferlini, A., Gualandi, F., Vicari, S., Bertini, E.,  
Berardinelli, A., & Mercuri, E. (2012). Attention deficit hyperactivity disorder and  
cognitive function in Duchenne muscular dystrophy: Phenotype-genotype  
correlation. The Journal of Pediatrics, 161(4), 705–9.e1.  
https://doi.org/10.1016/j.jpeds.2012.03.020 
Panepinto, J. A. (2008). Health-related quality of life in sickle cell disease. Pediatric Blood &  
Cancer, 51(1), 5–9. https://doi.org/10.1002/pbc.21557  
Pangalila, R. F., Bos, G. A., Stam, H. J., Exel, N. J., Brouwer, W. B., & Roebroeck, M. E. 
(2012). Subjective caregiver burden of parents of adults with Duchenne muscular 
dystrophy. Disability and Rehabilitation,34(12), 988-996. 
doi:10.3109/09638288.2011.628738 
Parkin, P. C., Kirpalani, H. M., Rosenbaum, P. L., Fehlings, D. L., Nie, A. V., Willan, A.  
R., & King, D. (1997). Development of a health-related quality of life instrument for use 
in children with spina bifida. Quality of Life Research, 6(2), 123-132. 
doi:10.1023/A:1026486016212 
Parkyn, H., & Coveney, J. (2013). An exploration of the value of social interaction in a boys'  
group for adolescents with muscular dystrophy. Child: Care, Health & Development, 
39(1), 81-89. https://doi.org/10.1111/j.1365-2214.2011.01353.x 




muscular dystrophy: lessons for earlier detection. European Journal of Paediatric 
Neurology: EJPN : Official Journal of the European Paediatric Neurology Society, 8(3), 
145–153. https://doi.org/10.1016/j.ejpn.2004.01.009 
Passamano, L., Taglia, A., Palladino, A., Viggiano, E., D'Ambrosio, P., Scutifero, M., Rosaria  
Cecio, M., Torre, V., DE Luca, F., Picillo, E., Paciello, O., Piluso, G., Nigro, G., & 
Politano, L. (2012). Improvement of survival in Duchenne Muscular Dystrophy: 
retrospective analysis of 835 patients. Acta Myologica : Myopathies and 
Cardiomyopathies: Official Journal of the Mediterranean Society of Myology, 31(2), 
121–125. 
Pegoraro, E., Hoffman, E. P., Piva, L., Gavassini, B. F., Cagnin, S., Ermani, M., Bello, L.,  
Soraru, G., Pacchioni, B., Bonifati, M. D., Lanfranchi, G., Angelini, C., Kesari, A., Lee, 
I., Gordish-Dressman, H., Devaney, J. M., McDonald, C. M., & Cooperative 
International Neuromuscular Research Group (2011). SPP1 genotype is a determinant of 
disease severity in Duchenne muscular dystrophy. Neurology, 76(3), 219–226. 
https://doi.org/10.1212/WNL.0b013e318207afeb 
Phillips, M., Quinlivan, R., Edwards, R., & Calverley, P. (2001). Changes in Spirometry  
Over Time as a Prognostic Marker in Patients with Duchenne Muscular Dystrophy. 
American Journal of Respiratory and Critical Care Medicine,164(12), 2191-2194. 
doi:10.1164/ajrccm.164.12.2103052 
Phipps, S., Dunavant, M., Garving, P. A., Lensing, S., & Rai, S. N. (2002). Acute health  
related quality of life in children undergoing stem cell transplant: I. Descriptive 
outcomes. Bone Marrow Transplantation, 29(5), 425-434. 




Aanalyses with Sas and Ibm's Spss. Routledge/Taylor & Francis Group.  
Podsakoff, P. M., MacKenzie, S. B., Lee, J.-Y., & Podsakoff, N. P. (2003). Common method  
biases in behavioral research: A critical review of the literature and recommended 
remedies. Journal of Applied Psychology, 88(5), 879–903. https://doi.org/10.1037/0021-
9010.88.5.879 
Poysky, J., & Kinnett, K. (2009). Facilitating family adjustment to a diagnosis of  
Duchenne muscular dystrophy: April 24–25, 2008, Miami, Florida. Neuromuscular 
Disorders,19(10), 733-738. doi:10.1016/j.nmd.2009.07.011 
Quast, L. F., Phillips, P. C., Li, Y., Kazak, A. E., Barakat, L. P., & Hocking, M. C. (2018). A  
prospective study of family predictors of health-related quality of life in pediatric brain 
tumor survivors. Pediatric Blood & Cancer, 65(6), e26976. 
https://doi.org/10.1002/pbc.26976 
Quinlivan, R., Roper, H., Davie, M., Shaw, N., Mcdonagh, J., & Bushby, K. (2005).  
Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 
16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and 
prevention. Neuromuscular Disorders,15(1), 72-79. doi:10.1016/j.nmd.2004.09.009 
Quittner, A. L., Davis, M. A., & Modi, A. C. (2003). Health-Related Quality of Life in Pediatric  
Populations. In M. C. Roberts (Ed.), Handbook of Pediatric Psychology (p. 696–709). 
The Guilford Press. 
Rae, M. G., & O’Malley, D. (2016). Cognitive dysfunction in Duchenne muscular  
dystrophy: A possible role for neuromodulatory immune molecules. Journal of 
Neurophysiology,116(3), 1304-1315. doi:10.1152/jn.00248.2016 




Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council 
bulletin, 27(1), 38–42. 
Rall, S., & Grimm, T. (2012). Survival in Duchenne muscular dystrophy. Acta Myologica:  
Myopathies and Cardiomyopathies: Official Journal of the Mediterranean Society of  
Myology, 31(2), 117–120. 
Ramaciotti, C., Heistein, L. C., Coursey, M., Lemler, M. S., Eapen, R. S., Iannaccone, S.  
T., & Scott, W. A. (2006). Left ventricular function and response to enalapril in patients 
with duchenne muscular dystrophy during the second decade of life. The American 
Journal of Cardiology, 98(6), 825-827. doi:10.1016/j.amjcard.2006.04.020 
Rando, T. A. (2001). The dystrophin-glycoprotein complex, cellular signaling, and the  
regulation of cell survival in the muscular dystrophies. Muscle & Nerve,24(12), 1575-
1594. doi:10.1002/mus.1192 
Ravens-Sieberer, U., Gosch, A., Rajmil, L., Erhart, M., Bruil, J., Duer, W., Auquier, P., Power,  
M., Abel, T., Czemy, L., Mazur, J., Czimbalmos, A., Tountas, Y., Hagquist, C., Kilroe, 
J., & European KIDSCREEN Group. (2005). KIDSCREEN-52 quality-of-life measure 
for children and adolescents. Expert Review of Pharmacoeconomics & Outcomes 
Research, 5(3), 353-364. doi:10.1586/14737167.5.3.353 
Ricotti, V., Mandy, W. P., Scoto, M., Pane, M., Deconinck, N., Messina, S., Mercuri, E., Skuse,  
D. H., & Muntoni, F. (2015). Neurodevelopmental, emotional, and behavioural problems  
in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations.  
Developmental Medicine & Child Neurology,58(1), 77-84. doi:10.1111/dmcn.12922 




E., Cunniff, C., Druschel, C. M., Mathews, K. D., Matthews, D. J., Meaney, F. J., 
Andrews, J. G., Conway, K. M., Fox, D. J., Street, N., Adams, M. M., Bolen, J., & MD 
STARnet (2015). Prevalence of Duchenne and Becker muscular dystrophies in the United 
States. Pediatrics, 135(3), 513–521. https://doi.org/10.1542/peds.2014-2044 
Ronen, G. M., Fayed, N., & Rosenbaum, P. L. (2011). Outcomes in pediatric neurology:  
A review of conceptual issues and recommendations: The 2010 Ronnie Mac Keith 
Lecture. Developmental Medicine & Child Neurology,53(4), 305-312. 
doi:10.1111/j.1469-8749.2011.03919.x 
Roye, D. P., Sheha, E. D., & Xu, N. (2015). Orthopedic Management. Neuromuscular  
Disorders of Infancy, Childhood, and Adolescence,1053-1071. doi:10.1016/b978-0-12-
417044-5.00052-4 
Santos, T., de Matos, M. G., Marques, A., Simões, C., Leal, I., & Machado, M. D. (2016).  
Adolescent's subjective perceptions of chronic disease and related psychosocial factors: 
highlights from an outpatient context study. BMC pediatrics, 16(1), 211. 
https://doi.org/10.1186/s12887-016-0748-x 
Sarrazin, E., von der Hagen, M. V., Schara, U., von Au, K. V., & Kaindl, A. M. (2014). Growth  
and psychomotor development of patients with Duchenne muscular dystrophy. European 
Journal of Paediatric Neurology,18(1), 38-44. doi:10.1016/j.ejpn.2013.08.008 
Sawyer, M. G., Whitham, J. N., Roberton, D. M., Taplin, J. E., Varni, J. W., & Baghurst, P. A.  
(2005). The relationship between health-related quality of life, pain and coping strategies 
in juvenile idiopathic arthritis. Rheumatology (Oxford, England), 43(3), 325–330. 
https://doi.org/10.1093/rheumatology/keh030 




quality of life and depressive symptoms in children, adolescents, and adults with 
duchenne muscular dystrophy: A cross-sectional survey study. Neuropediatrics,44(05), 
257-264. doi:10.1055/s-0033-1347935 
Shenk, Z., & Rodino-Klapac, L. (2014). Dystrophinopathies. In Neuromuscular  
Disorders in Clinical Practice (2nd ed., pp. 1169-1191). New York, NY: Springer. 
doi:10.1007/978-1-4614-6567-6 
Silvestri, N. J., Ismail, H., Zimetbaum, P., & Raynor, E. M. (2018). Cardiac involvement in the 
muscular dystrophies. Muscle & Nerve, 57(5), 707-715. doi:10.1002/mus.26014 
Simonds, A. K. (2002). Respiratory Complications of the Muscular Dystrophies.  
Seminars in Respiratory and Critical Care Medicine,23(3), 231-238. doi:10.1055/s-2002-
33031 
Skalsky, A. J., & McDonald, C. M. (2012). Prevention and Management of Limb  
Contractures in Neuromuscular Diseases. Physical Medicine and Rehabilitation Clinics 
of North America, 23(3), 675-687. doi:10.1016/j.pmr.2012.06.009 
Snow, W. M., Anderson, J. E., & Jakobson, L. S. (2013). Neuropsychological and  
neurobehavioral functioning in Duchenne muscular dystrophy: A review. Neuroscience 
& Biobehavioral Reviews,37(5), 743-752. doi:10.1016/j.neubiorev.2013.03.016 
Soim, A., Lamb, M., Campbell, K., Pandya, S., Peay, H., Howard, J., & Fox, D. (2016). A cross- 
sectional study of school experiences of boys with duchenne and becker muscular 
dystrophy. Physical Disabilities: Education and Related Services. 35(1). 
10.14434/pders.v35i2.21765. 




Rajmil, L. (2008). Health-related quality of life measurement in children and adolescents: 
A systematic review of generic and disease-specific instruments. Value in Health, 11(4), 
742-764. doi:10.1111/j.1524-4733.2007.00293.x 
Soltanzadeh, P., Friez, M. J., Dunn, D., von Niederhausern, A., Gurvich, O. L., Swoboda, K. J.,  
Sampson, J. B., Pestronk, A., Connolly, A. M., Florence, J. M., Finkel, R. S., 
Bönnemann, C. G., Medne, L., Mendell, J. R., Mathews, K. D., Wong, B. L., Sussman, 
M. D., Zonana, J., Kovak, K., Gospe, S. M., Jr, … Flanigan, K. M. (2010). Clinical and 
genetic characterization of manifesting carriers of DMD mutations. Neuromuscular 
Disorders: NMD, 20(8), 499–504. https://doi.org/10.1016/j.nmd.2010.05.010 
Somekh, B., & Lewin, C. (2005). Research methods in the social sciences. SAGE Publications. 
Spieth, L. E., & Harris, C. V. (1996). Assessment of health-related quality of life in  
children and adolescents: An integrative review. Journal of Pediatric Psychology, 21(2), 
175-193. doi:10.1093/jpepsy/21.2.175 
Sprangers, M. A., & Schwartz, C. E. (1999). Integrating response shift into health-related quality  
of life research: a theoretical model. Social science & medicine (1982), 48(11), 1507–
1515. https://doi.org/10.1016/s0277-9536(99)00045-3 
Starfield, B., Riley, A. W., Green, B. F., Ensminger, M. E., Ryan, S. A., Kelleher, K., Kim- 
Harris, S., Johnston, D., & Vogel, K. (1995). The adolescent child health and illness 
profile. Medical Care, 33(5), 553-566. doi:10.1097/00005650-199505000-00008 
Stehling, F., Bouikidis, A., Schara, U., & Mellies, U. (2014). Mechanical  
insufflation/exsufflation improves vital capacity in neuromuscular disorders. Chronic 
Respiratory Disease, 12(1), 31-35. doi:10.1177/1479972314562209 




neuromuscular disorder. Neuromuscular Disorders of Infancy, Childhood, and 
Adolescence,1072-1077. doi:10.1016/b978-0-12-417044-5.00053-6 
Svien, L., & Stuberg, W. (2001). Genetics. Pediatric physical therapy: The official publication of  
the Section on Pediatrics of the American Physical Therapy Association, 13(4), 155. 
Szabo, S. M., Audhya, I. F., Malone, D. C., Feeny, D., & Gooch, K. L. (2020). Characterizing  
health state utilities associated with Duchenne muscular dystrophy: A systematic 
review. Quality of Life Research: An International Journal of Quality of Life Aspects of 
Treatment, Care and Rehabilitation, 29(3), 593–605. https://doi.org/10.1007/s11136-019-
02355-x 
Tadros, H. J., Rawlinson, A. R., Martin, E., Pietra, B. A., Fricker, F. J., & Gupta, D. (2020).  
Family functioning in pediatric heart transplantation: Variables associated with poor  
outcomes. Pediatric transplantation, 24(8), e13883. https://doi.org/10.1111/petr.13883 
Tate, D. G., & Pledger, C. (2003). An integrative conceptual framework of disability: New  
 




Taylor, P. J., Betts, G. A., Maroulis, S., Gilissen, C., Pedersen, R. L., Mowat, D. R., Johnston,  
H. M., & Buckley, M. F. (2010). Dystrophin gene mutation location and the risk of  
cognitive impairment in duchenne muscular dystrophy. PLoS ONE,5(1). 
doi:10.1371/journal.pone.0008803 
Thompson, A. L., & Young-Saleme, T. K. (2015). Anticipatory Guidance and Psychoeducation  
as a Standard of Care in Pediatric Oncology. Pediatric Blood & Cancer, 62 Suppl 5, 
S684–S693. https://doi.org/10.1002/pbc.25721 




therapy for children with comorbid physical illness. Child and Adolescent Psychiatric 
Clinics of North America, 20(2), 329–348. https://doi.org/10.1016/j.chc.2011.01.013 
Thompson, R. J., Gustafson, K. E., Gil, K. M., Godfrey, J., & Murphy, L. M. (1998).  
Illness specific patterns of psychological adjustment and cognitive adaptational processes 
in children with cystic fibrosis and sickle cell disease. Journal of Clinical 
Psychology,54(1), 121-128. doi:10.1002/(sici)1097-4679(199801)54:13.0.co;2-m 
Tomiak, E. M., Samson, A., Miles, S.A., Choquette, M. C., Chakraborty, P.K. & Jacob,  
P.J. (2007). Gender-specific differences in the psychosocial adjustment of parents of a child 
with duchenne muscular dystrophy (DMD). Qualitative Research Journal. 7, 2-21. 
Toussaint, M., Chatwin, M., & Soudon, P. (2007). Review Article: Mechanical  
ventilation in Duchenne patients with chronic respiratory insufficiency: Clinical 
implications of 20 years published experience. Chronic Respiratory Disease,4(3), 167-
177. doi:10.1177/1479972307080697 
Tzeng, A. C., & Bach, J. R. (2000). Prevention of pulmonary morbidity for patients with  
neuromuscular disease. Chest, 118(5), 1390-1396. doi:10.1378/chest.118.5.1390 
U.S. Department of Health and Human Services. (1989). Report of the National  
Commission on Orphan Diseases.  
U.S. Food and Drug Administration. (1983). Orphan Drug Act of 1983.  
https://www.govinfo.gov/content/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf 
U.S. Food and Drug Administration. (2017, February 09). FDA approves drug to treat Duchenne  
muscular dystrophy. https://www.fda.gov/news-events/press-announcements/fda-
approves-drug-treat-duchenne-muscular-dystrophy 




W. (2012). Health-related quality of life in children and adolescents with Duchenne  
muscular dystrophy. Pediatrics, 130(6), e1559–e1566. https://doi.org/10.1542/peds.2012- 
0858 
Valdez, R., Grosse, S. D., & Khoury, M. J. (2016). The need for a next-generation public  
health response to rare diseases. Genetics in Medicine,19(5), 489-490.  
doi:10.1038/gim.2016.166 
van Ruiten, H. J., Straub, V., Bushby, K., & Guglieri, M. (2014). Improving recognition of  
Duchenne muscular dystrophy: A retrospective case note review. Archives of Disease in 
Childhood, 99(12), 1074–1077. https://doi.org/10.1136/archdischild-2014-306366 
Varni, J. W., Burwinkle, T. M., & Lane, M. M. (2005). Health-related quality of life  
measurement in pediatric clinical practice: An appraisal and percept for future research 
and application. Health and Quality of Life Outcomes,3(1), 34. doi:10.1186/1477-7525-3-
34 
Varni, J. W., Burwinkle, T. M., Seid, M., & Skarr, D. (2003). The PedsQL 4.0 as a pediatric  
population health measure: feasibility, reliability, and validity. Ambulatory Pediatrics: 
The Official Journal of the Ambulatory Pediatric Association, 3(6), 329–341. 
https://doi.org/10.1367/1539-4409(2003)003<0329:tpaapp>2.0.co;2 
Varni, J. W., Limbers, C. A., & Burwinkle, T. M. (2007). Impaired health-related quality  
of life in children and adolescents with chronic conditions: A comparative analysis of 10 
disease clusters and 33 disease categories/severities utilizing the PedsQL™ 4.0 Generic 
Core Scales. Health and Quality of Life Outcomes,5(1). doi:10.1186/1477-7525-5-43 




the pediatric quality of life inventory™ version 4.0 generic core scales in healthy and 
patient populations. Medical Care,39(8), 800-812. doi:10.1097/00005650-200108000-
00006 
Varni, J. W., Seid, M., & Rode, C. A. (1999). The PedsQL: Measurement model for the pediatric  
quality of life inventory. Medical Care, 37(2), 126–139. 
https://doi.org/10.1097/00005650-199902000-00003 
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E., & Dixon, P. (2004).  
Health and quality of life outcomes, 2(1), 55. doi:10.1186/1477-7525-2-55 
Veehof, M. M., Trompetter, H. R., Bohlmeijer, E. T., & Schreurs, K. M. (2016). Acceptance-  
and mindfulness-based interventions for the treatment of chronic pain: a meta-analytic  
review. Cognitive behaviour therapy, 45(1), 5–31.  
https://doi.org/10.1080/16506073.2015.1098724 
Verhaert, D., Richards, K., Rafael-Fortney, J. A., & Raman, S. V. (2011). Cardiac involvement  
in patients with muscular dystrophies: Magnetic resonance imagining phenotype and 
genotypic considerations. Circulation: Cardiovascular Imaging, 4 (1), 67-76.  
Vry, J., Gramsch, K., Rodger, S., Thompson, R., Steffensen, B. F., Rahbek, J., Doerken, S.,  
Tassoni, A., Beytía, M. L., Guergueltcheva, V., Chamova, T., Tournev, I., Kostera-
Pruszczyk, A., Kaminska, A., Lusakowska, A., Mrazova, L., Pavlovska, L., Strenkova, J., 
Vondráček, P., Garami, M., … Kirschner, J. (2016). European cross-Sectional survey 
of current care practices for duchenne muscular dystrophy reveals regional and age-
dependent differences. Journal of Neuromuscular Diseases, 3(4), 517–527. 
https://doi.org/10.3233/JND-160185 




D'Anjou, M. C., Commare, M. C., & Berard, C. (2010). Self-perception of quality of life 
by adolescents with neuromuscular diseases. The Journal of Adolescent Health: Official 
Publication of the Society for Adolescent Medicine, 46(1), 70–76. 
https://doi.org/10.1016/j.jadohealth.2009.05.005 
Watson, M. S., Lloyd-Puryear, M. A., Mann, M. Y., Rinaldo, P., & Howell, R. R. (2006). Main  
report. Genetics in Medicine, 8(5), 12-252S. 
https://doi.org/10.1097/01.gim.0000223467.60151.02 
Wei, Y., Speechley, K., & Campbell, C. (2015). Health-related quality of life in  
children with duchenne muscular dystrophy: A review. Journal of Neuromuscular 
Diseases, 2(3), 313-324. doi:10.3233/jnd-150071 
Wei, Y., Speechley, K. N., Zou, G., & Campbell, C. (2016). Factors associated with health- 
related quality of life in children with duchenne muscular dystrophy. Journal of  
Child Neurology, 31(7), 879–886. https://doi.org/10.1177/0883073815627879 
Wei, Y., Speechley, K. N., Zou, G., & Campbell, C. (2017). The relationship between quality of  
life and health‐related quality of life in young males with Duchenne muscular 
dystrophy. Developmental Medicine & Child Neurology, 59(11), 1152-1157. 
Wicksell, R. K., Kihlgren, M., Melin, L., & Eeg-Olofsson, O. (2004). Specific cognitive  
deficits are common in children with duchenne muscular dystrophy. Developmental 
Medicine and Child Neurology, 46(3), 154-9.  
Wingeier, K., Giger, E., Strozzi, S., Kreis, R., Joncourt, F., Conrad, B., Gallati, S., & Steinlin, M.  
(2011). Neuropsychological impairments and the impact of dystrophin mutations on 
general cognitive functioning of patients with Duchenne muscular dystrophy. Journal of 




Wu, J. Y., Kuban, K. C., Allred, E., Shapiro, F., & Darras, B. T. (2005). Association of  
duchenne muscular dystrophy with autism spectrum disorder. Journal of Child 
Neurology,20(10), 790-795. doi:10.1177/08830738050200100201 
Zurynski, Y., Frith, K., Leonard, H., & Elliott, E. (2008). Rare childhood diseases: How 


























































Colorado Multiple Institutional Review Board, CB F490
University of Colorado, Anschutz Medical Campus













UCD Anschutz Medical Campus | UCD Downtown Denver Campus | University of Colorado Health | Denver Health and Hospitals |




Title: Health-Related Quality of Life and Psychosocial Factors in Youth with NeuromuscularDisorders









This study was reviewed and approved under the “2018 Requirements” of the Federal Policy for the Protection of Human
Subjects.
 
If continuing review is required for your research, your submission is APPROVED until the expiration date listed above.
The investigator will need to submit this research for Continuing Review at least 30 days prior to the expiration date. If a
study's approval expires, investigators must stop all research activities immediately (including data analysis) and contact
the COMIRB office for guidance
 
If your study has not been assigned an expiration date continuing review is not required for your research.
 
Regardless of continuing review, you are required to submit changes to your research for approval prior to implementing
those changes. You are required to report unanticipated problems and serious or continuing noncompliance to COMIRB.
When your research is complete you must report the study closure to COMIRB.
 
Your responsibilities as Principal Investigator are posted here:
http://www.ucdenver.edu/research/Research%20Administration%20Documents/Responsibilities-of-Investigators.docx
 
REVIEW DETAILS– Please read carefully:
 
Comments: Approved with continuing review. Category 7 Expedited.
Affiliated Site(s):










- 1 - Generated on IRBNet
  
   
 I n s t i t u t i o n a l R e v i e w B o a r d  
 
DATE: April 2, 2020
  
TO: Noelle Whitney
FROM: University of Northern Colorado (UNCO) IRB
  
PROJECT TITLE: [1571311-1] Health-Related Quality of Life and Psychosocial Factors in Youth
with Neuromuscular Disorders
SUBMISSION TYPE: New Project
  
ACTION: APPROVED
APPROVAL DATE: April 2, 2020
EXPIRATION DATE: *see note in bold below* 
REVIEW TYPE: Expedited Review
  
Thank you for your submission of New Project materials for this project. The University of Northern
Colorado (UNCO) IRB has APPROVED your submission. All research must be conducted in accordance
with this approved submission.
This submission has received Expedited Review based on applicable federal regulations.
Please remember that informed consent is a process beginning with a description of the project and
insurance of participant understanding. Informed consent must continue throughout the project via
a dialogue between the researcher and research participant. Federal regulations require that each
participant receives a copy of the consent document.
Please note that any revision to previously approved materials must be approved by this committee prior
to initiation. Please use the appropriate revision forms for this procedure.
All UNANTICIPATED PROBLEMS involving risks to subjects or others and SERIOUS and UNEXPECTED
adverse events must be reported promptly to this office.
All NON-COMPLIANCE issues or COMPLAINTS regarding this project must be reported promptly to this
office.
Under the recently revised Common Rule, this project will not require annual continuing review
by the committee. Your project has been assigned a "Next Report Due" date of April 2, 2023. 
Just prior to that date, the IRB will check in with you to get a current status of your project.  This
will help us determine if your project needs to be extended or if your study is ready to be closed.
  If you have completed your project prior to that date, please contact the Office of Research &
Sponsored Programs to complete a closing report.   

























































Principal Investigator: Noelle Whitney, MA/CAS 
COMIRB No: 19-2552  
Version Date: 02/05/2020   
 





You are being asked to be in a research study. This form provides you with information about the 
study. A member of the research team will describe this study to you and answer all of your 
questions. Please read the information below and ask questions about anything you don’t 
understand before deciding whether or not to take part.  
 
Why is this study being done? 
This study plans to learn more about psychosocial factors, health-related quality of life, 
demographic and medical information in youth and young adults with dystrophinopathies (i.e., 
Duchenne or Becker muscular dystrophy). 
You are being asked to be in this research study because you are the parent/legal guardian of a 
male between the ages of 5- and 25-years-old who has a formal diagnosis or suspected 
diagnosis of a dystrophinopathy or you are a male between the ages of 5- and 25-years-old and 
have a formal diagnosis or suspected diagnosis of a dystrophinopathy. Additionally, you are a 
patient or parent/legal guardian who is being seen through the Children’s Hospital Colorado 
(CHCO) Neuromuscular Clinic. 
Other people in this study 
Up to 80 people will participate in the study. 
What happens if I join this study? 
If you join the study, you will participate during one of your routine clinic visits with the 
Children’s Hospital Colorado Neuromuscular Multidisciplinary Clinic. Your involvement in 
this study will take approximately between 30-45 minutes. You will be asked to complete a 
number of questionnaires about your thoughts, feelings, well-being, family life, and behavior. 
Your parent will also be asked to fill out a form to obtain demographic/background information 
and a questionnaire asking about their perspective of their youths’ thoughts, feelings, well-
being, and behavior. Additionally, parents will complete a questionnaire about their own 




Given the researchers involvement in the Children’s Hospital Colorado Neuromuscular Clinic, 
they will have access to your or your child’s medical chart to extract information about 
medications and the presence of other diagnoses.  
What are the possible discomforts or risks? 
Discomforts you may experience while in this study include feelings of guilt or embarrassment 
when thinking or reporting on their own behaviors or attitudes on the study measures. A 
licensed clinical psychologist, Andrea Miele, Ph.D., will be available if uncomfortable feelings 
arise that you wish to discuss.  
 
You do not have to complete any questions that make you feel uncomfortable. You can choose 
to stop participating in the study at any point for any reason.  
 
There is the potential risk that patient information is accidentally seen by someone who is not 
on the research protocol. We will do all that we can to protect your information, but it cannot 
be guaranteed. Your information and all the data gathered through this study will be stored in 
secure, encrypted, and password protected databases and servers. To further ensure 
confidentiality, you will be assigned a randomly generated study ID. This ID will be used to 
replace your name in all of your responses so that none of your responses will be linked to your 
name. 
What are the possible benefits of the study?  
This study is designed for the researcher to learn more about youth with dystrophinopathies. 
This study is not designed to treat any illness or to improve your health. Also, there may be 
risks, as discussed in the section describing the possible discomforts or risks. 
Will I be paid for being in the study?   
You will not be paid to be in the study. 
Will I have to pay for anything? 
It will not cost you anything to be in the study. 
Is my participation voluntary? 
Taking part in this study is voluntary. You have the right to choose not to take part in this 
study.  If you choose to take part, you have the right to stop at any time. If you refuse or decide 
to withdraw later, you will not lose any benefits or rights to which you are entitled.   




The researcher carrying out this study is Noelle Whitney, MA/CAS. You may ask any questions 
you have now. If you have questions later, you may call Noelle at (720) 777-6214.    
 
You may have questions about your rights as someone in this study. You can call Noelle 
Whitney with questions. You can also call the Multiple Institutional Review Board (IRB).  You 
can call them at 303-724-1055.  
Who will see my research information? 
The University of Colorado Denver (UCD) and its affiliated hospital(s) have rules to protect 
information about you. Federal and state laws including the Health Insurance Portability and 
Accountability Act (HIPAA) also protect your privacy. This part of the consent form tells you 
what information about you may be collected in this study and who might see or use it.   
The institutions involved in this study include:  
• University of Colorado Denver 
• Children’s Hospital Colorado  
• University of Northern Colorado 
•  Children’s Hospital Colorado shares a medical record system with the Barbara Davis 
Center and PedsConnect; therefore, it is also possible that your information could be 
viewed by healthcare professionals at these organizations. 
 
We cannot do this study without your permission to see, use, and give out your information.  
You do not have to give us this permission.  If you do not, then you may not join this study.   
 
We will see, use and disclose your information only as described in this form and in our Notice 
of Privacy Practices; however, people outside the University and its affiliate health systems 
may not be covered by this promise. 
 
We will do everything we can to keep your records a secret. It cannot be guaranteed.  
 
The use and disclosure of your information has no time limit. You can cancel your permission 
to use and disclose your information at any time by writing to the study’s Primary Investigator, 
at the name and address listed below. If you do cancel your permission to use and disclose your 
information, your part in this study will end and no further information about you will be 
collected. Your cancellation would not affect information already collected in this study.   
 
  Noelle Whitney, MA/CAS 
  Children’s Hospital Colorado 
  13123 East 16th Avenue 
  Aurora, CO 80045 
 
Both the research records that identify you and the consent form signed by you may be looked at 
by others who have a legal right to see that information, such as:   
§ Federal offices such as the Food and Drug Administration (FDA) that protect research 




§ People at the Colorado Multiple Institutional Review Board (COMIRB) 
§ The study doctor and the rest of the study team 
§ Officials at the institution where the research is being conducted and officials at other 
institutions involved in this study who are in charge of making sure that we follow all of 
the rules for research 
We might talk about this research study at meetings. We might also print the results of this research 
study in relevant journals. But we will always keep the names of the research subjects, like you, 
private.  
 
Some things we cannot keep private. If you give us any information about child abuse or neglect 
we have to report that to Colorado Department of Human Services. Also, if we get a court order 
to turn over your study records, we will have to do that. 
 
Some things we cannot keep private: If you tell us you are going to physically hurt yourself or 
someone else, we have to report that to the Colorado Department of Human Services.  Also, if we 
get a court order to turn over your study records, we will have to do that. 
 
You have the right to request access to your personal health information from the Investigator.  
 
What happens to Data that are collected in this study?  
 
Scientists at the University and the health systems involved in this study work to find the causes 
and cures of disease. The data collected from you during this study are important to this study 
and to future research. If you join this study: 
 
• The data are given by you to the investigators for this research and so no longer belong 
to you.   
• Both the investigators and any sponsor of this research may study your data collected 
from you. 
• If the data are in a form that identifies you, the University or the health systems 
involved in this study may use them for future research only with your consent or IRB 
approval. 
• Any product or idea created by the researchers working on this study will not belong 
to you. 
• There is no plan for you to receive any financial benefit from the creation, use or sale 




Agreement to be in this study and use my data 
I have read this paper about the study or it was read to me. I understand the possible risks and 
benefits of this study. I understand and authorize the access, use and disclosure of my information 
as stated in this form. I know that being in this study is voluntary. I choose to be in this study: I 
will get a signed and dated copy of this consent form. 
 
Signature:         Date:     
Print Name:         
Consent form explained by:      Date:    
Print Name:        
Signature of Witness:                  Date:     
Print Name:        
 
Witness of Signature     
Witness of consent process   
 
___________________________________________    Date_________ 
Child (13-17 year olds) 
 
 
Consent form explained by:_____________________   Date:________ 
 



















Person in Charge of the Study: Noelle Whitney 
COMIRB No: 19-2552  
Version Date: 02/05/2020  
Assent Form for: Health-Related Quality of Life and Psychosocial Factors in Youth with 
Neuromuscular Disorders 
 
What is this study about? 
You are being asked if you want to be in this research study. The goal of this study is to learn more 
about you, your health, and your family. 
 
Why are you asking me? 
You are being asked to be in the study because you are male, between the ages of 5- and 25-years-
old and have a formal diagnosis or suspected diagnosis of Duchenne muscular dystrophy or 
another dystrophinopathy (i.e., Duchenne or Becker muscular dystrophy).  
 
What Do I Have to Do or What Will Happen to Me? 
If you are in the study, you will be asked to independently complete several questionnaires 
regarding your thoughts, feelings, behaviors, physical functioning, and family life during your 
routine visit to the Children’s Hospital Colorado Neuromuscular Multidisciplinary Clinic. These 
questionnaires will take you approximately 30 to 45 minutes to complete. 
 
You don’t have to answer any questions that you don’t want to, and you can stop at any time. 
 
Will this Hurt? 
There are no medical procedures involved with this research study.  
 
Can I ask Questions? 
You can ask any questions that you have now about the study. 
 
If you have a question later, you can ask and get an answer. If you want to, you can call Noelle 
Whitney, principal investigator, at (720) 777-6214 or Andrea Miele, co-investigator, at (720) 
777-5513. 
 
Do I Have to Do This? 
You do not have to be in this study. No one will be mad at you if you say, “no.” You can choose 
to stop at any time. Just tell the researcher if you want to stop.  
 
Do you want to be in the study at this time? (Check one box) 
o   Yes o   No 
 





Child’s Signature:         Date:    
Child’s Printed Name:        _____ 
 
Consent form explained by:         _____________________ 




I have explained the research at a level that is understandable by the child and believe that the 
child understands what is expected during this study. 
 

























































































Today’s Date: ______________ 
 
Who is completing this form? 
  Mother, Stepmother, or Foster mother   Guardian (please specify): ____________ 
  Father, Stepfather, or Foster father   Other: _____________________________ 
 
INFORMATION ABOUT YOUR CHILD 
 
Age: ________  Gender: _________________ Grade: _______ 
 
Preferred Language: ______________________   
 
Race/Ethnicity (Check all that apply): 
  Asian/Pacific Islander   Black or African American    Hispanic or Latino  
  Native American or American Indian   White, Non-Hispanic 
  Other (Please specify): ______________ 
 
Age of diagnosis of neuromuscular disorder: __________ 
 
Ambulation status:   
  Walking without the use of orthotic devices (e.g., braces) or mobility aids (e.g., cane, walker)  
  Walking with the use of orthotic devices (e.g., braces) or mobility aids (e.g., cane, walker)  
  Intermittent wheelchair use   
  Full-time wheelchair use 
 
In the past 12 months, has your child had any overnight hospital visits for issues related to their 
neuromuscular disorder?   No   Yes 
If yes, how many times? ________ 
 
In the past 12 months, has your child been seen in an emergency department for issues related to 
their neuromuscular disorder?   No   Yes 
If yes, how many times? ________ 
 
Is your child currently receiving formal supports and services in school for their academic, 
physical, and/or medical needs via an Individualized Education Program (IEP)?  
  No    Yes    I don’t know   Not applicable 
 
Is your child currently receiving formal supports and services in school for academic, physical, 
and/or medical needs via a Section 504 Plan? 
  No    Yes    I don’t know   Not applicable 
 





Age: ________     Gender: _________________  
 
Preferred Language: ______________________   
 
Race/Ethnicity (Check all that apply): 
  Asian/Pacific Islander   Black or African American    Hispanic or Latino  
  Native American or American Indian   White, Non-Hispanic 
  Other (Please specify): ___________________ 
 
Relationship Status:    Single    Living with someone   Married  




What is the highest degree or level of school you completed? (If you are currently enrolled in 
school, please indicate the highest degree you have received). 
  5th grade or less     6th-8th grade     9th-12th grade  
  High school graduate    Some college or certification course   
  Associate degree    Trade/Technical/Vocational Training    Bachelor’s degree  
  Graduate or professional degree    Other, please specify: ____________________ 
 
What is your family’s estimated yearly income (from all sources and before taxes)? 
  Less than $20,000    $20,000 to $34,999    $35,000 to $49,999  
  $50,000 to $74,999    $75,000 to $99,999    Over $100,000 
 
What is your current work status? 
  Employed full-time (Over 35 hours/week) outside the home  
  Employed part-time (Less than 35 hours/week) outside the home 
  Unemployed and currently looking for work  
  Unemployed and not currently looking for work  
  Student    Retired    Active military     Homemaker  
  Self-employed     Disabled; unable to work 
 
How would you describe your household? Please choose only one of the following: 
  Two-parent household   One-parent household   Step-parent household 
  Other, please specify: _________________ 
 
Have you or anyone in your immediate family completed genetic carrier testing? 
   No    Yes 
 If yes, who (please specify): ____________________ 
 What were the results of the testing?   
  Positive for a mutation in the DMD gene   Negative for a mutation in the  





Have you been diagnosed by a medical or mental health professional with a psychiatric condition 
(e.g., anxiety, depression, bipolar disorder)?    No    Yes 
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Mapi Research Trust, a non-for-profit organisation subject to the terms of the French law of 1st July 1901, registered in 
Carpentras under number 453 979 346, whose business address is 27 rue de la Villette, 69003 Lyon, France, hereafter referred 
to as “MRT” and the User, as defined herein, (each referred to singularly as a “Party” and/or collectively as the “Parties”), do 
hereby agree to the following User Agreement Special and General Terms:
Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66
Recitals
The User acknowledges that it is subject to these Special Terms and to the General Terms of the Agreement, which are included 
in Appendix 1 to these Special Terms and fully incorporated herein by reference.  Under the Agreement, the Questionnaire 
referenced herein is licensed, not sold, to the User by MRT for use only in accordance with the terms and conditions defined 
herein.  MRT reserves all rights not expressly granted to the User. 
The Parties, in these Special Terms, intend to detail the special conditions of their partnership.
The Parties intend that all capitalized terms in the Special Terms have the same definitions as those given in article 1 of the 
General Terms included in Appendix 1.
In this respect, the Parties have agreed as follows:
 
Article 1. Conditions Specific to the User
        Section 1.01      Identification of the User
User Name Noelle Whitney
Legal Form Student
Address 501 20th Street 
80639 Greeley 
Country United States of America
Email address noelle.whitney@unco.edu
        Section 1.02      Identification of the Questionnaire
Title Pediatric Quality of Life Inventory™ (PedsQL™) 
Author(s) Varni JW 
